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(iii) Summary 
Summary 
The incidence of urolithiasis in South Africa's black population is extremely rare «1%) 
while in the white population it is similar to that of western countries (-15%). The present 
thesis was aimed at shedding more light on the complex nature of the physicochemical, 
biochemical and physiological mechanisms in black South Africans which provide this 
group with a natural protection against urolithiasis in contrast to their white compatriots. 
Four studies comprise this thesis. 
In the first study, the frequency of alanine:glyoxylate aminotransferase (AG7) 
Proline11 Leucine (Pro 11 Leu) polymorphism was investigated to ascertain whether this 
polymorphism was a contributory factor in the differences in stone incidences between 
the two race groups. This study was prompted by the lack of any genetic studies 
attempting to explain this anomaly in stone incidence in the two race groups. Three 
groups of healthy male subjects ('rural' black (n=10), 'semi-urban' black (n=10) and 
white subjects (n=20) partiCipated in the study. Each subject collected a spot morning 
urine sample and provided a blood sample which was drawn by a qualified phlebotomist 
on an E DTA-tu be. In addition, 24hr food dietary records as well as a questionnaire which 
assessed the subjects' food frequency diet, medical history, medications, lifestyle and 
other practices of interest as well as history of kidney stone disease were completed. 
Determination of AGT Pr011 Leu polymorphism through DNA sample analysiS was 
achieved using the polymerase chain reaction-restriction fragment length polymorphism 
method. Data revealed that the frequency of this polymorphism was similar between the 
subjects from the two race groups who participated in this study. It seems that this 
polymorphism may not playa key role in the low incidence of stone formation in the 
black group, but further stUdies involving much larger cohorts of participants are needed 
before the role of genetics can be fully resolved. 
In the second study, the role of gut permeability as a key to identifying possible 
differences in the handling of dietary oxalate in healthy black (n=10) and white (n=10) 
South African male subjects following various dietary challenges was investigated. The 
study was divided into three protocols - (regular diet (P1), standardized diet (P2) and 
high-oxalate standardized diet (P3). Each protocol was conducted over a 3-day period 
with a one week wash-out period between protocols. Subjects followed the respective 
protocol's diets on day 1 and 2. On day 3 of each protocol, subjects provided a baseline 
(iv) Summary 
sample (1 hr) following an overnight fast, to test for the presence of endogenous sugars, 
and then ingested 200 ml of a dual-sugar isotonic test solution containing 5g lactulose 
(LA) and 2g mannitol (MA) dissolved in tapwater. Subjects then collected a 5hr test 
sample followed by an 18hr post-test sample. The ratios of the percentage recoveries of 
two sugar probes (LAo/oIMA%), an accurate index of gut permeability, were determined 
on the 5hr test samples using high performance anion exchange chromatography 
coupled with pulsed amperometric detection. The 24hr samples were reconstituted for 
measurements of urine parameters including urinary oxalate excretions. 
Physicochemical risk factors such as the relative supersaturation of calcium oxalate and 
Tiselius risk index were computed from the urinary parameters. 
The results from this study showed that administration of the high-oxalate standardized 
diet in protocol 3 reduced MA excretions by more than 50% in the two race groups 
indicating a defect in the mucosal defense system in both groups. Based on this 
observation, it is tentatively concluded that there was an induced general malabsorption 
of nutrients following this protocol. The gut permeability index was slightly higher in 
blacks than in whites (0.007 vs 0.003, respectively) while the Tiselius risk index was 
unfavourably and significantly elevated in the black group (p=0.0003). Although the latter 
parameter was also elevated in white subjects it did not change significantly in this group 
(p=0.101S). These observations were surprising considering the low incidence of stone 
formation in the black population. Equally surprising was the fact that data showed that 
black subjects handled oxalate more transiently than whites as demonstrated by the 
significantly elevated levels of mean urinary excretion of oxalate in the black group 
(p=0.0021) but not in the white group (p=0.8491). Further research is warranted in this 
area. 
In the third study, the effects of vitamin E (dl-a-tocopheryl acetate) ingestion on lipid 
peroxidation and urinary kidney stone risk factors were investigated. In this study, 
healthy black (n=5) and white (n=5) male subjects from the two race groups were 
required to ingest one vitamin E capsule (4001U) every day immediately after supper for 
60 days. Blood samples (5ml) were collected in EDTA tubes by a qualified phlebotomist 
from each subject at baseline (day 0) and postsupplementaion (day SO) following an 
overnight fast. 24hr urine samples were also collected on the days in which blood 
samples were drawn. Subjects were instructed to continue taking their free and 
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unrestricted regular diets for the duration of the study period and to complete 24hr 
dietary food records on the days in which urine and blood samples were collected. The 
subjects' dietary food intakes were assessed using a Foodfinder 2 computer software 
programme. Plasma vitamin E (a-tocopherol) levels were determined using high 
perfonnance liquid chromatography (HPLC) while urinary and plasma thiobarbituric 
reactive substances (TBARS) levels were measured using OXI-TEK TSARS assay kits. 
24hr urine samples were rigorously analyzed for biochemical risk factors using routine 
standard biochemical techniques. 
The results from this study appear to show a dual-role for vitamin E ingestion in the two 
race groups. On one hand, plasma a-tocopherol and urinary citrate were favourably and 
significantly elevated in both groups while on the other hand, urinary calcium, oxalate, 
relative supersaturation and Tiselius risk index as well as urinary and plasma TSARS 
(MDA equivalents) were not altered. Subtle differences in handling mechanisms of 
vitamin E in black and white subjects were apparent. Overall, vitamin E appeared to 
have minimal beneficial effects in the small group of black and white South African 
subjects, which supports the findings of previous studies on vitamin E ingestion in 
healthy subjects. However, the findings of favourable and significant increase in mean 
urinary excretion of citrate coupled with an increase of plasma a-tocopherol levels in 
both groups supports the protective role of vitamin E ingestion in calcium oxalate 
urolithiasis albeit it does not explain the differences in stone incidences in the two race 
groups. 
In the final study, the effects of omega-3 fish oil ingestion alone (protocol 1) and in 
tandem with vitamin E (dl-a-tocopheryl acetate) (protocol 2) on urinary kidney stone risk 
factors was investigated. 20 healthy male subjects participated in this study, one group 
of black (n=5) and white (n=5) subjects participated in protocol 1 and ingested a fish oil 
capsule (salmon oil, 1000mg) providing 164 mg eicosapentaenoic acid (EPA) and 110 
mg docosahexaenoic acid (DHA) every day immediately after supper for 30 days while a 
second group of black (n=5) and white (n=5) healthy male subjects participated in 
protocol 2 and ingested the aforementioned fish oil capsule in tandem with vitamin E (dl-
a-tocopheryl acetate, 4001U) capsule for a similar period. Following an overnight fast, 
two venous blood samples (5ml) were collected (EDTA tube and lithium heparin tube) by 
a qualified phlebotomist from each subject at baseline (day 0) and postsupplementation 
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(day 30). Blood samples collected in lithium heparin tubes were used for analysis of 
plasma uric acid using Synchron LX systems kits and for analysis of ferric reducing 
antioxidant power (FRAP) using colorimetric FRAP assay kits. Blood samples collected 
in EDTA tubes were analysed for plasma vitamin E (a-tocopherol) using HPLC and for 
plasma malondialdehyde (MDA) using BIOXYTECHMDA-566 kits. 24hr urine samples 
were also collected on the days in which blood samples were drawn and were analysed 
as described above. 
The results for protocol 1 showed no significant changes in any of the urinary or plasma 
risk fadors and biomarkers for calcium oxalate stone formation in the two race groups. 
However, protocol 2 favourably and significantly raised plasma a-tocopherol levels in 
both groups but did not have any effed on the other parameters. Between-group 
comparisons revealed that there were no statistically significant differences at baseline 
for this parameter in the two race groups (p=0.OB2B). However, significantly higher 
plasma a-tocopherol levels were observed post-supplementation (day 30) in whites than 
in blacks in protocol 1 (p=0.0372) and protocol 2 (p=0.0577). These observations are 
counter-intuitive considering the lower incidence of stone formation in the black group. 
Although no profound insights were gained regarding explanations for the rarity of stone 
incidences in the black population as compared to their white compatriots, the present 
thesis has made significant contributions to the body of scientific knowledge in this area. 
The results of this thesis have demonstrated that explanation of the phenomenon of 
stone rarity in blacks is extremely complex and serve to motivate further studies to 
elucidate this intriguing phenomenon. 
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Chapter One General Introduction 
1.1 Introduction 
Urolithiasis (kidney stone disease) is the third most common pathological disease 
afflicting the urinary tract, next to infection and prostatic pathology. It is a multi-factorial 
disease, the on-set and severity of which is influenced by both genetic and 
environmental factors (Blacklock 1982, Li et al. 1985, Ljunghall et al. 1985, Kohri et al. 
1988, Smith 1989, Curhan et al. 2004, Holmes and Assimos 2004, Goldfarb et al. 2005, 
Moe and Bonny 2005, Stoller and Rubenstein 2005). It is likely due to a variety of 
etiological factors, many of which currently remain unknown. 
A number of well recognized risk factors favour the development and progression of 
stone disease. These include biochemical/metabolic perturbations, anatomical 
anomalies within the kidney and genetic susceptibility (Friedman 2000, Jonassen et al. 
2004). Although, it is difficult to determine how these factors converge to promote stone 
disease, it is an accepted factor that stones can form anywhere in the urinary tract, from 
kidneys to the bladder (Jonassen et al. 2004, Khan 2006). There is interest in the revival 
of Randall's plaque as the possible first step in calcium stone formation (Evan et al. 
2003). These apatite plaques begin at the tip of Henle's loop, and as yet little is known 
regarding the factors that cause them, or the factors that lead to calcium oxalate stone 
growth on Randall's plaques. 
It is also worth noting that in the industrialized and affluent countries, stone formation is 
generally restricted to the kidneys, where the most common type is calcium oxalate. In 
fact, approximately 80% of all kidney stones are composed of calcium oxalate and 
calcium phosphate, while the remaining percentage is shared among struvite (10%) and 
uric acid (9%), with only 1% of stones composed of cystine or ammonium acid urate or 
are diagnosed as drug-related stones (Ramello et al. 2000, Coe et al. 2005, Khan 2006). 
It is of interest that in South Africa, calcium oxalate stones occurs in the white population 
(-15%) to the same extent as in other western countries, but that the incidence of stones 
in the black population is extremely rare «1 %) (Muskat 1951, Wise and Kark 1961, 
Modlin 1967, Whalley et al. 1998, Whalley et al. 1999). Studies described in the present 
thesis are aimed at shedding more light on the complex nature of the physicochemical, 
biochemical and physiological mechanisms in black South Africans which provide this 
group with a natural protection against urolithiasis in contrast to their white compatriots. 
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1.2 Epidemiology and risk factors in urolithiasis 
The incidence, prevalence and recurrence of stone formation is a worldwide disease 
sparing no age, gender, geographical or cultural groups (Moe 2006). 
Age and gender 
Although the aetiology of urolithiasis in children is different to that of adults, kidney 
stones can develop at any age, from as early as the first 2-3 months of life (van't Hoff 
2004). However, stone disease varies according to gender. For males (who form the 
basis of investigations of this thesis) the incidence of stone formation has been reported 
to be most prevalent between the ages of 30 and 60 years while in females the risk is 
said to peak between the ages of 20 and 30 (Johnson et al. 1979, lIiatt et al. 1982, 
Hesse et al. 1986, Curhan et al. 1993, Curhan et al. 2004). In addition, the risk slowly 
falls with age in both groups. A study by Hesse and co-workers (1986) has shown that 
certain urinary parameters active in urolithiasis are influenced by age-dependent 
metabolism. This is in agreement with findings of earlier studies that reported similar 
observations (Ljunghall et al. 1977a, Iliatt et al. 1982, Robertson et al. 1984). For 
example, magnesium excretion was shown to decline continually after the age of 30. 
This was associated with absorption of magnesium in the bowel, which declines with 
increasing age (Hesse et al. 1986). 
The prevalence of stone formation in males is estimated to be between 7 and 15 % 
(Chandoke 2002) while it is reported to be only between 3 and 6 % in females (Fetter et 
al. 1963, Ljunghall 1977b, Scott et al. 1977, Hesse et al. 2003, Stamatelou et al. 2003, 
Dall'Era et al. 2005). A recent study by Scales and co-workers (2007) has reported a 
change in the prevalence of gender of patients treated for stone disease from 1.7:1 to 
1.3:1 male-to-female ratio. Nevertheless, an explanation for gender disparity is based on 
several scientific observations. Firstly, it has been suggested that in males, high 
testosterone levels may cause an increased endogenous oxalate production by the liver, 
resulting in an increased urinary oxalate excretion (Baker et al. 1996, Lee et al. 1996, 
Yoshihara et al. 1999). Secondly, the low stone incidence in females may be accounted 
for by the presence of estrogens, which are known to decrease urinary oxalate 
excretion, plasma oxalate levels and kidney oxalate deposition (Liao and Richardson 
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1972, Finlayson 1974, Ferrari et al. 2007). Thirdly, another possible explanation is that 
females have been shown to excrete a high level of urinary citrate, which may protect 
them from calcium urolithiasis (Welshman and McGeown 1975). 
Occupation 
A number of stUdies have found an interesting correlation between stone disease and 
occupation. It has been shown that occupation and social class are related to a higher 
urinary stone risk. For example, in a study by Ekane and co-workers (1997), manual 
workers presented a much lower frequency of urinary stones than professional and 
managerial groups. Although other factors might be involved, such as infrequent voiding 
that may increase stone forming salts, it is possible that this may be due to the manual 
workers' active lifestyle. Nonetheless, this finding has been corroborated by other 
studies that have consistently shown that the more sedentary the work, the higher is the 
prevalence of stone formation (Borghi et al. 1993, Zheng et a/. 2002). 
Economics 
The health care costs associated with treatment of stone disease has risen over recent 
years. These have been estimated in the USA at $ 2-5.3 billion/year and about € 54.38 
million in Germany (Strohmaier and Hormann 2000, Chandoke 2005, Porena et al. 
2007). Moreover, it has also been reported in the UK, that every stone episode costs the 
local health authority almost £2000 (Robertson 2006). Notwithstanding that the 
prevalence and incidence of nephrolithiasis are estimated at 5-10% and 100-
300/100000/year respectively, and that the relapses occur in 50-70% of all cases (Sa ita 
et a/. 2007), the rising medical cost of treatment of stone disease, is another stark 
reminder that prevention of stone formation is of great importance. 
Geography and climate 
The overall probability of forming stones has been shown to vary in different parts of the 
world. The risk of developing stone disease in normal adults appears to be lower in Asia 
(1-5%) than Europe (5-9%) and North America (12% in Canada and 13% in USA) 
(Ramello et a/. 2000). These discrepancies could be attributable to various reasons 
4 Chapter One General Introduction 
related to different lifestyle, diet, climate, daily water intake, physical activity and 
corporeal overweight (Yoshida and Okada 1990, Curhan et a/. 1993, Trinchieri 1996, 
Hesse et al. 2003). In addition, other authors have attributed these differences in stone 
incidences to comorbidity (diabetes, overweight, hypertension, surgery for obesity, etc) 
(Hall et al. 2001, Timio et al. 2003, Oaudon et a/. 2006, Lieske et al. 2006, Cupisti et al. 
2007). 
According to Rodgers (2006), urolithiasis in Africa has not been extensively investigated, 
due to a general lack of research facilities in the continent. However, there are regions 
(Ethiopia, Cameroon, Niger, A/geria, Egypt) in which endemic paediatric bladder stones 
are known to occur, regions (South Africa, Tanzania, Northern Sudan) in which calcium 
oxalate upper urinary tract stones have been reported and regions (Nigeria, Southern 
Sudan and South Africa) where the occurrence of stones has been found to be 
extremely rare in some population groups. It is further stated that, the endemic stones in 
Africa maybe due to infection, hyperuricosuria (rna/nutrition) and poor diet. The stone 
rarity in Southern Sudan has been attributed to the relatively low temperature, high 
relative humidity, low urinary calcium and high urinary volume (Kambal et al. 1981) while 
Esho (1978) attributed the stone rarity in Nigeria to low calcium content of the drinking 
water, the low consumption of dairy products and the labour intensive lifestyle. 
Of particular concem, is the highest risk of stone formation that has been reported in 
Saudi Arabia, with 20.1 % of the population afflicted with the disease (Robertson and 
Hughes 1994) and the notorious South Eastern United States 'stone belt' (Blacklock 
1982). These geographic areas are well-known for their hot climate. It is plausible that 
increased vitamin 0 levels that may arise, possibly due to exposure to ultra-violet portion 
of sunlight, which may activate the conversion of 7 -dehydrocholesterol to vitamin 0 3, 
which (together with its hydroxy/a ted derivate, 1.25-dihydroxyvitamin 0 3) has been 
reported to act on the intestine and bone to increase plasma calcium and phosphate 
ions levels (Broadus et al. 1984). As a result of this activation, an increase in intestinal 
calcium absorption and urinary excretion may occur, which might be responsible for the 
reported stone propensity (Robertson and Peacock 1981, Broadus et al. 1984). In 
addition, it is also possible that, high temperatures may increase perspiration, which may 
lead to increased incidence of stone formation as a result of urines being more 
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concentrated with stone forming salts (AI-Dabbagh and Fahadi 1977, Schwille and 
Hermann 1992). 
Furthermore, seasonal stone recurrence has also been observed, with incidences 
reported to be higher in spring and summer than in autumn and winter (Parry and Lister 
1975, Bartoletti et al. 2007). It seems very likely that this can be ascribed to low fluid 
intake and low urinary output during the cooler seasons. This has been confirmed by 
studies showing the highest incidence of ureteral stones during the summer months 
(Prince et al. 1956, Alhadramy 1997). 
Race 
It is interesting that certain races or groups of people appear to be immune to urinary 
stones. These include the Indians of Mexico, Peru, Ecuador and Bolivia, South African 
blacks, inhabitants of Greenland and Aborigines (Muskat 1951, Wise and Kark 1961, 
Modlin 1967, Widdowson and McCance 1970, Finlayson 1974, Scott et al. 1977, 
Whalley et al. 1998, Whalley et al. 1999). 
Stone rarity in the inhabitants of Greenland has been attributed to their high 
consumption of dietary essential fatty acids (oily fish), which are rich in eicosapentaenoic 
acid. The latter has been shown to reduce urinary calcium, one of the major risk factors 
for stone formation (Dyerberg 1981, Dyerberg and Bang 1982, Buck et a/. 1991, Yasui et 
al. 2001). 
Of further interest in the context of this thesis, is that whites have been consistently 
shown to have a higher incidence of stone formation than blacks, irrespective of 
geographical and environmental area (Robertson and Peacock 1981, Soucie et al. 1994, 
Ramello et al. 2000, Maloney et al. 2005). Despite numerous research studies on this 
anomaly, there is currently no definitive conclusive explanation to this apparent natural 
immunity of the black population to stone disease (Muskat 1951, Wise and Kark 1961, 
Soucie et al. 1994, Whalley et al. 1998, Whalley et al. 1999, Rodgers 2006). It is clear 
that further studies are warranted in this regard. Indeed, this phenomenon forms the 
basis of the present thesis with special reference to the South African black and white 
population. 
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1.3 Urinary risk factors 
Urolithiasis is associated with a variety of abnormalities in urinary composition, which are 
due to dietary indiscretions, physiological-metabolic disturbances or both (Pak 2004b, 
Taylor and Curhan 2004). These urinary risk factors have been identified as those 
urinary characteristics that are widely accepted to influence the likelihood of calcium 
stone formation or recurrence and are routinely measured as part of the metabolic 
investigations of both calcium stone formers and non-stone formers (Rodgers 2006, 
Sutton 2006). 
Urinary risk factors for stone formation include pH, volume, calcium, oxalate, citrate, 
magnesium, phosphate and uric acid. A number of risk models of stone formation have 
been developed over the years (Robertson et a/. 1978, Khan 1997, Robertson 2003, 
Jaeger and Robertson 2004). Fortunately, the correction of abnormal risk factors by 
dietary modification and pharmacologic intervention has been shown in several studies 
to reduce the risk of stone formation as well as prevent recurrent stone formation 
(Massey et al. 1993, Anbazhagan et al. 1999, 8aggio et a/. 2002, Rodgers and 
Lewandowski 2002, Massey 2003, Jaeger and Robertson 2004, Pak 2004b, Taylor and 
Curhan 2004, Goldfarb et a/. 2005, Siener and Hesse 2005, Taylor et a/. 2005, Hesse 
and Straub 2006, Thomas et a/. 2008). 
Urinary calcium 
The ultimate driving force for stone formation is supersaturation with respect to stone-
forming salts, with urinary calcium being a major risk factor (along with urinary oxalate in 
the case of calcium oxalate stones). As stated earlier, about 80% of all kidney stones 
contain calcium. Most of these occur as calcium oxalate (Robertson et al. 1978, Wilson 
1989, Hess et a/. 1998). Moreover, between 30-60% of all patients with calcium oxalate 
kidney stones have increased urinary calcium excretion in the absence of elevated 
serum calcium. This condition is generally referred to as idiopathic hypercalciuria (8alaji 
and Menon 1997, Worcester and Coe 2008). 
In 1974, Pak and ccrworkers suggested that idiopathic hypercalciuria is of heterogenous 
origin (absorptive hypercalciuria, renal hypercalciuria and resorptive hypercalciuria). The 
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primary defect in absorptive hypercalciuria, which is inherited as an autosomal dominant 
trait, is increased passive mucosal absorption of calcium and oxalate in the jejunum. 
Renal hypercalciuria, which is characterized by primary renal leak of calcium and 
resorptive hypercalciuria, which is secondary to increased bone demineralization, are 
relatively uncommon (Pak et al. 1974, Coe et al. 1992, Pak 2004a, Moe 2006). 
Hypercalciuria is often a predisposing factor for nephrolithiasis (Coe and Kavalich 1974, 
Coe 1978, Coe et al. 1979, Licata et al. 1979, Curhan et al. 1993, Hess 1996, Messa et 
al. 1997, Heller 1999). In fact, early studies regarded raised urinary calcium to be the 
most important urinary risk factor for calcium oxalate urolithiasis. As a result, patients 
were advised to restrict calcium intake (Marshall et al. 1972, Bleich et al. 1979, Rao et 
al. 1982, Vahlensieck 1986, Rose 1987, Goldfarb 1994). However recent studies have 
shown that a reduction in calcium intake increases the risk of calcium stone formation 
and also causes a negative calcium balance and further loss of bone tissue (Coe et al. 
1992, Curhan et al. 1993, Lemann 2002). This is probably because a low intake of 
calcium leads to an increase in the amount of oxalate available for absorption in the gut 
and a consequent increase in urinary oxalate (Marshall et a/. 1972). Conversely, some 
evidence suggests that a high intake of dietary calcium inhibits the absorption of oxalate 
and in this way, is a means of reducing urinary oxalate excretion and therefore for 
reducing calcium oxalate stone forming risk (Zarembski and Hodgkinson 1969, Barilla et 
al. 1978, Hess et al. 1998, Holmes et al. 2001). 
Urinary oxalate 
Urinary oxalate was originally considered merely as a major component of calcium 
oxalate stones, forming crystals in the lumen of the renal tubules. However, there is now 
much evidence to suggest that oxalate is the limiting or determinant factor in urinary 
calcium oxalate crystallization (Robertson et al. 1978, Robertson and Peacock 1980, 
Borsatti 1991, Bensatal and Ouabrani 2008, Tsujihata 2008). In fact. even a slight 
increase in urinary oxalate has been shown to have adverse effects on calcium oxalate 
stone formation (Robertson et al. 1981, Taylor and Curhan 2004). Oxalate also affects 
renal tubular epithelial cells, influencing the pathogenesis of nephrolithiasis (Robertson 
et al. 1978, Kim et al. 2002). 
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Many studies in normal individuals, have reported increases in oxaluria of approximately 
8-289% following oxalate loads (Marshall et a/. 1972, Barilla et a/. 1978, Finch et a/. 
1981, Balcke et a/. 1989, Nguyen et a/. 1994, Hess et a/. 1998, Liebman and Costa 
2000, Holmes et al. 2001). As might be expected, other studies have shown that stone 
formers present a higher mean oxalate level in the urine than healthy controls (Schwille 
et a/. 1989, Wilson et a/. 1989). This has prompted Jaeger and Robertson (2004) to posit 
that being able to control the urinary excretion of oxalate would undoubtedly constitute a 
major break-through in the prevention of calcium oxalate stone recurrence. 
In normal individuals, the majority of urinary oxalate is derived from the endogenous 
metabolism of glycine, glyoxylate and ascorbic acid, while 10 to 20% is derived from oral 
ingestion (Zimmerman et a/. 2004). However, in patients, hyperoxaluria may be due to 
various factors. Firstly, primary hyperoxaluria type I (described in more details in chapter 
two of this thesis) is caused by deficiency of the enzyme alanine:glyoxylate 
aminotransferase in the liver, which causes glycolate to be oxidized to oxalate thus 
increasing urinary oxalate and the risk of calcium oxalate stone formation (Danpure et a/. 
2003, Danpure et al. 2005). Secondly, enteric hyperoxaluria can also occur in patients 
with short bowel syndrome, as malabsorption of fats may cause calcium to bind to the 
unabsorbed fats rather than oxalates (Dobbins and Binder 1976, Dobbins 1985, 
Laminiski et a/. 1991, Thomas et a/. 2008, Cirillo et a/. 2008). Thirdly, it has been 
postulated that apparent inconsistencies between dietary oxalate and oxaluria can be 
explained by oxalate-degrading gastrointestinal bacteria (e.g Oxalobacter fonnigenes) 
(Holmes et a/. 1995, Sidhu et a/. 1998, Sidhu et a/. 1999, Sidhu et a/. 2001, Siener et al. 
2001, Kwak et a/. 2003, Massey 2003, Jaeger and Robertson 2004, Hoppe et al. 2005). 
These bacteria may be important for controlling oxaluria and may be a significant factor 
contributing towards stone rarity. There is some compelling evidence to support this 
latter assertion. In studies in stone-formers, the absence of O. fonnigenes has been 
associated with an increase in urinary oxalate (Kwak et al. 2003). Furthermore, several 
studies have also shown that stone-formers generally have lower levels of colonisation 
with O. fonnigenes than non-stone-formers (Sidhu et al. 1998, Sidhu et a/. 1999, Sidhu 
et a/. 2001, Kumar et al. 2002). 
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Urinary citrate 
Urinary citrate is widely regarded as an extremely important naturally-occurring inhibitor 
of calcium stone formation (Fleisch 1978, Pak 1994, Ryall 1997, Chow et al. 2004, 
Rodgers et al. 2005). Indeed, several studies have reported hypocitraturia in calcium 
stone formers (Pak et al. 1978, Rudman et al. 1982, Nicar et al. 1983, Pak et al. 1985, 
Nicar et al. 1987, Cupisti et al. 1992). 
The most important cause of this condition in calcium stone formers is probably 
metabolic acidosis, which causes increased proximal tubular reabsorption of citrate and 
is seen in 15% to 63% of patients with urolithiasis (Nicar et al. 1983, 8alaji and Menon 
1997). In addition to these clinical scenarios, in vitro crystallization studies have also 
shown that citrate is able to complex urinary calcium thereby reducing its ionic 
concentration and concomitantly reducing the risk of calcium oxalate stone formation 
(Meyer and Smith 1975, Ryall et al. 1981, Hallson et al. 1983, Kok et al. 1986, Tiselius et 
al. 1993). 
Urinary magnesium 
Magnesium is known for its ability to complex oxalate, potentially reducing oxalate 
absorption in the gastrointestinal tract, and decreasing the risk of stone formation 
(Desmars and Tawashi 1973, Hallson et al. 1982, Rushton and Spencer 1982, Li et al. 
1985, Trinchieri et al. 1992). For example, magnesium has been shown to lower the 
urinary supersaturation of calcium oxalate and increase urinary citrate in two separate 
studies by Lindberg (1990a, 1990b). This finding is in agreement with other studies that 
have also observed a decrease in calcium oxalate supersaturation in the urine following 
magnesium therapy (Liebman and Costa 2000, Taylor and Curhan 2004). 
Consequentially, this makes it a potent inhibitor of calcium oxalate stone formation. 
However, several studies have reported contradictory findings on urinary magnesium 
levels. Some studies have shown lower urinary magnesium excretion in stone formers 
compared to controls (Faragalla and Gershoff 1963, Yendt 1970, Tiselius et al. 1978, 
Trinchieri et al. 1991, Trinchieri et al. 1992), while in other studies it was found to be 
equal to or higher (Johansson et al. 1980, Drach et al. 1985). To compound matters, one 
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randomized clinical trial demonstrated no effect of magnesium supplementation on 
recurrent calcium oxalate stone formation (Ettinger et al. 1988). More studies are 
required to elucidate the actions of magnesium on relative levels of urinary magnesium 
in stone formers and controls. 
Urinary uric acid 
Hyperuricosuria, which may occur as a result of an excessive dietary intake of purine, is 
the major cause of uric acid stones along with low urinary pH (Coe and Kavalich 1974, 
Moe 2006). Several other conditions are also known to induce supersaturation of uric 
acid andlor lower urinary pH. These include chronic dehydration, severe diarrhea and 
hyperuricemia (Vella et al. 2007). 
In a study by Coe (1978), a third of calcium oxalate patients were shown to have a high 
urinary uric acid excretion, from which 70% was attributed to excessive intake of dietary 
protein while the remaining 30% was attributed to endogenous overproduction of uric 
acid. Previous studies have shown that allupurinol therapy can reduce stone recurrence 
in calcium oxalate stone patients with hyperuricosuria by blocking uric acid production 
and reducing purine absorption (Pak et al. 1978, Ettinger 1991). 
Urinary phosphate 
An increase in urinary phosphate causes an increase in calcium phosphate 
complexation thereby reducing the risk of calcium oxalate crystallization (Schwille et al. 
1989, Baumann et al. 2001). However, it concomitantly increases the risk of calcium 
phosphate stone formation. Calcium phosphate occurs in stones as either apatite (the 
principal constituent of bones and teeth) or brushite (calcium monohydrogen phosphate) 
(Mandel and Mandel 1989, Coe et al. 2005). It has been reported that calcium 
phosphate is present as a constituent of kidney stones in amounts ranging from 1-10% 
(Mandel and Mandel 1989) although Evan and co-workers (2005) estimate the more 
recent figure at 15%. 
In a study comparing calcium phosphate and calcium oxalate stone formers, it was 
observed that calcium phosphate stone formers had high urine volume and calcium 
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excretion with low citrate excretion relative to calcium oxalate stone formers (Evan et a/. 
2005). This was attributed to the morphological changes of each stone forming group 
which correlated with their metabolic profiles. 
Urinary pH 
Urine is a complex chemical solution containing dissociated and non-dissociated solutes 
in equilibrium. These equilibria are sensitive to changes in pH. Thus, the latter is a 
critical risk factor for urolithiasis. 
As alluded to above, low urinary pH is a risk factor for uric acid stone formation. In fact, 
excessively low urine pH is much more common than hyperuricosuria as a cause of uric 
acid stone, as it can convert urinary urate into sparingly soluble uric acid, resulting in an 
increased risk of stone formation (Finlayson and Smith 1974, Moe et a/. 2002, Tiselius 
2003, Moe 2006). On the other hand, higher pH values pose a risk for calcium oxalate 
stone formation, while still higher values increase the risk of calcium phosphate 
(brushite) stone formation (Tiselius 1981, Tiselius and Larsson 1993, H0jgaard et a/. 
1999). 
This may seem like a gloomy situation, however it is not entirely so, as it has also been 
suggested that therapeutic alkalization for treatment of uric acid stones should be 
combined with calcium reducing measures so as to avoid brushite formation (Tiselius 
1981). In addition, a high pH has been shown to have inhibitory activity towards calcium 
oxalate crystallization, as it causes more phosphate and citrate ions to be dissociated, 
which results in complexation with calcium, thereby reducing the urinary saturation of 
calcium oxalate (Kohri et a/. 1993, Pak 1994, Rodgers et a/. 2005). 
The risk of calcium phosphate stone formation increases at pH above 6.2 (H0jgaard et 
a/. 1999, Jaeger and Robertson 2004). In fact, according to Jaeger and Robertson 
(2004), a small increase in pH above this value produces a logarithmic increase in the 
urinary concentration of phosphate ions. At a pH 5.75 half of the uric acid is ionized as 
urate salts and is soluble, while the other half exists as free insoluble uric acid. However, 
as pH falls below 5.5, uric acid stones can form as its concentration would exceed that of 
urate (Asplin 1996, Moe 2006, Vella et a/. 2007). The pH range in which there is a high 
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risk of calcium oxalate stones is not lucid. However, it has been reported that an alkaline 
pH seems to reduce the risk of calcium oxalate crystallization (Kohri et al. 1993, Pak 
1994). 
It has been suggested that the best case scenario with regard to urinary pH levels, is to 
maintain pH between 6-7, as the inhibitory activity of citrate and pyrophosphate is 
enhanced as a result of more of these species being in the active ionic form and the 
undissociated concentration of uric acid is low in this range (Pak 1994, Messa et al. 
1997, Lewandowski et al. 2005). 
Urinary volume 
The single most common factor that initiates stone formation is inadequate fluid intake, 
which results in low volume of concentrated urine and relative urinary supersaturation of 
stone forming salts (Hall 1995, Moe 2006). 
The positive effect of fluid intake on stone formation has been proven in epidemiological 
and prospective intervention studies (Pak et al. 1980, Borghi et al. 1996, Curhan et al. 
1998, Moe 2006). For example, it is generally accepted that stone patients with a urine 
volume less than 2Uday can often avoid further events by increasing their fluid intake as 
shown in a randomized clinical trial by Borghi and co-workers (1996), who reported a 
significant and favourable decrease in urinary calcium and urinary oxalate thereby 
reducing the stone recurrent rate from 27% to 12%. 
However, in attempts to increase fluid intake, caution should be exercised as some 
beverages have been reported to increase the risk of stone formation. Although the 
mechanism for the increased risk observed is unknown, two independent studies by 
Curhan and co-workers (1996,1998), on the effect of apple and grapefruit juices on 
stone formation risk, have shown that the risk of stone formation is increased by 35% 
and 37% respectively. Other workers have cautioned against the use of cola and hot 
chocolate, which because of their high oxalate content, probably contribute to their 
adverse effects on urolithiasis (Hesse et al. 1993, Rodgers 1999). Moreover, an 
increased calcium/creatinine ratio and elevated Tiselius Risk Index was observed after 
acute load of caffeine in a group of 39 normocalcaemic patients with calcium stones. 
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Thus caffeinated beverages should also be consumed in moderation (Massey and 
Sutton 2004, Siener 2006). On the other hand, other fruit juices (notably lemon) have 
been shown to decrease the risk of calcium stone formation (Seltzer et al. 1996, 
Oussama et al. 2005, Kang et al. 2007). 
Relative supersaturation and risk indices 
Considerable effort has been expended in trying to develop robust indicators of the risk 
of stone formation. Risk indices include quotients calculated from the above urinary risk 
factors such as relative supersaturation (RS) of calcium oxalate (COM, COD and COT), 
brushite and uric acid (Werness et al. 1985, Ackermann et aJ. 1989, Brown et al. 1994). 
RS is the ratio between the activity product of the stone forming ions in urine and the 
corresponding solubility product obtained from artificial solutions. It gives an estimate of 
the driving forces favouring crystallization of common urinary salts and is readily 
computed using special software called EQUIL 1.5 (Werness et al. 1985). 
The BONN-Risk index (BRI), is based on in vitro studies of crystallization in urine (Laube 
et al. 2004, Laube et al. 2005). It combines the direct measurement of urinary free 
ionised calcium with an index of oxalate tolerance and calcium oxalate crystal formation. 
It can be calculated using the formula: 
BRI = [Ca2+] = free ionised calcium (mmo/IL) 
(ox'1-) conc (NH4hOx required to initiate spontaneous crystallization (mmo/1200 m/ urine) 
According to this formula, the risk for stone formation is low at BRI values less than 0.50, 
moderate at less than 1.00 and elevated at 2 and higher values (Laube et al. 2004). 
The Tiselius risk index expresses the biochemical risk of calcium oxalate stone formation 
(Tiselius 1982). The mathematical expression is given by 
(Ca/Cr) 0.71 X (OxlCr) 
(Mg/Cr) 0.14 X (CiVCr) 0.10 
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Where Ca, Ox, Mg, Cit (mmoV24ht) and Cr (moI124ht) are the urinary excretions of 
calcium, oxalate, magnesium, citrate and creatinine, respectively. Using the Tiselius risk 
index formula, normal values correspond to about 366±14, while a higher risk will 
correspond to a value about 527±17 (Tiselius 1982). 
1.4 Diet 
Diet plays an important role in the pathogenesis of calcium-containing kidney stones 
(Lewandowski et al. 2001, Massey 2003, Lewandowski and Rodgers 2004a, Taylor and 
Curhan 2004, Goldfarb et al. 2005, Massey et al. 2005, Siener and Hesse 2005, Taylor 
et al. 2005, Hesse and Straub 2006, Kynast-Gales and Massey 2007, Thomas et al. 
2008). While most physicians agree that dietary modifications should be encouraged 
after the development of a kidney stone, consensus on the specifics of these 
modifications, with the exception of increasing fluid intake, has been lacking (Harvey et 
al. 1985, Curhan et al. 1993, Curhan et al. 1997a, Messa et al. 1997, Lemann 2002, 
Heller et al. 2003). 
Dietary oxalate 
Since urinary oxalate concentration affects calcium oxalate relative supersaturation, any 
conditions that increase oxalate absorption from food or lead to increased oxalate 
production can cause calcium oxalate stone formation (Pak et al. 2004a, Coe et al. 
2005). 
About 85-90% of urinary oxalate comes from endogenous production in the liver, which 
is derived from three principal metabolic ways: ascorbic acid (30-50%), tryptophane 
«10%) and glyoxylate (40%). Because oxidation of glyoxylate to oxalate is an 
irreversible process, accumulated glyoxylate consequently leads to hyperoxaluria, a 
major risk factor for calcium oxalate stone formation (Balaji and Menon 1997, Danpure et 
al. 2003, Danpure et al. 2005, Vella et al. 2007). The contribution of dietary oxalate to 
urinary oxalate is much higher than previously estimated and has recently been reported 
to be in the range 24.4±15.5% to 41.5±9.1 % (Holmes et al. 2001). 
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It has been recognized for several years that the bioavailability of oxalate from different 
foods may be an important factor in determining how much oxalate is absorbed from a 
given diet (Brinkley et al. 1981). It has been shown in a rat model study that oxalate may 
be absorbed passively at all segments of the intestinal tract (Hatch and Freel 1995). In 
normal individuals, only small amounts of ingested oxalate are said to be absorbed into 
the body, with most estimates suggesting this to be 6-14%. On the other hand, stone 
formers may absorb -50% more oxalate than normal individuals (Holmes et al. 1995, 
Hesse et a/. 1999, Holmes and Assimos 2004). In addition, hyperoxaluric stone formers 
have been reported to absorb more oxalate than normo-oxaluric stone formers 
(Krishnamurthy et al. 2003). Holmes and Assimos (2004) posit that the reasons for these 
differences and their physiological, biochemical and genetic underpinnings require 
further research. 
Nevertheless, studies have shown that oxalate-rich foods (spinach, rhubarb, beetroot, 
peanuts, chocolate, parsley, strawberries, wheat bran and tea), cause a significant 
increase in urinary oxalate excretion, increasing the risk of calcium oxalate stone 
formation (Finch et al. 1981, Brinkley et al. 1990, Hesse et al. 1993, Massey et al. 1993, 
Holmes and Kennedy 2000). Therefore calcium oxalate stone patients should reduce 
their intake of such foods. 
Dietary calcium 
According to Moe (2006), the recommendation for the optimum dietary calcium intake 
has changed from the traditional wisdom of calcium restriction, to high dietary calcium 
being protective, to a position in between, although some clarification is needed. 
This may have been prompted by studies that have shown that a higher dietary calcium 
intake was associated with a reduced risk of incident stone formation (Bataille et al. 
1983, Coe et al. 1992, Curhan et al. 1993, Curhan et al. 1997 a, Messa et al. 1997, 
Lemann 2002, Heller et al. 2003). The mechanism by which dietary calcium reduces the 
risk of stone formation is unknown, but may be related to the impact on dietary oxalate 
absorption, as it has been shown that a higher calcium intake reduce dietary oxalate 
absorption in the gut, thereby lowering urinary oxalate excretion (Barilla et al. 1978, 
Hess et al. 1998, Curhan 2004). 
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Furthermore, metabolic studies in healthy people have shown that when daily dietary 
calcium intake is reduced from high (45 mmollL per day, 1800 mg) to intermediate (30 
mmol/L per day, 1200 mg), there is a small increase of oxalate absorption, whereas 
stringent reduction (5 mol/L per day, 200 mg) greatly raises the oxalate absorption. 
Therefore it is recommended that a calcium intake between 800 mg and 1200 mg per 
day should be maintained rather than restricting or exceeding its input (Jaeger et al. 
1985, Brinkley et al. 1990, Wahl and Hess 2000, Holmes et al. 2001, von Unruh et al. 
2004, Moe 2006). 
Interestingly, although a high dietary calcium intake has recently been shown to 
decrease the risk for calcium oxalate stone formation, studies on supplemental calcium 
have produced inconclusive evidence. A previous study by Curhan (1993), has also 
reported an increase in the risk of stone formation in females. This was attributed to the 
timing of ingestion of the supplement relative to meals, as it is postulated that when 
taken between meals rather than with them, supplemental calcium may increase gut 
intestinal tract calcium absorption, thereby increasing urinary calcium (Curhan et al. 
1997a, Harvey et al. 1985). 
Dietary sodium 
A high dietary sodium intake is a risk factor for stone formation, as it has been shown to 
increase urinary calcium excretion independent of calcium intake (Kok et al. 1990, 
Sakhaee et al. 1993, Pak 2004b). This is probably due to the inhibition of sodium and 
calcium reabsorption in the proximal tubule and along the loop of Henle (Muldowney et 
al. 1982, Curhan 2004). 
The major effect of dietary sodium restriction is to reduce urinary calcium, although it has 
additional effects, such as raising urinary citrate and reducing sodium urate saturation, 
all of which can reduce calcium oxalate precipitation. Moreover, reducing dietary salt 
intake has a positive effect on both urinary calcium excretion and bone turnover, the 
latter aspect assuming clinical relevance in recurrent idiopathic calcium nephrolithiasis 
and postmenopausal women (Devine et a/. 1995, Ferrari et al. 2007). 
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On the other hand, it has been shown that combined dietary protein with salt restriction 
is effective in reducing stone recurrence (Borghi et al. 2002). However, observational 
studies with high sodium intake have found an increased risk of stone formation in 
women but not in men (Curhan et al. 1993, Curhan et al. 1997a, Curhan et al. 2004). It is 
postulated that the differences may be due to true differences in the risk factors or an 
incomplete assessment of sodium intake. Nonetheless, the findings in men have been 
supported in a recent study, which showed that sodium salts such as sodium citrate and 
sodium bicarcabonate have no significant effect on urinary calcium in white South 
African males (Allie-Hamdulay and Rodgers 2005). 
Dietary animal protein 
Data from epidemiological studies provide evidence for a strong correlation between 
consumption of animal protein and the incidence of stone disease (Robertson et al. 
1979, Yoshida and Okada 1990, Curhan et al. 1993, Hesse et al. 2003, Siener 2006). 
Animal protein intake may increase the risk of stone formation as a result of increased 
excretion of calcium and uric acid and a decreased excretion of citrate (Robertson et al. 
1979, Breslau et al. 1995, Curhan 2004). These findings have been supported by 
studies that have reported similar observations after a high purine intake (Brockis et al. 
1982, Fellstr6m et al. 1984, Nguyen et al. 2001, Reddy et al. 2002). It has been 
suggested that this may occur through an increased endogenous acid production with 
consequent metabolic acidosis, which may elicit buffering from bone, increasing calcium 
reabsorption (Brockis et al. 1982, Ferrari et al. 2007). Moreover, a high protein intake 
seems to affect the glomerular filtration rate by decreasing distal tubular cell calcium 
reabsorption. This mechanism may even be amplified in hypercalciuric patients 
(Schuette et al. 1981, Brandle et al. 1995). 
18 Chapter One General Introduction 
1.5 Genetics and urolithiasis 
Kidney stones develop more frequently in individuals with a family history of stone 
formation than in those without. However, little information is available regarding whether 
the increased risk is attributable to genetic factors, environmental exposures or some 
combination thereof (Curhan et a/. 1997b). The first clues that idiopathic nephrolithiasis 
might have a large genetic component were reported in 1894 when familial aggregations 
of urinary calculi were recorded (Griffin et al. 2004). 
A number of studies (Coe et aJ. 1979, Marya et al. 1981, Goodman et aJ. 1995, Jaeger 
1996, Goodman et al. 1997, Saborio and Scheinman 1998, Baggio 1999, Thomas and 
Stapleton 2000, Milosevic et al. 2002, Goldfarb et aJ. 2005, van Woerden et aJ. 2006, 
Gambaro and Abaterusso 2007) have focussed their investigations on the genetic 
aspects of kidney stone disease. It is very clear from these studies that a comparison of 
risks attributed to dietary factors and those attributed to genetic factors, indicates that 
the genetic risks exceed the risks associated with dietary factors. For example, the latter 
study by Gambaro and Abaterusso (2007) has observed that, genetic background 
accounts for 56% of the risk of stone formation. Indeed, this is larger than a combination 
of both dietary and environmental influences. It is probable that there is considerable 
genetic heterogeneity in renal stone disease. 
Although an environmental effect cannot be excluded fully, findings in a study by Mente 
and co-workers (2006) have suggested that the disturbance in calcium metabolism in 
hypertension and kidney stone disease has a genetic basis. Another independent study 
has also shown that half of the variance of calciuria is due to genetic factors (Bianchi et 
a/. 1988). This conclusion has been recently confirmed in families studied for 
nephrolithiasis (Loredo-Osti et al. 2005). In the context of the present thesis, a study 
investigating the influence of a genetic aspect (frequency of a/anine:glyoxylate 
aminotransferase Proline11 Leucine polymorphism) on the risk of kidney stone formation 
in black and white South African subjects will be described in much more detail in 
Chapter 2 of this thesis. 
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1.6 Gut permeability and oxalate handling 
Gut permeability describes a situation where the lining of the gut mucosa is damaged 
allowing toxic materials (undigested foods, bacteria, toxins, parasites, etc.) to pass into 
the body that would normally be eliminated. It is well recognized that the primary function 
of the gut mucosa is the digestion and absorption of nutrients, in addition to exhibiting a 
barrier function and to facilitate active transport (through the cell themselves) or 
paracellular pathway (through 'tight junctions' between the cells) (Allison et al. 1986, 0' 
Boyle et al. 1998, Robertson 1999). According to Verdu and Collins (2004) infection, 
drugs, certain foods and psychological stress can cause the paracellular pathway to 
become more permeable or leaky, thus resulting in the so called 'leaky gut syndrome'. 
One of the most commonly used non-invasive, highly sensitive tests for screening of 
diseases that affect gut permeability is the 'Lactulose-mannitol absorption tesr (Judy et 
al. 1989, Andre et al. 1991, Laudat et al. 1994, Paroni et al. 2006). A full description of 
this test including the relevance of abnormal gut permeability to renal stone formation is 
described in detail in Chapter 3 of this thesis. 
1.7 Supplemental vitamin E 
As stated earlier, it is well known that hyperoxaluria is a major risk factor for calcium 
oxalate urolithiasis and that stone formation is augmented and promoted when 
combined with cellular degradation products derived from renal tubular injury 
(Thamilsevan et al. 2003). This injury may be due to the production of free radicals in 
patients with calcium oxalate stones. The latter can be caused by several mechanisms, 
one of which is lipid peroxidation (LPO), a process in which tissue is damaged by 
superoxide, hydroxyl radicals or hydrogen peroxide. Exposure of renal cells to oxalate 
itself can induce peroxidative injury. However cells are endowed with several antioxidant 
systems including ascorbic acid, vitamin E and thiols which provide protection against 
oxidative damage (Scheid et al. 1996, Thamilselvan et at. 2000, Thamilselvan et al. 
2003).lt has been suggested in the latter study that antioxidant administration may 
prevent oxalate-mediated peroxide injury and hence may prevent calcium oxalate 
nucleation and retention in the renal tubules. A study of the effects of vitamin E ingestion 
on kidney stone risk factors as well as a full description of the relevance of lipid 
peroxidation to renal stone formation will be given in detail in Chapter 4 of this thesis. 
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1.8 Supplemental fish oil (omega 3) 
It has been well documented that ingestion of omega 3 (n-3) polyunsaturated fatty acids 
(PUFA) has positive effects on human health, especially the very long chain (n-3) 
molecules, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (Kris-
Etherton et at. 2002, Din et at. 2004, Schram et a/. 2007). Several cohort, dietary 
intervention and case control studies have shown that fish and n-3 PUFAs confer 
significant health benefits (Kromhout et at. 1985, Burr et at. 1989, Dolecek et a/. 1991, 
de Lorgeril et at. 1994, Siscovick et at. 1995, Daviglus et at. 1997, Albert et at. 1998, 
GISSI investigators 1999, Albert et at. 2002, Hu et at. 2002, Moore et a/. 2006). For 
example, the low incidence of cardiovascular disease, kidney stone disease and other 
degenerative diseases including atherosclerosis in the inhabitants of Greenland has 
been attributed to their high consumption of oily fish with its high concentration of EPA 
(Dyerberg 1981, Dyerberg and Bang 1982, Buck et at. 1991, Yasui et at. 2001). 
It has been proposed that greater intake of n-3 fatty acids such as EPA and DHA 
(through dietary sources or fish oil supplementation) may reduce the risk of kidney stone 
formation (Buck et at. 1991, Yasui et a/. 2001, Naya et at. 2002, Taylor et at. 2005). 
Indeed, stUdies by Gambaro and co-workers (1995, 1997,2000) have shown that dietary 
manipulation by long chain polyunsaturated fatty acids play an important role in the 
pathogenesis of calcium nephrolithiasis by inter alia reducing urinary parameters 
(notably calcium and oxalate). In fact, clinical and experimental investigations have 
underlined the important role of fatty acids in the control of hypercalciuria, a well-known 
risk factor for lithogenesis (Rothwell et at. 1993, Baggio et a/. 1996, Baggio and 
Budakovic 2005). Many treatment modalities in clinical practice are directed towards 
reducing urinary calcium excretion and dietary modifications with long chain n-3 fatty 
acids might be a useful adjunct in the treatment of idiopathic hypercalciuric urolithiasis 
(Tulloch et at. 1994). 
A study investigating the effects of fish oil (n-3) on urinary calcium, oxalate and other 
kidney stone risk factors will be described in Chapter 5 of this thesis. 
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1.9 Fish oil and concomitant vitamin E requirement 
Concurrent with the aforementioned proposed beneficial effects of fish consumption, 
several workers have cautioned that potential side effects are increased oxidative stress 
in vivo, as shown by studies that have reported increased lipid peroxidation observed 
following consumption of fish or fish oil (Yamamoto et at. 1985, Bartoli et at. 1988, 
Meydani et at. 1991, Wander et at. 1996, Wood et at. 2003). 
It is well recognized that the major fat soluble antioxidant responsible for preventing 
oxidative damage to PUFA in membranes is vitamin E (Vatassery 1994, Turley et at. 
1998, Wood et at. 2003). A study investigating the effects of n-3 fish oil ingestion on its 
own and in tandem with vitamin E in South Africa's relatively stone-free and stone prone 
groups will be fully described in Chapter 5 of this thesis. 
1.10 Urolithiasis in South Africa 
As stated eartier, in South Africa, the incidence of urolithiasis in the black population is 
extremely rare «1%) while in the white population it occurs to the same extent as in 
many western societies (-15%) (Muskat 1951, Wise and Kark 1961, Modlin 1967, 
Whalley et at. 1998, Whalley et at. 1999). Although the explanation for stone rarity in the 
black group is not apparent at this time, several studies have addressed this intriguing 
phenomenon during the past 40 years. 
In 1967, Modlin suggested that it is reasonable to assume that the answer to this 
problem may be found in the differences between the compositions of urine in the black 
and white groups (Modlin 1967). However, those studies pursued in this regard have 
reported unexpected and perplexing results. 
Urinary calcium and phosphate excretions have been found to be Significantly lower in 
black subjects than in whites, but these values all lie within the normal range (Muskat et 
at. 1951, Modlin 1967, Whalley et at. 1998, Lewandowski et at. 2001, Rodgers and 
Lewandowski 2002). Thus, although the relatively lower excretion of these two 
parameters might explain a relatively lower incidence of stones in the black group, it 
cannot account for its near absence. 
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More intriguing are the results which have been reported for urinary oxalate, citrate and 
pH. Some studies have shown that there is no difference in oxalate excretion between 
the groups (Whalley et al. 1998, Lewandowski et al. 2001, Rodgers and Lewandowski 
2002) which is surprising, given that this parameter is a critical determinant of calcium 
oxalate stone formation. Even more surprising is that one study involving a small group 
of subjects found higher urinary oxalate levels in black subjects (Lewandowski and 
Rodgers 2004a). Urinary citrate has been found to be lower in blacks (Modlin 1967, 
Whalley et al. 1998, Lewandowski et al. 2001). This too is surprising because this would 
suggest an increased predisposition towards stone formation. The same inference can 
be drawn about urinary pH which has been found to be lower in blacks (Modlin 1967, 
Lewandowski et al. 2001, Rodgers et al. 2005). Thus, urine composition values have 
proven to be counter-intuitive and are unable to adequately account for the difference in 
stone incidence in the two population groups. 
Some authors believe that dietary differences can account for the difference in stone 
incidence between the two race groups (Wise and Kark 1961, Modlin 1967). Black South 
Africans have been reported to ingest significantly greater quantities of sodium in the 
form of seasoning or table salt than their white counterparts (Modlin 1967, Whalley et al. 
1998). Modlin has attributed the low stone incidence in blacks to their relatively higher 
urinary ratio of sodium/calcium, which might playa protective role against urolithiasis in 
this group. In addition, hyperoxalurogenic eating habits (high dietary intake of oxalate, 
low intake of calcium, and a low intake of magnesium) have been reported among the 
black population (Viljoen and Gericke 2001). Despite this, studies have shown that 
urinary oxalate in this group is unaffected and lies within the normal range (Whalley et al. 
1998, Rodgers and Lewandowski 2002, Lewandowski and Rodgers 2004a, 
Lewandowski and Rodgers 2004b, Lewandowski et al. 2005). There are difficulties in 
reliably measuring urinary oxalate, plasma oxalate and food oxalate (Holmes and 
Assimos 2004), which may in part explain the differences in the presented data that 
were obtained from literature. 
Of particular interest is that studies in the Kidney Stone Research Laboratory at the 
University of Cape Town in South Africa, have found empirical evidence to suggest that 
different oxalate handling mechanisms exist in this group compared to the white 
population in which the stone incidence is comparable to the rest of the world 
(Lewandowski et al. 2001). For example, in the latter study, it was shown that when a 
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high oxalate/low calcium diet was administered to white and black subjects, the urinary 
oxalate increased in the former as expected, but remained unchanged in the latter. In 
addition, other studies in the Kidney Stone Research Laboratory have shown that black 
subjects have significantly more oxalate degrading bacteria relative to healthy and 
stone-forming white subjects and that the oxalate-degrading bacteria capability of the 
bacteria isolated from black subjects is also significantly greater than that of the other 
two groups (Lewandowski et al. 2004a, Lewandowski et al. 2004b, Lewandowski et al. 
2005). It was concluded that these results confirm that the South African black 
population is able to handle dietary oxalate in a more efficacious way than the white 
population, which might be a contributory factor to their low stone incidence. 
Intriguingly, in another study by the same authors in which the [13C21 oxalate absorption 
test was applied on a standardized diet with normal oxalate intake it was observed that 
there is no significant difference between the two race groups with regard to 
gastrointestinal oxalate absorption (Lewandowski et al. 2005). These findings have 
prompted us to evaluate the role of gut permeability as a possible key to understanding 
the different oxalate handling in black and white South African subjects and therefore 
allude to the disparity of prevalence in the black group. 
The handling of various lithogenic and anti-lithogenic dietary supplements in black and 
white subjects has also been investigated in the Kidney Stone Research Laboratory. 
Here too interesting results have been obtained. For example, in a study by 
Lewandowski and Rodgers (2004a), in which the renal response to 5 different dietary 
and supplemental challenges (high dietary calcium, calcium, vitamin 86, L-glutamine 
and L-cysteine supplements) in the two race groups was studied, it was reported that 
none of the challenges had an effect in black subjects while in white subjects, the 
calcium diet significantly increased urinary potassium (p=O.0001) and decreased the 
relative supersaturation of brushite (p=O.035), the calcium supplement significantly 
decreased the Tiselius risk index (p=O.014), vitamin B6 supplement significantly 
decreased urinary calcium (p=O.016), urinary phosphate (p=O.027) and the relative 
supersaturation of brushite (p=O.004), L-glutamine supplement significantly decreased 
relative supersaturation of calcium oxalate (p=O.01), L-cysteine supplement significantly 
decreased urinary calcium (p=O.031) and the Tiselius risk index (p=O.013). The authors 
speculated that a renal or gastrointestinal homeostatic adjustment occurs in the black 
group keeping urinary concentration of substances in balance. 
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In another approach aimed at understanding the occurrence of calcium oxalate kidney 
stones in the white population but its rarity in the black population, the role of several 
urinary proteins (urinary prothrombin fragment 1, Tamm Horsfall mucoprotein, bikunin, 
osteopontin and albumin) with regard to their inhibitory or promotory properties in the 
urines from the two race groups has also been probed (Craig et al. 2000, Craig et al. 
2001, Mabizela et al. 2004, Webber et al. 2004, Deppa et al. 2005, Rodgers et al. 2006). 
For example, in a study investigating N-linked glycans on urinary prothrombin fragment 
1, it was shown that the N-glycans from black subjects had a significantly greater 
proportion of disialylated structures than those from white subjects (Webber et al. 2004) 
while Tamm Horsfall mucoprotein, which is a known inhibitor of calcium oxalate 
crystallization, has been reported to have different molecular structures in the two 
groups, with those isolated from the black group having superior inhibitory properties 
(Craig et al. 2000, Craig et al. 2001). 
In addition, osteopontin derived from urine of black subjects has been shown to inhibit 
calcium oxalate aggregation and deposition to a greater extent and to promote 
nucleation to a lesser extent than that derived from white subjects (Deppa et al. 2005). In 
yet another study, Bikunin, a protease inhibitor inter-u-inhibitor (lui), isolated from matrix 
extract proteins was found to be in greater amounts in black subjects' matrix when 
quantitatively compared to that from white subjects (Mabizela et al. 2004), indicating that 
it may playa contributory role in the extremely low incidence of urolithiasis in the black 
population. More recently, evidence of molecular and structural differences between 
albumin isolated from urines of black and white subjects were also reported (Rodgers et 
al. 2006). The aforementioned stUdies demonstrated that these urinary proteins may be 
key role players in protecting the South African black population against stone disease. 
1.11 Objectives of this thesis 
Interrogation of the available literature on studies of the South African black and white 
kidney stone phenomenon indicates that further investigations are warranted in many 
areas. The present thesis will address some of these. 
Firstly, the absence of any genetic studies attempting to explain the differences of kidney 
stone disease incidence in South Africa's black and white population groups is notable. 
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Thus, the recent speculation by Danpure (2005) that the presence, absence or 
frequency of the alanine:glyoxylate aminotransferase Proline11 Leucine polymorphism 
might be a contributory factor in calcium oxalate kidney stone disease, provides a 
meaningful motivation for exploring whether there are differences in the frequency of this 
polymorphism in South Africa's black and white populations which might contribute 
towards explaining the difference in stone occurrence. 
Secondly, as stated earlier, urinary oxalate is the most critical determinant of calcium 
oxalate stone formation relative to other risk factors like hypercalcuria, hyperuricosuria 
and hypocitraturia. As such, it is of fundamental interest and importance to investigate 
the role of gut permeability in South Africa' s black and white groups, as a possible key 
to providing insights into the alleged different renal handling mechanisms for oxalate in 
the two race groups. 
Thirdly, the favourable results in the context of kidney stone risk factors, which have 
been reported following the ingestion of vitamin E and fish oil supplements, coupled with 
the observations of different handling by South African black and white subjects of 
supplements in general, provide the basis of the final set of objectives. 
The objectives of this thesis are therefore: 
(i) To investigate the absence, presence or frequency of the alanine:glyoxylate 
aminotransferase Pr011 Leu polymorphism in the South African black and white 
population groups with respect to calcium oxalate kidney stone disease. 
(ii) To investigate the role of gut permeability as a possible key to providing insights into 
the alleged renal handling mechanisms for oxalate in the two race groups. 
(iii) To investigate the effects of supplemental vitamin E ingestion on kidney stone risk 
factors in the two race groups. 
(iv) To investigate the effects of supplemental omega 3 fish oil ingestion on kidney stone 
risk factors in the two race groups. 
(v) To investigate the additive effects of the simultaneous ingestion of vitamin E and 
omega 3 fish oil supplements on kidney stone risk factors in the two race groups. 
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2.1 Introduction 
As described in the previous chapter, the incidence of urolithiasis in South Africa differs 
between different populations with urolithiasis being extremely rare in the black or 
indigenous populations «1%) and more prevalent (-15%) in populations of European 
descent. The reasons for this anomaly are unknown in spite of many previous 
physicochemical and biochemical investigations (Muskat 1951, Wise and Kark 1961, 
Modlin 1967, Whalley et at. 1998, Whalley et a/. 1999). 
It is well recognized that calcium oxalate stone formation is influenced by the patient's 
genetic make-up (Goodman et a/. 1995, Baggio 1999, Shah et at. 2005, Watts 2005, 
Wolf et at. 2005, Mittal et at. 2006, Gambaro and Abaterusso 2007). Although calcium 
oxalate nephrolithiasis is considered as being a polygenic disease (Curhan et at. 1997, 
Holmes et at. 1998), any genes influencing the excretion of urinary calcium, oxalate and 
citrate must be considered prime candidates for screening as genetic components in its 
pathogenesis (Goodman et at. 1995, Baggio 1999). 
More than 50 mutations have been identified in the AGXT gene, half of which are point 
missense mutations. Many of these are predicted to decrease the stability of 
alanine:glyoxylate aminotransferase (AGT) , a pyridoxal-phosphate dependent enzyme 
that metabolizes glyoxylate by converting it into glycine (Dan pure 2005, Danpure 2006). 
Moreover, mutations of the AGXT gene lead to deficient hepatic AGT activity which 
causes primary hyperoxaluria 1 (PH1) (Langman 2004, Yuen et at. 2004). Although it 
has long been recognized that hyperoxaluria plays an important aetiological role in 
nephrolithiasis, until recently little consideration has been given to the possibility of a 
common genetic defect being responsible (Griffin 2004). 
PH 1 is an autosomal recessive disorder that leads to recurrent calcium oxalate 
nephrolithiasis, nephrocalcinosis, progressive renal failure and systemic oxalosis 
(Milosevic et at. 2002, Coulter-Mackie et at. 2005, Watts 2005, Milliner 2006, Kemper et 
at. 2007). When AGT is deficient, glyoxylate is either oxidized to oxalate or reduced to 
glycolate, leading to hyperoxaluria and hyperglycolic aciduria, respectively, which then 
culminate in PH1 (Yuen et a/. 2004, Danpure 2006). 
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AGT is localized exclusively in the peroxisomes in healthy people, but, it is instead 
localized mainly in the mitochondria in PH1 patients. When in the mitochondria, AGT is 
unable to perform its function because glyoxylate is synthesized in the peroxisomes 
(Lumb et al. 2000). It has been hypothesized that AGT mistargeting is the combined 
effects of the Pr011 Leu polymorphism and the PH1-specific G170R mutations (Purdue 
et al. 1990). The presence of this polymorphism alone reduces the specific activity of 
AGT by up to 75% and it has at least 3 significant effects (Oanpure et al. 2003). Firstly, it 
reduces the specific catalytic activity of purified recombinant AGT by a factor of three. 
Secondly, it redirects a small proportion (-5%) of AGT from the peroxisomes to 
mitochondria. Thirdly, it sensitises AGT and the untoward effects of many of the most 
common mutations found in PH1. 
Buoyed by the speculation that the presence, absence or frequency of the 
alanine:glyoxylate aminotransferase (AGT) Pr011 Leu polymorphism might be a 
contributory factor in an individual's susceptibility to idiopathic calcium oxalate kidney 
stones (Oanpure 2005), this thesis investigates whether there are differences in the 
frequency of this polymorphism in South Africa's black and white populations which 
might be a contributory factor in explaining their difference in stone occurrence. 
2.2 Subjects and methods 
Study population 
Fourty healthy South African male subjects (20 whites and 20 blacks) were recruited for 
the study. The white subjects were recruited from the student cohort of the University of 
Cape Town via advertisement on the university notice boards. The black subjects 
comprised two experimental groups: 10 'semi-urban' black subjects were recruited from 
the University of Cape Town student cohort in the same way as white subjects while 10 
'rural subjects were recruited from 'Khayelitsha Township' near the city of Cape Town 
via referrals by volunteers familiar with the area. 
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Inclusion criteria 
Healthy black and white South African male subjects (age 18-30 years) were allowed to 
participate in this study. Black subjects were recruited from the same ethnic group 
'Xhosa'. 
Exclusion criteria 
Subjects were excluded if: 
• they or their first-degree relatives had a history of urolithiasis or any renal 
disorder 
• they had chronic digestive disease and/or gut disease 
• they were taking any supplements and/or minerals 
Questionnaire for subjects 
Each subject was required to complete a questionnaire assessing their diet, medical 
history, medications, lifestyle and other practices of interest as well as history of kidney 
stone disease (appendix COIChapter2/questionnaire). In addition, a 24-hour dietary food 
record (appendix COIChapter2/24hr dietary food record) was also completed on the day 
of blood and spot urine collection and analysed using the Foodfinder 2 software package 
(Langen hoven et al. 1991). 
Blood sample collection 
Five ml of venous blood was collected into EDTA-tubes and was assigned an 
unambiguous unique identity number. One ml blood sample was aliquoted into a clearly 
labelled 1.5 mL eppendorf tube and stored at -20 ·C until analysis. The remainder of the 
sample was stored at -80 ·C. Blood samples were used for isolating DNA, which was 
typed for Pr011 Leu polymorphism. 
51 Chapter Two Genetics & urolithiasis 
Detection of Pr011Leu polymorphism 
The Pr011 Leu polymorphism was detected by a PCR-RFLP (Polymerase chain reaction 
- restriction fragment length polymorphism) method (Caldwell et al. 2004). 
DNA was extracted from 1 00 J..I I whole venous blood using a DNeasy® Blood and Tissue 
Kit (QIAGEN, Hilden, Germany). DNA concentrations were estimated for all samples 
using a NanoDrop 1M 1000 Spectrophotometer (Thermo Scientific, Cheshire, United 
Kingdom). DNA samples were individually amplified by polymerase chain reaction (PCR) 
using a GeneAmp® 2700 thermocycler (Applied Biosystems, California, USA). PCR 
amplification was performed in thin-walled 0.2ml PCR tubes containing the following 
reagents in a 20 J..I I reaction volume: 10 to 50 ng genomic DNA, 0.25 units of Super-
Therm DNA polymerase (Hoffman-La-Roche, New Jersey, USA), 1 x reaction buffer 
(final concentration: 20 mM Tris-HCI pH 8.0, 100 mM NaCI, 0.1 mM EDTA, 1 mM DTT, 
50% glycerol and stabilisers), 0.4 J..IM of primers MIT 2 (5'-
GCACAGAT AAGCTTCAGGGA-3') and EX-2R (5'-CTTGAAGGA TGGATCCAGGG-3'), 
1 mM MgCI2 and 0.2 mM dNTPs. 
The PCR cycling parameters consisted of one denaturing step at 95°C for 3 minutes, 
followed by 35 cycles of 94°C for 1 minute, 60°C for 1 minute, 72°C for 1 minute, and a 
final incubation step of 72°C for 10 minutes. For all samples, 15J..11 of the PCR product 
was digested overnight at 3rC using 10 units of Ec01301 restriction enzyme (Styl; 
Fermentas, Helsingborg, Sweden) in 10x Buffer orange (Fermentas, Helsingborg, 
Sweden). Restriction enzyme digest products were electrophoresed on a 2% agarose 
gel and visualised with ethidium bromide, and the product size estimated according to a 
BenchTop 100bp DNA Ladder (Promega, Southampton Hampshire, United Kingdom). 
Spot urine col/ection and treatment 
Subjects also provided a sample of a freshly voided morning spot urine on the day the 
blood sample was drawn. These were tested for haematuria and nitrite using urinalysis 
test strips (Medi Test Combi 5N, Macherey-Nagel; Duren). All urines tested negative. 
Urine pH (PH 211 microprocessor pH meter, Hanna Instruments, Cape Town, South 
Africa) and volume were routinely measured. Urine aliquots were filtered through a 0.74 
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IJm filter to remove cellular debris and proteinaceous material. The samples were then 
analysed for calcium, potassium, magnesium and sodium (Trudeau and Freier 1967, 
Willis et al. 1967, Fernandez et al. 1971) using a Varian 1275 Model flame atomic 
absorption spectrometer. Oxalate was determined using oxalate decarboxylase 
(Chiriboga et al. 1963), while citrate was determined by conversion to oxaloacetate using 
citrate lyase (Gruber and Moellering 1966). Inorganic phosphorus was determined using 
ammonium molybdate (Dryer and Routh 1963), creatinine using picric acid (Rock et a/. 
1986) and uric acid using uricase (Fossati et al. 1980). 
Statistical analysis 
Data were analysed statistically using one-way analysis of variance (ANOVA), Pearson's 
chi-squared risk test method, and the student's t-test. Data were considered significant if 
p s 0.05. 
2.3 Results 
Pr011Leu polymorphism 
DNA concentration of the samples ranged between 2.4-22.8 ng/lJl (appendix 
CD/Chapter/ DNA concentrations. The genotypes of each individual and genotype 
frequencies are shown in tables 2.1 to 2.4. Comparisons for the frequency distribution of 
the AGXT gene alleles for . rurar blacks, . semi-urban' blacks, combined blacks (both 
'rural and semi-urban) and white subjects are given in table 2.5. 
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Table 2.1 Distribution of the AGXT gene alleles in healthy 'rural' black subjects 
Subjects Bands Sizes of bands Alleles· 
GRB01 1 512 C C 
GRB02 1 512 C C 
GRB03 1 512 C C 
GRB04 1 512 C C 
GRB05 1 512 C C 
GRB06 1 512 C C 
GRB07 2 512 619 C T 
GRB08 1 512 C C 
GRB09 1 512 C C 
GRB10 2 512 619 C T 
Table 2.2 Distribution of the AGXT gene alleles in healthy 'semi-urban' blacks 
Subjects 
Bands Sizes of bands Alleles· 
GSB01 1 512 C C 
GSB02 1 512 C C 
GSB03 1 512 C C 
GSB04 1 512 C C 
GSB05 1 512 C C 
GSB06 2 512 619 C T 
GSB07 2 512 619 C T 
GSB08 2 512 619 C T 
GSB09 1 512 C C 
GSB10 1 512 C C 
, , 
* Note: Allele C corresponds to the AGXT major allele encoding Pr011 and allele 'T' 
corresponds to the AGXT minor allele encoding Leu11. 
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There were no notable differences in the AGXT gene allelic distribution between 'rural' 
black subjects and 'semi-urban' black subjects. Therefore data from the two black 
groups (table 2.1 and 2.2) were combined (table 2.3) for comparison with their white 
compatriots (table 2.4) and the results of the comparisons of the frequency distribution of 
the major and minor alleles of the AGXT gene in the two race groups are given in table 
2.5. 
Table 2.3 Distribution of the major and minor alleles of the AGXT gene in healthy combined black 
subjects (both 'rural' and 'semi-urban'subjects) 
Subjects Bands Sizes of bands Alleles 
GRB01 1 512 C C 
GRB02 1 512 C C 
GRB03 1 512 C C 
GRB04 1 512 C C 
GRB05 1 512 C C 
GRB06 1 512 C C 
GRB07 2 512 619 C T 
GRB08 1 512 C C 
GRB09 1 512 C C 
GRB10 2 512 619 C T 
GSB01 1 512 C C 
GSB02 1 512 C C 
GSB03 1 512 C C 
GSB04 1 512 C C 
GSB05 1 512 C C 
GSB06 2 512 619 C T 
GSB07 2 512 619 C T 
GSB08 2 512 619 C T 
GSB09 1 512 C C 
GSB10 1 512 C C 
* Note: Allele 'C' corresponds to the AGXT major allele encoding Pro11 and allele 'T 
corresponds to the AGXT minor allele encoding Leu11. 
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Table 2.4 Distribution of the major and minor alleles of the AGXT gene in healthy white 
subjects 
Sample Bands Size of Bands Alleles· 
GSW01 1 512 C C 
GSW02 1 512 C C 
GSW03 2 512 619 C T 
GSW04 1 512 C C 
GSW05 1 512 C C 
GSW06 2 512 619 C T 
GSW07 1 512 C C 
GSW08 1 512 C C 
GSW09 1 512 C C 
GSW10 1 512 C C 
GSW11 2 512 619 C T 
GSW12 1 512 C C 
GSW13 1 512 C C 
GSW14 1 512 C C 
GSW15 1 512 C C 
GSW16 1 512 C C 
GSW17 1 512 C C 
GSW18 2 512 619 C T 
GSW19 2 512 619 C T 
GSW20 1 512 C C 
Table 2.5 Frequency distribution of the major and minor alleles of AGXT gene in healthy 
black and white subjects 
Genotypes 
Subjects Frequency CC Frequency CT 
'Rural' blacks 0.80 0.20 
'Semi-urban' blacks 0.70 0.30 
Combined blacks 0.75 0.25 
Whites 0.75 0.25 
* Note: Allele 'C' corresponds to the AGXT major allele encoding Pr011 and allele 'T' 
corresponds to the AGXT minor allele encoding Leu11. 
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Comment 
As shown in table 2.5. the frequency distribution of the AGXT gene allelic variants was 
80% for the major allele 'C' and 20% for the minor allele T in 'rural' black subjects while 
for 'semi-urban' black subjects it was 70% and 30% for the major and minor alleles, 
respectively. When black subjects were treated as one group, the frequency of the 
alanine:glyoxylate aminotransferase (AGT) Pro11 Leu polymorphism in the black and 
white subjects was the same given the small sample sizes. The association of variables 
(such as daily caloric intake and urinary parameters) with the presence or absence of 
this polymorphism was statistically investigated for all subjects irrespective of race 
group. 
Dietary analysis 
Comparison of the mean nutrient intakes derived from the dietary records from 'rural' 
black subjects (n=10), 'semi-urban' black subjects (n=10) and white subjects (n=20) as 
well as those of the combined black subjects (n=20) are given in table 2.6 while the 
summary is given in table 2.7. The association of daily caloric intake with the distribution 
of genotypes ICC' and 'CT' of the AGXT gene encoding the Pro11 Leu polymorphism is 
given in table 2.8. The raw data are presented in appendix CD/Chapter 2/Dietary 
analysis. 
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Table 2.6 Comparisons of the mean dietary intakes (SE) of black (,rural', 'semi-urban' and 
combined) and white subjects 
:: 
'rural' 'semi- Combined Statistical comparisons (p-va/ues) 
itutnents blacks urban' blacks Whites 
RBvs RBvsW SBvsW (RB+SB) 
~ (RB) blacks (RB+SB) (W) SB vsW 
I}: (SB) 
8MI (kg/m2) 24.19(0.58) 24.64(0.58) 24.14(0.37) 24.68(0.36) 0.5885 0.4342 0.9574 0.6227 
Energy (kJ) 10485 11479 10983 14910 0.6088 0.0059* 0.0285* 0.0030* 
(1350) (1349) (935) (808) 
Moisture 1262 1613 1437 3301 0.2471 <0.0001* <0.0001* <0.0001* 
(g/day) (197) (500) (148) (200) 
Total Protein 87.3 88.6 88.0 123.7 0.9229 0.0037* 0.0028* 0.0003* 
(g/day) (10.13) (8.21) (6.35) (6.35) 
Total Fat 60.5 93.3 76.9 131.9 0.0880 <0.0001* 0.0072* <0.0001* 
(g/day) (14.27) (11.22) (9.60) (7.57) 
Carbohydrate 369 339 354 370 0.6690 0.9762 0.5528 0.7103 
(g/day) (49.36) (46.32) (33.12) (28.32) 
Fibre (g/day) 29.9(3.86) 30.6(3.44) 30.3(2.52) 29.9(2.45) 0.0741 0.9847 0.8633 0.9076 
Total Sugar 53.6 26.8 40.2 69.7 0.9014 0.1809 <0.0001* 0.0024* 
(g/day) (13.36) (4.61 ) (7.53) (5.02) 
Oxalate(mg) 0.8(0.36) 317(46.30) 158(42.56) 152(15.30) <0.0001* <0.0001* 0.0002* 0.8856 
Ca (mg/day) 421.6(65) 644.9(96) 533.3(62) 1142.7(65) 0.0690 <0.0001* <0.0001* <0.0001* 
Mg (mg/day) 406(46) 396(35) 401(28) 503(25.59) 0.8652 0.0568 0.0222* 0.0114* 
Phosphate 1326 1407 1366 2133 0.7135 0.0015* 0.0027* <0.0001* 
(mg/day) (168) (139) (107) (138) 
K(mg/day) 2470(540) 2864(378) 2667(324) 4321 (278) 0.5577 0.0021* 0.0048* <0.0001* 
Na (mg/day) 2286(362) 3399(4538) 2793(318) 4302(264) 0.0710 0.0001* 0.0763 <0.0001* 
Vitamin A 335 1284 809 1418 0.0002* <0.0001* 0.5232 0.0043* 
(REI day) (174) (98) (146) (137) 
Vitamin 86 1.56 2.31 1.94 3.06 0.1014 0.0017* 0.0860 0.0024* 
(mg) (0.32) (0.29) (0.22) (0.26) 
Vitamin C(mg) 70(36) 86(24) 78(21) 108(11 ) 0.7127 0.1948 0.3318 0.2027 
Vitamin D pg) 7.62(2.66) 4.31(0.87) 5.97(1.41) 5.07(0.58) 0.2515 0.2178 0.4603 0.5622 
Vitamin E(mg) 12.13(2.43) 11.38(1.09) 11.75(1.23) 11.40(1.26) 0.8298 0.7405 0.9871 0.8397 
. . 
(*Slgniflcance at p~O.05) . 
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Comment 
Consideration of the results in table 2.6 and the summary thereof in table 2.7 shows that 
for most of the nutrients (labelled *) there is no difference between the RB and SB 
groups but that in all cases, they are Significantly lower than in the W group. Other 
nutrients (labelled rf) show subsets of the aforementioned trends with black subjects 
again having lower values. Oxalate is somewhat unique with SB surprisingly having the 
highest value. These trends will be fully interpreted in the discussion section of this 
chapter. Since in most cases there were no differences between RB and SB, 
consolidation of these groups into one is feasible. Statistical comparisons between 
combined blacks (RB+SB) and whites showed that in all of the * and ~ nutrients, these 
nutrients were significantly lower for the combined blacks group than in W group. This 
trend will also be fully interpreted in the discussion section of this chapter. 
Table 2.7 Summary of comparisons of mean dietary intakes of black ('rural', 'semi-urban' 
and combined) and white subjects 
Nutrient intake Summary 
Energy .. B (combined) < W, (RB-SB)<W 
Moisture .. B (combined) < W, (RB=SB)<W 
Total Protein ., B (combined) < W, (RB=SB)<W 
Total Fat ., B (combined) < W, (RB=SB)<W 
Carbohydrate No differences 
Fibre No differences 
Total Sugar $ B (combined) <W, SB<W 
Oxalate B (combined) =W, RB<W<SB 
Calcium ., B (combined) <W, RB<SB<W 
Magnesium ., B (combined) <W, (RB=SB)<W 
Phosphate .. B (combined) <W, (RB=SB)<W 
Potassium .. B (combined) <W, (RB=SB)<W 
Sodium .. B (combined) <W, (RB=SB)<W 
Vitamin A$ B (combined) <W, RB«SB-W) 
Vitamin B6 $ B (combined) <W, RB=SB, RB<W 
Vitamin C No differences 
Vitamin D No differences 
Vitamin E No differences 
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Table 2.8 The associations of daily caloric intake with the distribution of genotypes 'CC' 
and 'CT' of the AGXT gene encoding the Pro11 Leu polymorphism 
Genotype 
Nutrient intake CC CT P-values 
(Average) (Average) 
Energy (kJ) 13010.83 12752.80 0.8731 
Moisture (g/day) 2461.00 2096.86 0.4221 
Total Protein (g/day) 105.25 107.51 0.8731 
Total Fat (g/day) 107.38 95.43 0.4868 
Carbohydrate (g/day) 378.89 311.90 0.0830 
Fibre (g/day) 29.39 32.02 0.5222 
Total Sugar (g/day) 55.31 53.83 0.9008 
Oxalate (mg/day) 156.80 149.30 0.8866 
Calcium (mg/day) 804.31 938.90 0.3838 
Magnesium (mg/day) 453.20 447.40 0.9044 
Phosphate (mg/day) 1695.87 1911.30 0.3843 
Potassium (mg/day) 3456.17 3607.80 0.7959 
Sodium (mg/day) 3764.40 2896.60 0.1135 
Vitamin A (RElday) 1118.53 1097.80 0.9363 
Vitamin 86 (mg/day) 2.60 2.18 0.3482 
Vitamin C (mg/day) 93.17 92.90 0.9924 
Vitamin D (j.Jg/day) 5.21 6.44 0.4910 
Vitamin E (mg/day) 11.58 11.57 0.9985 
Comment 
There was no significant association between daily nutrient intakes and the presence or 
absence of the Pr011 Leu polymorphism as shown in table 2.8. 
Urinary analysis 
Comparison of urine data from the freshly voided morning urine samples of black and 
white subjects is given in table 2.9 while the summary is given in table 2.10. The 
association of urinary composition of spot morning urine sample with the distribution of 
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genotypes 'CC' and 'CT' of the AGXT gene encoding the Pro11 Leu polymorphism is 
given in table 2.11. The spot urine composition data are standardized and expressed per 
mg creatinine (e.g. mg calcium/mg creatinine) as the values were not obtained from 24hr 
urine samples (llich et al. 2009). The raw data from each subject are presented in 
appendix CD/Chapter 21urinary analysis. 
Table 2.9 Comparisons of mean spot urine parameters (SE) from urines of black ('rural', 'semi-
urban' and combined) and white subjects 
'rural' ' .. mi- Combined Whites Statistical comparisons (p-va/ue.s) 
Parameter blacks urban' blacks (W) 
(RB+SB) RBvsSB RBvsW SBvsW (RB+SB) (RB) blacks 
vsW 
(SB) 
pH 5.745 5.703 5.724 5.732 0.8554 0.9225 0.8582 0.9479 
(0.122) (0.192) (0.111) (0.067) 
Volume (ml) 231.80 290.50 261.15 260.50 0.3292 0.6375 0.6061 0.9889 
(45.22) (30.17) (29.27) (36.03) 
Citrate 0.2985 0.3198 0.3073 0.1634 0.8977 0.1276 0.1588 0.1136 
(mg/mg creatinine) (0.12) (0.12) (0.06) (0.06) 
Oxalate 0.0086 0.0105 0.0095 0.0116 0.5870 0.5740 0.8370 0.5936 
(mg/mg creatinine) (0.002) (0.002) (0.003) (0.003) 
Calcium 0.0431 0.0650 0.0537 0.0412 0.5042 0.8955 0.3454 0.4945 
(mg/mg creatinine) (0.02) (0.02) (0.013) (0.008) 
Magnesium • 0.0338 0.0119 0.0227 0.0230 0.1283 0.3700 0.1590 0.9722 
(mg/mg creatinine) (0.010) (0.010) (0.006) (0.007) 
Sodium 2.368 2.0187 2.1771 0.7949 0.8030 0.0405* 0.1065 0.0566** 
(mglmg creatinine) (0.98) (0.98) (0.50) (0.42) 
Potassium 1.2399 0.3639 0.7932 0.1832 0.0107* <0.0001* 0.1116 0.0022* 
(mg/mg creatinine) (0.22) (0.22) (0.13) (0.12) 
Uric acid 0.2330 0.2263 0.2297 0.2801 0.8966 0.2773 0.3099 0.1890 
(mg/mg creatinine) (0.04) (0.04) (0.03) (0.02) 
Phosphate 1.0361 2.1023 1.5260 1.8135 0.0910 0.0355* 0.5762 0.4637 
(mg/mg creatinine) (0.42) (0.42) (0.27) (0.20) 
*Slgmficance at p~O. 05, **approachlng slgmficance 
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Table 2.10 Summary of the comparisons of mean spot urine parameters 
Parameter Summary 
pH No differences 
Volume No differences 
Citrate No differences 
Oxalate No differences 
Calcium No differences 
Magnesium No differences 
Sodium B(combined»W, (RB=SB»W 
Potassium B(combined»W, RB>SB>W 
Uric acid No differences 
Phosphate RB<W 
Comment 
Only two urinary parameters - sodium and potassium - demonstrated consistently 
significant intergroup differences between 'rural' black and combined black subjects in 
comparisons with white subjects. In all two cases, values were individually and 
collectively higher for the indicated black groups than for white subjects. However, this 
two parameters were not significantly different between 'semi-urban' black subjects and 
the white subjects. 
Table 2.11 The associations of mean spot urine parameters with the distribution of genotypes 
'CC' and 'CT' of the AGXT gene encoding the Pro11 Leu polymorphism 
Parameter Genotype (average) P-values 
CC CT 
pH 5.74 5.70 0.8088 
Volume (mn 282.10 197.00 0.1087 
Citrate (mglmg creatinine) 0.2669 0.1407 0.2329 
Oxalate (mglmg creatinine) 0.0123 0.0052 0.1122 
Calcium (mglmg creatinine) 0.0534 0.0296 0.2556 
Magnesium (mglmg creatinine) 0.0255 0.0149 0.2993 
Sodium (mglmg creatinine) 1.7159 0.7964 0.2798 
Potassium (mglmg creatinine) 0.5308 0.3601 0.4840 
Uric acid (mglmg creatinine) 0.2675 0.2170 0.2562 
Phosphate (mglmg creatinine) 1.8327 1.1811 0.1462 
.. 
* SIgnifIcance at p~O. 05 
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Comment 
Statistical analysis showed that there was no association between mean urinary 
composition (mg) of spot morning urine samples expressed per mg creatinine with the 
presence or absence of the Pr011 Leu polymorphism as shown in table 2.11. 
Questionnaire analysis 
As previously described, all subjects completed questionnaires in which they provided 
details of their self-defined ethnic identity and place of birth (Caldwell et al. 2004). 
Similar information was also sought about their parents. An attempt was made to extend 
the enquiry to grandparents but efforts in this regard were unsuccessful as information 
was mostly unknown, with most respondents indicating that their grandparents had 
passed away. Subjects were also asked if any of their siblings, parents or grandparents 
had ever had a kidney stone or renal disease (Curhan et al. 1997). All respondents 
reported no family history of kidney stone formation and identified themselves as South 
Africans born in the country. Relatives of subjects were not contacted. Responses to the 
questionnaire were statistically analysed for the association of selected factors with the 
frequency of AGXT gene allelic variants (genotype 'CC' and 'CT') using the Pearson's 
chi-squared test method and the student's t-test. The results are given in tables 2.12 and 
2.13 below. 
r , 
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Table 2.12 The associations of dietary habits and lifestyle with the distributions of genotypes 'CC' 
and 'CT' of the AGXT gene encoding the Pro11 Leu polymorphism 
Genotype 
Dietary habits CC(%) CT(%) p-values 
Childhood diet 
Personal 0.4494 
Vegetarian 0 0 
Mainly vegetarian but with some meat 2.5 2.5 
Mixed 47.5 12.5 
Mainly meat but with some vegetables 17.5 10 
Lots of meat 7.5 0 
Mother 0.1132 
Vegetarian 2.5 0 
Mainly vegetarian but with some meat 10 5 
Mixed 50 12.5 
Mainly meat but with some vegetables 10 7.5 
Lots of meat 2.5 0 
Father 0.6603 
Vegetarian 0 0 
Mainly vegetarian but with some meat 10 2.5 
Mixed 47.5 15 
Mainly meat but with some vegetables 12.5 7.5 
Lots of meat 5 0 
Current diet 
Personal 0.5817 
Vegetarian 0 2.5 
Mainly vegetarian but with some meat 5 0 
Mixed 37.5 7.5 
Mainly meat but with some vegetables 22.5 15 
Lots of meat 10 0 
Mother 0.7024 
Vegetarian 0 0 
Mainly vegetarian but with some meat 7.5 0 
Mixed 52.5 22.5 
Mainly meat but with some vegetables 12.5 2.5 
Lots of meat 2.5 0 
64 Chapter Two Genetics & urolithiasis 
Father 0.2487 
Vegetarian 0 0 
Mainly vegetarian but with some meat 2.5 0 
Mixed 20 12.5 
Mainly meat but with some vegetables 15 12.5 
Lots of meat 7.5 0 
Other personal dietary habits 
Salty foods 0.8219 
Not salted 10 2.5 
Lightly salted 52.5 20 
Very salted 12.5 2.5 
Salty snacks 0.5796 
No 45 12.5 
Yes 30 12.5 
Add pepper_cooking 0.5094 
No 27.5 12.5 
lightly 40 12.5 
A lot 7.5 0 
Add pepper_eating 0.7601 
No 45 17.5 
Lightly 27.5 7.5 
A lot 2.5 0 
Add sugar_tea/coffee 0.1705 
No 12.5 0 
<2 teaspoons 35 12.5 
3 teaspoons 10 10 
<5 teaspoons 17.5 2.5 
>5 teaspoons 0 0 
Add sugar-pudding 0.3492 
No 60 20 
<2 teaspoons 5 2.5 
3 teaspoons 0 2.5 
<5 teaspoons 7.5 0 
> 5 teaspoons 2.5 0 
Add sugar_cereal 0.8841 
No 20 7.5 
<2 teaspoons 27.5 10 
3 teaspoons 10 5 
<5 teaspoons 12.5 2.5 
>5 teaspoons 5 0 
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Other (affluence) 
Personal_birthplace 0.4357 
Village 22.5 2.5 
Township 7.5 2.5 
City 45 20 
Mother_birthplace 0.9036 
Village 35 10 
Township 5 2.5 
City 35 12.5 
Father_birthplace 0.5587 
Village 35 7.5 
Township 7.5 5 
City 32.5 12.5 
Mother_Job 0.5828 
Farmer 0 0 
Farm labour 0 2.5 
Shop worker 10 5 
Street Cleaner 0 0 
Office worker 10 5 
Professional (e.g doctor, teacher) 30 7.5 
Policeman 0 0 
Seasonal or occasional employment 5 0 
Housewife 7.5 5 
Self-employed 7.5 0 
Hotel worker 0 0 
Politician 0 0 
Taxi/bus driver 0 0 
Domestic worker 2.5 0 
Unemployed 2.5 0 
Retired (Indicate field) 0 0 
Other specify 0 0 
Father_Job 0.4564 
Farmer 0 2.5 
Farm labour 0 0 
Shop worker 7.5 0 
Street Cleaner 0 2.5 
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Office worker 7.5 0 
Professional (e.g doctor, teacher) 27.5 10 
Policeman 2.5 0 
Seasonal or occasional employment 0 0 
Househusband 2.5 0 
Self-employed 2.5 0 
Hotel worker 2.5 0 
Politician 2.5 0 
Taxi/bus driver 10 5 
Domestic worker 7.5 5 
Unemployed 0 0 
Retired (Indicate field) 5 0 
Other (specify) 0 0 
Exercise 0.6101 
No 12.5 5 
Yes 62.5 20 
Exercise example 
Jogging 0.3613 
No 57.5 22.5 
Yes 17.5 2.5 
Hiking 0.2965 
No 67.5 7.5 
Yes 25 0 
Tennis 0.1251 
No 67.5 17.5 
Yes 7.5 7.5 
Squash 1.1000 
No 67.5 22.5 
Yes 7.5 2.5 
Soccer 0.6733 
No 55 20 
Yes 20 5 
Gym (cardio) 0.1250 
No 67.5 17.5 
Yes 7.5 7.5 
Gym (weights) 0.6360 
No 75 22.5 
Yes 0 2.5 
Gym (both) 0.4076 
No 67.5 20 
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Yes 7.5 5 
Rugby 0.1492 
No 72.5 17.5 
Yes 2.5 7.5 
Golf 0.0794 
No 60 22.5 
Yes 17.5 0 
Other 0.5321 
No 60 22.5 
Yes 17.5 0 
Level exercise activity 0.7076 
Not at all 5 2.5 
Some, but < average 17.5 5 
Average 17.5 10 
Fairly active, > average 12.5 5 
Very active 22.5 2.5 
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Table 2.13 The associations of food and beverage intakes with the distributions of genotypes 
'CC' and 'CT' of the AGXT gene encoding the Pro11 Leu polymorphism 
Food and Beverage Genotype 
intakes CC(%) CT(%) p-values 
Cereal 0.5819 
No 27.5 10 
Everyday or two 40 15 
Every few weeks 7.5 0 
Once or twice a year 0 0 
Milk 0.4295 
No 10 7.5 
Everyday or two 62.5 17.5 
Every few weeks 2.5 0 
Once or twice a year 0 0 
Yogurt 0.3084 
No 60 25 
Everyday or two 5 0 
Every few weeks 10 0 
Once or twice a year 0 0 
Chocolate 0.0044 
No 65 10 
Everyday or two 7.5 5 
Every few weeks 2.5 10 
Once or twice a year 0 0 
Cheese 0.5109 
No 32.5 15 
Everyday or two 30 5 
Every few weeks 12.5 5 
Once or twice a year 0 0 
Eggs 0.2807 
No 17.5 12.5 
Everyday or two 35 7.5 
Every few weeks 22.5 5 
Once or twice a year 0 0 
Porridge 0.7491 
No 32.5 15 
Everyday or two 25 5 
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Every few weeks 15 5 
Once or twice a year 2.5 0 
Pasta 0.9397 
No 47.5 15 
Everyday or two 22.5 7.5 
Every few weeks 5 2.5 
Once or twice a year 0 0 
Rice 0.8170 
No 20 7.5 
Everyday or two 40 12.5 
Every few weeks 15 5 
Once or twice a year 0 0 
Fruits 0.0975 
No 20 2.5 
Everyday or two 42.5 10 
Every few weeks 12.5 12.5 
Once or twice a year 0 0 
VegetableS/Salad 0.2413 
No 25 15 
Everyday or two 25 2.5 
Every few weeks 25 7.5 
Once or twice a year 0 0 
Potatoes 0.4020 
No 32.5 17.5 
Everyday or two 32.5 5 
Every few weeks 10 2.5 
Once or twice a year 0 0 
Fried Chips 0.4594 
No 47.5 12.5 
Everyday or two 5 5 
Every few weeks 22.5 7.5 
Once or twice a year 0 0 
Chicken 0.2588 
No 7.5 5 
Everyday or two 52.5 20 
Every few weeks 15 0 
Once or twice a year 0 0 
BeeflPorklMutton 0.8532 
No 10 5 
Everyday or two 37.5 12.5 
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Every few weeks 27.5 7.5 
Once or twice a year 0 0 
Fish 0.60943 
No 50 0 
Everyday or two 20 5 
Every few weeks 5 0 
Once or twice a year 0 0 
Cool drink (eg Coke) 0.0204 
No 50 5 
Everyday or two 10 12.5 
Every few weeks 15 7.5 
Once or twice a year 0 0 
Juice 0.0031 
No 30 7.5 
Everyday or two 37.5 2.5 
Every few weeks 7.5 15 
Once or twice a year 0 0 
Tea/Coffee 0.1444 
No 12.5 0 
Everyday or two 52.5 25 
Every few weeks 10 0 




No 0 2.5 
Yes 75 22.5 
Hard liquor 1.0000 
No 30 10 
Yes 45 15 
Wine 0.3558 
No 35 7.5 
Yes 40 17.5 
Homebrew 0.5119 
No 60 17.5 
Yes 15 7.5 
Fermented cider 0.3458 
No 50 12.5 
Yes 25 12.5 
• 
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Frequency alcohol 
intake 0.3996 
1-4 days per week 0 2.5 
5/more days per week 27.5 10 
1-3 days a month 7.5 0 
<once a month 25 7.5 
Amount alcohol per 
week 0.1808 
(no. units x volume) 
No (0 ml) 0 2.5 
<1000ml 17.5 7.5 
<5OOOm1 57.5 15 
> SOOOml 0 0 
Comment 
When comparing the usual patterns of food consumption, the only variables that showed 
an association with the distribution of the major AGXT allelic variants 'T' encoding the 
presence of Pr011 Leu polymorphism was dietary intake of juice (p=O.0031), cool drink 
(e.g coke) (p=O.0204) and chocolate (p=O.OO44). The association with alcohol intake 
(bee" tended towards significance (p=O.0794) while there was no association with the 
intake of other types of alcoholic beverages (p>O.05). There was no significant 
association of the frequency of this polymorphism with fish (p=O.6094) and meat intake 
in the studied group (p=O.8532 for red meat and p=O.2588 for chicken). All other food 
items investigated did not show a significant association with the polymorphism. AnalYSis 
of vitamin and supplement use is not included as the respondents were not taking any 
supplements and/or minerals. 
2.4 Discussion 
It is well recognized that nephrolithiasis is a complex, multifactorial disease resulting 
from an interaction between environmental and genetiC factors (Goodman et al. 1995, 
Baggio 1999, Watts 2005, Wolf et al. 2005, Mittal et al. 2006, Gambaro and Abaterusso 
2007). According to Baggio (1999), the lack of convincing findings on genetic factors and 
genes responsible for nephrolithiasis is due to an inadequate understanding of the 
pathogenesis of this disease. 
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Although urolithiasis is a polygenic disease, there is some evidence for a monogenic 
basis for a small number of cases of hyperoxaluria, which predisposes the patient to 
nephrolithiasis (Holmes et al. 1998, Caldwell et al. 2004, Griffin 2004, Gambaro and 
Abaterusso 2007). It is widely accepted that primary hyperoxaluria 1 is due to a 
functional defect of the liver-specific peroxisomal enzyme AGT (Oanpure 1998, Milosevic 
et al. 2002, Coulter-Mackie et al. 2003, Coulter-Mackie and Rumsby 2004, Yuen et a/. 
2004). While the liver-specific nature of AGT expression in humans precludes a 
comprehensive analysis of the relationship between the presence of the minor and major 
AGXT alleles and AGT activity in situ (Lumb et al. 2000), AGT itself has been shown to 
have a number of polymorphisms (including Pr011 Leu polymorphism), which can 
change the amino acid sequence but have no apparent pathological effect (Rumsby et 
al. 2004). 
In the present study, the potential influence of the frequency of this polymorphism in 
black and white South African subjects was examined with respect to the differences in 
stone incidence in the two groups. Firstly, the association of urinary parameters with the 
frequency of the above-mentioned polymorphism was investigated. No association was 
demonstrated. However, as stated previously this may have been due to the nature of 
the urine collections (spot) and the treabnent of the data. For example, different results 
might be anticipated according to the time of day of the spot urine is collected. In fact, a 
"fasting" spot urine might miss peaks of urinary excretion following ingestion of food. It is 
uncertain whether measurements from 24hr urine samples would have shown any 
associations with this polymorphism. However, such collections were generally not 
feasible for this study. On the other hand, according to llich and co-worXers (2009), 
although replacing burdensome 24hr urine collection with spot urine sampling might not 
provide associations in all cases, results show spot urine samples could be useful. 
The two urinary parameters (potassium and sodium) that were significantly higher in 
'rural' black (p<O.OOO1 for potassium and p=O.0405 for sodium) and combined black 
(p=O.OO22 for potassium and p=O.0566 for sodium) subjects when compared with white 
subjects are recognized risk factors for kidney stone formation. It has been reported that 
low urinary potassium excretion may potentially increase the risk because of its 
associated calciuria (Parivar et al. 1996). Thus, the higher urinary excretion of potassium 
in blacks as opposed to whites may be a contributory factor in their low incidence of 
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stone formation. In addition, it has also been reported that sodium intake of blacks is 
higher than that of whites (Modlin 1967, Whalley et al. 1998). Although this 
commensurate with high urinary sodium excretion, it seems to have no effect on urinary 
calcium excretion as it has also been reported that urinary calcium is lower in blacks 
than in whites (Modlin 1967, Whalley et al. 1998, Rodgers and Lewandowski 2002). 
Secondly, association of dietary intake with polymorphism frequency was investigated. 
According to Curhan and c~workers (1997) environmental exposures, such as diet, are 
thought to play an important role in stone formation. In support, there is a wealth of data 
suggesting that this assertion might indeed be accurate (Curhan et al. 1993, Parivar et 
at. 1996, Lewandowski et at. 2001, Goldfarb et at. 2005). Interest in dietary analysis in 
the present study arose mainly because the qualitative relationship between AGT 
distribution and diet is compelling (Birdsey et al. 2005). 
Analysis of dietary records supplied by all subjects, revealed a number of Significant 
differences in dietary intakes between 'rural' black subjects, 'semi-urban' black subjects 
and white subjects. The lower nutrients intake in blacks of nutrients which are important 
in pathogenesis of kidney stones (calcium, magnesium, phosphate, potassium, sodium, 
vitamin A and vitamin 86) have been previously reported (Muskat 1951, Wise and Kark 
1961, Modlin 1967, Whalley et al. 1998, Lewandowski et at. 2001). The low intake of 
calcium has been attributed to lactose intolerance in blacks (Viljoen and Gericke 2001) 
while low magnesium has been attributed to a low intake of vegetables (Whalley et al. 
1998, Charlton et al. 2005). 
It is noted that in the present study, blacks had lower sodium intake than whites, which 
contradicts the findings of Modlin (1967). The reasons for this anomaly are unclear. 
According to Massey and Whiting (1996), dietary assessment of salt is very inaccurate. 
However, this does not seem to diminish its importance as it has been indicated that 
dietary salt is a much stronger predictor of urinary calcium than dietary calcium and 
protein (Brutis et al. 1994). In fact, a high sodium intake leads to increased urinary 
calcium excretion independent of calcium intake due to the inhibition of sodium and 
calcium reabsorption in the proximal tubule and along the loop of Henle (Muldowney et 
al. 1982, Curhan 2004). A positive association between sodium intake and new kidney 
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stone formation has been demonstrated in women but not in men (Curhan et al. 1993, 
Curhan et al. 1997, Taylor and Curhan 2004). 
In the present study, there were no significant differences in the intake of vitamin 86 
between 'rural' blacks and 'semi-urban' blacks (p=0.1014) as well as in 'semi-urban' 
blacks and whites (p=0.0860). Statistically significant differences in the intake of this 
vitamin were observed between 'rural' blacks and whites (p=0.0017) as well as between 
combined blacks and whites (p=0.0024). There seem to be controversy with regard to 
the role of vitamin B6 intake in stone formation. According to Lewandowski and Rodgers 
(2004), its role has not been clearly defined. In support, studies have shown that 
prolonged vitamin 86 deficiency can result in an increase in urinary oxalate excretion 
leading to a potentially higher incidence of calcium oxalate stones (Faber et al. 1963, 
Tommaso et al. 2002) while in contrast, a study by Curhan and co-workers (1999) has 
reported that a high intake of vitamin B6 is inversely associated with the risk of stone 
formation. 
There were no sjgnificant differences in the intake of vitamin A between 'semi-urban' 
blacks and whites (p=0.5232). However, statistically significant differences were 
observed between 'rural' blacks and 'semi-urban' blacks (p=0.0002, RB<SB), 'rural' 
blacks and whites (p<0.OOO1) as well as combined blacks and whites (p=O. 0043) , with 
blacks having lower intakes of this vitamin than whites. The intake of vitamin A has been 
shown to be Significantly higher in idiopathic calcium stone formers than normal control 
subjects (AI Zahrani et al. 2000). This is surprising as the deficiency of this vitamin has 
been reported to potentially aggravate tubular cell necrosis, an initial promoter of renal 
lithiasis, which can be caused by vitamin E deficiency and overproduction of free 
radicals (Sakly et al. 2003). However, it is worth mentioning that vitamin A might not be a 
potent free radical scavenger (Schunemann et al. 2001, Alfonso et at. 2005) as it has 
been shown to have a limited capacity to act as a scavenging antioxidant in vivo 
(Lesgards et al. 2005, Dragsted 2008). 
The intake of dietary phosphate was similar between 'rural' blacks and 'semi-urban' 
blacks (p=0.7135) while it was lower in 'rural' blacks (p=0.0021), 'semi-urban' blacks 
(p=0.0048) and combined blacks (p<0.0001) when compared to their white compatriots. 
Previous studies have shown that dietary phosphate intakes of stone formers and 
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healthy subjects are similar (Fellstr6m et al. 1989, Trinchieri et a/. 1991). Although 
dietary phosphate restriction has been reported to increase calcium excretion (Roberts 
and Knox 1990), neutral phosphate intake has been shown to decrease renal calcium 
excretion (Lau et a/. 1979). 
The intake of dietary potassium is also worthy of attention. Although it was similar 
between 'rural' blacks and 'semi-urban' blacks (p=O.5577) in the present study, it was 
lower in 'rural' blacks (p=O.0021), 'semi-urban' blacks (p=O.OO48) and combined blacks 
(p<O.OOO1) when compared to their white compatriots. This supports the findings of a 
recent study which has also shown racial differences in potassium intakes, with blacks 
typically consuming less dietary potassium than whites (Turban et al. 2008). This is 
surprising as it has been shown that potassium administration reduces and potassium 
deprivation increases urinary calcium excretion in healthy adults (Lemann et al. 1991, 
Rafferty et a/. 2005). In fact, a prospective study of dietary calcium and other nutrients 
and the risk of symptomatic kidney stones has also shown that potassium intake is 
inversely related to the risk of stone formation (Curhan et al. 1993). It has also been 
shown that the mean daily intakes of potassium were greater in patients with 
hyperoxaluria than in stone formers with normal oxalate excretion (Siener 2003) while no 
differences were found in the potassium intake of stone formers compared to healthy 
subjects (Fellstr6m et a/. 1989), 
It is noted that since most food sodium and potassium are absorbed, there is an obvious 
discrepancy in that the sodium and potassium diets of whites are higher than those of 
blacks, but their urinary sodium and potassium values are lower. The possible 
explanation for this anomaly is that urinary solutes were determined in spot urine 
samples (standardized with creatinine values) rather than in 24hr urines. 
The intake of oxalate is interesting. As mentioned in the introduction, there does not 
seem to be any consistent trends. The relatively high intake of oxalate in blacks has 
been previously attributed to a high intake of spinach (Viljoen and Gericke 2001). 
Whether this is peculiar to 'semi -urban' blacks (58) or not remains to be established in 
future studies. However, attention has certainly been drawn in previous studies that the 
dietary features identified in the present project (and others) for black subjects - lower 
calcium, relatively high oxalate, low magnesium and low vitamin 86 - are prescriptive 
76 Chapter Two Genetics & urolithiasis 
features for hyperoxaluria which, as has been noted, was not obselVed. Although the 
one day diet diary is an imperfect way to assess long-term dietary intakes, the high 
oxalate intakes in semi-urban blacks and extraordinarily low dietary intake in rural blacks 
is notable. According to Kennedy et al. 2004, 24hr dietary recall tends to underestimate 
and the food frequency questionnaire tends to overestimate nutrient intakes. It is 
uncertain whether the extraordinarily low oxalate intakes are a manifestation of this type 
of questionnaire or are peculiar to rural blacks or not. Perhaps this remains to be 
established in Mure studies. 
There were no significant associations between daily caloric intakes and the presence or 
absence of the Pr011 Leu polymorphism. Unfortunately this study could not be extended 
to grandparents. It has been suggested that the frequency of the Pr011Leu 
polymorphism is much higher in populations in which the ancestral diet is extremely 
meat-rich than it is in those in which it is more mixed or more vegetarian (Caldwell et al. 
2004). It would have been interesting to explore this relationship. Thus it was not 
surprising that there were no significant association between fish (p=O.6094) and meat-
intake and the frequency of this polymorphism (p=O.8532 for red meat and p=O.2588 for 
chicken). A previous study investigating genetic and dietary influences on 
nephrolithiasis, also ObselVed that the consumption of the amount of meat and fish were 
not significantly related to kidney stones (Goldfarb et a/. 2005). Reasons for this are 
unclear. Moreover, in another study by Curhan and co-wo!1(ers (1997) investigating 
family history and risk of kidney stones, it was also found that the magnitude of the risks 
for animal protein appeared to be higher in men with a family history, but these were not 
statistically different from the risks in men without. 
Thirdly, the association of the frequency of this polymorphism with alcohol intake (beet) 
tended towards significance (p=O.0794) but there was no association with the intake of 
other types of alcoholic beverages (p>O.05). Goldfarb and co-workers (2005) found that 
the consumption of alcohol was marginally associated with a decreased report of kidney 
stones compared to no recent intake of alcohol (Ptrend=O.06). Other studies have also 
demonstrated protective effects for wine and beer (Curhan et a/. 1996, Krieger et a/. 
1996, Hirvonen et a/. 1999, Goldfarb et al. 2005). Interestingly, in the latter study, there 
was an increased prevalence of stones among current nondrinkers of alcohol. 
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Fourthly, in the present study, the only observed significant associations of dietary intake 
with the frequency of the polymorphism in both groups were that of juice (p=O.OO31), 
cool drink (e.g coke) (p=O.0204) and chocolate (p=O.OO44). Thus, in the present 
analysis, routine consumers of these items are more likely to have the polymorphism 
than non-users. 
In summary, the differences in urinary compositions of spot morning urine samples and 
dietary intakes in 'rural' and 'semi-urban' black subjects and white subjects do not 
appear to have led to any notable variation in the frequency of the alanine:glyoxylate 
aminotransferase (AGT) Pr011 Leu polymorphism in the studied groups, as experimental 
data revealed that the frequency of this polymorphism is the same in the white and black 
subjects who participated in this study (i.e 75% and 25% of the AGXT major allele 'C' 
and minor al/ele T, respectively). 
It has been stated earlier that in healthy individuals AGT is localised exclusively in the 
peroxisomes in liver parenchymal cells but in PH 1 patients it is mistargeted to 
mitochondria (Cooper et al. 1988, Oanpure et al. 2003). 
It is well recognized that pr011 Leu polymorphism redirects a small proportion of AGT 
from the peroxisome to mitochondria (Oanpure et al. 1994, Oanpure 1998). This effect is 
predicted to be detrimental due to the fact that the peroxisome, not the mitochondria, is 
the major site of synthesis of its substrate (glyoxylate). Although AGT is still catalytically 
active after the import, it is metabolically ineffective. Thus, it would seem reasonable to 
expect that this polymorphism should occur at a low frequency in normal individual. 
Therefore, at first sight, it is difficult to understand why the minor AGXT allele 'T' 
encoding the Pr011 Leu polymorphism should occur at such a high frequency in the 
healthy Caucasians, Sami, European and North American populations (Oanpure et al. 
1994, Oanpure 1998, Caldwell et aJ. 2004, Coulter-Mackie et al. 2005, Ross et al. 2006, 
Kozlov et al. 2008) as well as in the present study. 
A plausible explanation is provided by Danpure (2006) , who has proposed that the 
evolutionary history of mammals suggests that this mistargeting in humans, which might 
lead to a subcellular distribution of AGT, is more compatible with an individual's lifestyle 
(e.g. omnivOlUs dietary habits rather than herbivorous). In support, previous studies 
have also shown an adaptive dietary lifestyle for the high prevalence of the AGXT allele 
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'T' encoding this polymorphism in healthy populations (Caldwell et al. 2004, Kozlov et al. 
2008). This might explain the observed frequency for white subjects in the present study, 
which is similar to that previously reported for healthy Caucasians as described below 
(Danpure et al. 1994, Danpure 1998, Coulter-Mackie et al. 2005). Although scant data 
exists in literature on the frequency of Pr011 Leu polymorphism, the latter studies have 
shown that in Caucasian populations, the sc:rcalled major AGXT allele 'C' has a 
frequency of about 80% while the minor AGXT allele 'T' has a frequency of about 20%. 
This is in very good agreement with data in the present study. 
According to Lumb and co-workers (2000), the explanation of the high frequency of the 
minor AGXT allele in European and North American population (-20%) is unclear. 
Nevertheless, the frequency of this polymorphism seems to vary between human 
populations, with the highest frequency reported in the Sami (27.9%) and the lowest in 
the Japanese (2%) and Chinese (2.3%), who have a more mixed ancestral diet (Ross et 
al. 2006). 
Furthermore, it has been reported that the frequency of this polymorphism is low (2.3-
6.9%) in eastern and southern Asia, intermediate (8.9-10.9%) in Africa and high (14.6-
27.9%) in Europe and the Middle East (Caldwell et al. 2004). Interestingly, the frequency 
of the AGXT minor allele 'T' in the Kola Sami is very close to the frequency of this allele 
in the Swedish Sami at 27.9%, although it is lower in Norwergians (19.7%) and Russians 
(17.6%) (Kozlov et al. 2008). This has been attributed to the traditional diet of the Sami, 
which has been reported to be high in meat, based on circumpolar hunting, fishing and 
reindeer herding. 
As the reasons for the high frequency observed especially in black subjects are vague, it 
is tempting to look at other possible explanations such as family history of stone 
formation. However, this seems unlikely, as all subjects reported an absence of family 
history of stone formation albeit that the present study did not extend to grandparents 
and great-great grandparents. Perhaps the answer might be provided by recent reports 
that have indicated that true lack of stones in subjects reporting no family history of 
stones is less easily documented, as renal stones may remain asymptomatic for years 
since detection of such subclinical disease would require radiological imaging (Griffin 
2004, Goldfarb et al. 2005). In fact, according to Griffin (2004), many individuals with 
renal stones may never have symptomatic disease, and their stones may go unnoticed 
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throughout life or be diagnosed as an incidental radiological finding during investigation 
of unrelated symptoms. In support, radiological studies have shown a prevalence of 
3.5% for renal stone disease among a random population (Scott 198?). 
The present study has some limitations. These limitations include the small sample size, 
the lack of control of diets, the use of a spot urine rather than a 24hr collection, and the 
inherent errors in estimating dietary intakes. It is noted that large-cohort studies are 
needed for much deeper and rigorous investigations. In addition, the present results are 
only applicable to the black ethnic group which participated in the study, namely 
'Xhosas'. However, the selection of only one ethnic group was necessary as it eliminated 
confounding factors due to possible genetic diversity among the ethnic groups from the 
black population. It might be interesting to investigate this polymorphism in black and 
white calcium oxalate stone formers and PH1 patients, but this is likely to be extremely 
difficult and probably unfeasible given the dire paucity of both types of subjects and the 
near absence of stone formation in South African blacks. 
The strong evidence of the importance of environmental factors in renal stone disease 
seems to diminish the role of genetic factors, but these are clearly involved (8aggio 
1999). According to Goldfarb and co-workers (2005), despite suggestive data favouring 
a heritable component of stone disease in the general population, the genetiC basis for 
calcium stones in general remains unknown. 
Notwithstanding that the present study had limitations, the question of whether the 
reported differences in stone incidence between the two groups has a genetic basis 
could not be answered from the present data, as the results have clearly indicated that 
there is no significant differences in the frequency of the alanine:glyoxylate 
aminotransferase (AGT) Proline11 Leucine polymorphism in the black and white subjects 
who participated. Nonetheless, in view of the fact that the frequency of this 
polymorphism (a genetic factor') did not vary, it might seem reasonable to tentatively 
assume that environmental factors might help explain the high proportion of stone 
disease variation between the two groups and that other genetic and non-genetic factors 
(that remain to be identified) rather than this polymorphism might be responsible for the 
reported differences in stone incidence. Further research is undoubtedly warranted in 
this area. 
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Chapter Three 
Investigation of the role of gut permeability as a key to 
identifying possible differences in the handling of 
dietary oxalate in black and white South African 
subjects 
87 Chapter Th ree gut permeability & oxalate handling 
3.1 Introduction 
In the study described in the previous chapter, an attempt was made to evaluate and 
investigate whether the reported differences in the incidence of stone formation between 
black «1%) and white (-15%) South African subjects have a genetic basis. It was 
shown through DNA sample analysis that the frequency of alanine:glyoxylate 
aminotransferase Pr011 Leu polymorphism does not appear to be a contributory factor 
towards the prevalence of stone formation in the white group. As such, it is able to 
explain stone rarity in the black group. Further stUdies are deemed necessary to 
investigate other avenues that might explain this phenomenon. One such area might be 
to investigate the role of gut permeability to establish whether different oxalate handling 
mechanisms occur in the two race groups and therefore allude to their disparity in stone 
prevalence. This Chapter describes such a study. 
It was pointed out in Chapter 1 (section 1.6), that previous studies have found empirical 
evidence to suggest that different oxalate handling mechanisms exist in the black group 
compared to the white group and that it proceeds via mechanisms other than dietary and 
renal (Lewandowski et al. 2001, Rodgers and Lewandowski 2002, Lewandowski et al. 
2004a, Lewandowski et al. 2004b). Moreover, it has also been shown that there is no 
significant difference between the two race groups with respect to gastrointestinal 
oxalate absorption (Lewandowski et al. 2005). 
Four mechanisms have been identified that could account for elevated urinary oxalate. 
Firstly, increased dietary intake of oxalate allows for more oxalate to reach the colon, 
increasing its availability for absorption (Brinkley et al. 1981, Massey et al. 1993, Pak et 
al. 2004, Coe et al. 2005). Secondly, intestinal hyperabsorption of oxalate might occur 
(Stauffer 1977, Dobbins 1985, Cirillo et al. 2008, Thomas et al. 2008). Thirdly, a 
deficiency of oxalate-degrading bacteria (in particular O. formigenes) has been 
suggested as causing an increase in the risk of hyperoxaluria and subsequently calcium 
oxalate urolithiasis (Sidhu et al. 1998, Sidhu et al. 1999, Sidhu et al. 2001, Holmes and 
Assimos 2004, Lewandowski and Rodgers 2004a). Finally, increased endogenous 
production of oxalate is yet another mechanism (Finch et al. 1981, Jaeger and 
Robertson 2004, Lewandowski et al. 2004b). 
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The hypothesis in the present study is that blacks have a better intestinal integrity and 
therefore better intestinal control mechanisms which allow for less oxalate to be 
absorbed when challenged by a high dose of oxalate. On the other hand, it is 
hypothesized that the integrity of the gut wall might be lowered (made more permeable) 
in whites and thus passive intestinal absorption of oxalate could occur when challenged 
by a high dose of oxalate. 
This hypothesis seems plausible, since a previous study has reported that when a high 
oxalatellow calcium diet was administered to white and black subjects, the urinary 
oxalate increased in the former as expected, but remain unchanged in the latter 
(Lewandowski et al. 2001). Moreover, black subjects have been shown to have 
hyperoxalurogenic eating habits (high dietary intake of oxalate, low intake of calcium, 
low magnesium intake), while their urinary oxalate lies within the normal range (Whalley 
et al. 1998, Viljoen and Gericke 2001, Rodgers and Lewandowski 2002, Lewandowski et 
al. 2005). 
In 2005, Coe stated that as a clinician, he would counsel patients to avoid boluses of 
oxalate. The effects of oral oxalate loads in both calcium oxalate stone formers and 
normal individuals have been investigated by several workers with many studies 
reporting increases in oxaluria of approximately 8-289% (Marshall et al. 1972, Barilla et 
al. 1978, Finch et al. 1981, Balcke et al. 1989, Nguyen et al. 1994, Hess et al. 1998, 
Liebman and Costa 2000, Holmes et al. 2001). In addition, in a study by Krishnamurthy 
and co-workers (2003), investigating urinary response to an oral oxalate load (5 mM 
sodium oxalate in 250 ml distilled watery, recurrent calcium stone formers with mild 
hyperoxaluria were reported to have higher fasting urinary oxalate and an exaggerated 
urinary response to an oral oxalate load compared with recurrent calcium stone formers 
with normal urinary oxalate excretion. It was also shown that stone formers without 
hyperoxaluria excrete similar fractions of an oral oxalate load. Renal oxalate excretion 
following an oral oxalate load (500 mg), was also investigated in patients with urinary 
calculus disease (15 calcium oxalate stone formers, 7 non-oxalate stone formers and 10 
healthy controls), it was shown that the mean increments of urinary oxalate were 
significantly higher in calcium oxalate stone formers than in both healthy controls and 
non-oxalate stone formers (Ebisuno et al. 1986). 
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On the other hand, in a study by Holmes and co-workers (2005), the authors concluded 
(after administering oral oxalate loads of up to 8 mmol sodium oxalate) that no evidence 
of acute renal injury or oxidative stress was observed under these experimental 
conditions. 
According to Cirillo and co-workers (2008), calcium oxalate stones may be caused by 
colonic oxalate hyperabsorption (secondary to gut dysfunction) or by parenteral nutrition. 
Although relationships between malabsorptive intestinal diseases and urinary stones are 
less well defined, it is known that increased gut permeability can cause hyperabsorption 
of nutrients which can lead to the passive diffusion of oxalate (Stauffer 1977, Dobbins 
1985). Patients with ileal resection and jejune-ileal bypass are at an increased risk of 
forming calcium oxalate renal calculi because of enhanced absorption of dietary oxalate 
(Stauffer 1977). Thus, gut diseases may cause the formation of urinary stones through 
changes in the metabolism of oxalate, calcium and uric acid. 
The most widely accepted method for the evaluation of changes in gut permeability and 
monitoring the intestinal mucosa integrity is the measurement of permeation through the 
gut mucosa of two or more sugar probes of different molecular weight (Hamilton et al. 
1987, Lifschitz and Shulman 1990, Lostia et al. 2008). As alluded to in the first chapter, 
one of the most commonly used non-invasive, highly sensitive tests for screening of 
diseases that affect gut permeability is the 'Lactulose-Mannitol absorption tesf (Juby et 
al. 1989, Andre et al. 1991, Laudat et al. 1994, Paroni et al. 2006). This test is based on 
coupled oral ingestion of dual-sugar probes, lactulose (LA) (Figure 3. 1) and a low 
molecular weight polyol, mannitol (MA) (Figure 3.2) and determination of the ratio of their 




CH~ OH OH 
OH 
Figure 3.1 LA (a synthetic disaccharide) Figure 3.2 MA (a monosaccharide) 
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The test uses LA and MA for measuring differential sugar absorption mainly because 
they have a negligible affinity for the monosaccharide transport system and are 
passively absorbed and not metabolized before urine excretion, therefore intraindividual 
differences in gastric emptying, small gut transit, and urinar)' excretion are eliminated 
(Juby at al 1989, Marsillo et al. 1989, Barboza et a/. 1999. Liu et a/. 2004). Moreover. 
LA and MA excretion are thought to be good markers of permeation via transcellular and 
paracellular pathways, respectively and as shown in figure 3.3, MA theoretically enters 
the cell through the hydrophilic portion of the cell membrane. while LA goes through the 
tight junctions and extrusion zones of the intervillous spaces (Barboza et a1. 1999, 
Farhadl et al. 2003). Consequently, the loss of mucosal integrity should cause increased 
LA absorption, while the loss of absorptive areas decreases the absorption of MA. 
Tight JunCliOIl 
. 0 -"",,"1 <dl 
I 
Figure 3.3 Permeation through the intestinal mucosa can be via transcellular uptake (MA) 
or paracellular uptake (LA) (hllp//wwtN life- enthusiast. com/index/arliclesi 
cabotJIeaky_9ut _syndrome) 
Mucosal damage or loss of villus surface area (as shown in figure 3.4) alters the rate of 
permeation of the sugars across the mucosal surface, with decreased MA and increased 
LA recoveries, resulting in high LA%fMA% ratios (Kukuruzovic et al. 1999). Thus, MA 
recoveries are a measure of mucosal absorptive capacity, whereas LA permeability 
reflects barrier function. 
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Figure 3.4 DIagram showing mucosal damage or loss of villus surface (damaged intestinal 
microVIllI) (hffp."JIfBSI gsd/comlhome/assessmenfslipl} 
If the mucosal barrier is damaged, the gut is more permeable to intact sugars and 
proteins, therefore an abnormal intestinal permeability with an imbalance in the di/mono 
saccharide excretion in urine will indicate either an abnormal passive uptake of larger 
molecules (e.g LA) through the paracellular route across the damaged mucosal barrier 
or a reduction of the integral mucosa with a reduced passage of the smaller molecules 
(e 9 MA ) (Sullivan at al 1992, Peters et aJ 1994, Catassi at 8/ 1997, Marsiho et aI 
1998. Kukuruzovic at al 1999. Haase at al 2000. Generoso et aI. 2003. uu et aJ 2004 , 
Paroni at 81. 2006). 
It is widely accepted in literature that for an oral dose of 5g LA and 29 MA, the reference 
intervals determined for the percentage recoveries of sugars excreted duri ng the 5hr 
period are %LA (0,069-0.393%) mean (0.231%) and %MA (5,0-22.0%) mean (13.6%), 
the ratio of LA%/MA% (0.006-0.030) mean (0.018) (Menzies at 81. 1979, Ford et aJ 
1985, Eha el 81 1987, Juby .1.1 1989, Kyoaston .1 0/. 1993, Oastych el 81 2008). 
These ranges are very similar to published data in other studies by Pearson and co-
WOOters (1982) and Fleming and co-workers (1990,1993), who report a mean %LA 
excretion of 0,25% (range 0.065-0.45%), a mean % MA excretion of 14% (range 8.5-
24.5%) and a mean LA%/MA% ratio of 0.018 (range 0.005-0.028) (Pearson at 81 1982. 
Fleming et 81 1990). Although they used a different method of analysis 
(spectrophotometery vs chromatographic methods in above studies), Benjamin and co-
workers (2008), have also recently reported a similar range, LA% 0.293% (range 
0.0089-0.665). MA% 14,2% (range 4.95-30.8) and LA%/MA% ratio of 0.0164 (range 
00018·0.0548) 
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For example, in an effort to determine gut permeability in patients with coeliac disease, a 
previous study has found that the median % urinary recoveries of LA was significantly 
higher in patients with the disease than in controls (0.63 VS 0.18, p<0.001). Although the 
difference was not statistically significant, the mean MA% recovery was lower in patients 
with the disease than in controls (17.6 vs 18.5). Moreover, the median urinary 
LA%/MA% ratio was significantly higher in patients with the disease than in controls 
(0.038 vs 0.014, p<0.OO1). It is worth noting that 16 of the 29 patients with coeliac 
disease showed a LA%IMA% ratio within the normal limits «0.044) (Catassi et al. 1997). 
In addition, the LAlMA gut permeability test has also been evaluated in 100 healthy 
controls and 47 patients with Crohn's disease, on a whole, patients with the disease 
were shown to have lower mean MA and higher mean LA and mean LAlMA ratio than 
controls (Andre et al. 1988). These findings have recently been confirmed by Generoso 
and co-workers (2003) who evaluated gut permeability in 25 healthy volunteers and 
reported a LAlMA ratio (gut permeability index) of 0.018 ± 0.014. 
Several methods (paperAhin layer chromatography, enzymatic method, gas liquid 
chromatography and high performance liquid chromatography) have been developed to 
assay sugar probes for determination of gut permeability, however, they have been 
shown to be time-consuming, increase the possibility of analytical errors, limit the 
number of samples that can be processed and require derivatization (Menzies 1973, 
Menzies et al. 1978, Laker 1979, Laker and Mount 1980, Behrens et al. 1984, Petchey 
and Crabbe 1984, Engelhardt and Ohs 1987, Fleming et al. 1993, Kynaston et al. 1993, 
Willems et al. 1993). Fortunately, high performance anion-exchange chromatography 
coupled with pulsed amperometric detection (HPAEC-PAD) using an alkaline elution 
protocol has proven to be a method well-suited for the separation of neutral, acidic, and 
reduced sugars (e.g LA and MA) and as such was selected to be used in the present 
study (Fleming et a/. 1990, Ricci et a/. 2001, Liu et a/. 2004, Bruggink et a/. 2005). 
Moreover, this technique has the advantage of greatly increased sensitivity, specificity, 
minimal sample preparation and derivatization is not required (Rocklin 1983, Fleming et 
a/. 1990). 
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The present Chapter describes an invest~gation of the effect of a dietary oxalate load 
(with normal calcium intake) on urinary oxalate excretion and gut permeability in subjects 
from South Africa's two population groups. 
3.2 Subjects and Methods 
Study population 
10 healthy black and 10 white South African age-matched male volunteers were 
recruited from the student cohort of the University of Cape Town via advertisement on 
the university notice boards. After verbal and written information had been provided, the 
subjects signed a declaration of informed consent form in order to participate in the tests 
(see appendix CD/Chapter 3linformed consent form). 
Biographical data 
For each subject, brief information about their social and medical history was collected. 
(see appendix CD/Chapter 31Biographical data). 
Inclusion criteria 
Healthy black and white South African male subjects in the age range 18-30 years 
without any family history of renal or kidney stone disease were recruited for the study. 
In addition, standard tests with urinary dip sticks (Medi Test Combi 5N, Macherey-Nagel; 
Daren) confirmed their health status. 
Exclusion criteria 
Subjects were excluded from the study if they: 
• had a history of gastrointestinal disease (e.g celiac disease, inflammatory bowel 
disease, irritable bowel disease, food allergies) or any history of digestive, 
gastrointestinal disorders or complains 
• had galactosaemia. 
• were diabetic. 
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• were on any medication or taking supplements that might affect LA and MA 
metabolism e.g. neomycin, ciprofloxacin, sodium polystyrene sulfonate, oral 
tetracyclines, potassium supplements, antiacids and antibiotics. 
• were on nonsteroidal anti-inflammatory drugs (NSAlos) 
• had a family history of renal or kidney stone disease 
• had a history of excess alcohol consumption 
Study design 
The study was divided into three protocols conducted over a three week period: 
Week 1. Protocol 1: Regular diet (3 days) 
Week 2. Protocol 2: Standardized diet (3 days) 
Week 3. Protocol 3: High-oxalate standardized diet (3 days) 
On day 3 of each protocol, the gut permeability test was performed and urinary oxalate 
as well as other urinary parameters were measured. Risk indices of stone formation 
were computed. The three protocols were separated by a wash-out period of four days. 
All subjects followed and completed all three protocols and no adverse effects were 
reported. 
Protocol 1 (Week 1, Day 1- Day 3) 
Subjects were requested to take their regular diet for three consecutive days and keep 
3x 24hr dietary food records (see appendix CD/Chapter 3I24hr dietary food record). The 
subjects' regular home-diet food intake was assessed using the FoodFinder 2 computer 
software programme (Langenhoven et a/. 1991) (see appendix C~/Chapter 3Idietary 
analysis). 
On day 3, following an overnight fast (19h45-7h45), subjects were required to discard 
the first morning urine sample and then collect a pre-test (1 hr) sample in order to 
confirm that no endogenous sugars were present (Andre et al. 1988, Ventura et a/. 2006). 
At 08H45, while on an empty stomach, subjects ingested a dual-sugar isotonic test 
solution consisting of 5g LA and 2g MA dissolved in 200 ml of tapwater (Ventura 
et a/. 2006). After 1 hr (09h45), an intake of fluids was encouraged to maintain an 
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adequate urine output (Goren et al. 1995). Caledon mineral water was provided for this 
purpose: 700 ml until 14hOO, 600 ml until 19hOO and a further 700 ml until 22hOO. 
Caledon water was used as it has a low content of all minerals, especially calcium 
(6.1 mg/L). The content of each mineral in Caledon 'Still" water is given in table 3.3. 
Subjects were allowed to ingest food Oof the respective diets after the second hour 
(10h45) (Kynaston et at. 1993, Goren et al. 1995, Duerksen et al. 2005). The timing of 
the meals was as follows: Breakfast (10h45), Lunch (12h45), Snack (16hOO), Supper 
(18hOO) and late meal (19h45). 
The 5hr test sample was then collected (09h00-14hOO), followed by the 18hr post-test 
sample (14hOO-08hOO). Urine volume was recorded for each fraction. After thorough 
mixing of individual fractions, a 10 ml aliquot was stored without preservatives (van 
Nieuwenhoven et al. 1999) at -20°C until determination of gut permeability (Fleming et 
at. 1990, Generoso et al. 2003, Bosi et at. 2006, Paroni et al. 2006, Ventura et at. 2006). 
In addition, 24hr urine samples were reconstituted from the urine fractions (pre-test, 5hr 
test and 18hr post-test) from each subject for measurement of urinary parameters. 
Protocol 2 (Week 2, Day 1 - Day 3) 
In the second week, the same subjects followed a standardized diet for three 
consecutive days. The standardized diet was based on the 2001 South African food-
based dietary guidelines (Vorster et al. 2001). The meals and liquid intakes were 
prescribed with regard to type, quantity and timing. The actual food ingested and nutrient 
contents of the diet are listed in table 3.1 and 3.2, respectively. On day 3, urine fractions 
were collected and analysed as described in protocol 1. 
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Table 3.1 Constituents of the strict and controlled standardized diet for protocol 2 
Meals (Week 2) Day 1-Day 3 
Breakfast (1 0h45) 100g bread rolls, 
8g butter 
15g apricot jam 
18g melrose cheese 
55g cornflakes 
250ml coffee (2 sachet sugar (10g) + 1 sachet creamer (4g) 
1 muesli bar (Kellog's all-bran bar,27 g), 150 9 banana 
Lunch (12h45) 60 9 turkey ragout, 60 9 creamy sauce 
120 9 mixed vegetables 
120 9 pasta 
Snack (16hOO) 150 9 apple, 175 9 low fat fruit yoghurt 
Supper (18hOO) 3 slices of whole wheat bread 
10 9 margarine 
30 9 cheddar cheese, 17 9 cream cheese 
50 9 tomato 
150 9 apple 
Late night snack 1 slice of whole wheat bread 
(19h45) 5 9 margarine, 17 9 cream cheese 
50 9 tomato 
Beverages: (21/day): 700 ml Caledon water unti/14hOO, 600 ml Caledon water unti/19hOO 
700 ml Caledon water until 22hOO 
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Table 3.2 Nutrients contents of the standardized diet (protocol 2) 
Nutrients Standardized 
diet 
Energy (kJ) 11060 
Moisture (g/day) 1204.0 
Total Protein (g/day) 82.9 
Total Fat (g/day) 79.6 
Carbohydrate (g/day) 357.7 
Fibre (g/day) 36.8 
• Total sugars (g/day) 104.6 
Oxalate (mg/day) 55 
Calcium (mg/day) 923 
Magnesium (mg/day) 391 
Phosphate (mg/day) 1377 
Potassium (mg/day) 2687 
Sodium (mg/day) 2773 
Vitamin A (pg/day) 1065 
Vitamin B6 (mg/day) 2.58 
Vitamin C (mg/day) 99 
Vitamin D (pg/day) 3.23 I 
Vitamin E (mg/day) 7.04 







• Magnesium 1.0 
Iron 0.01 
Manganese 0 
i Chloride 23 
Sulphate 1.7 
Bicarbonate 32 
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Protocol 3 (Week 3, Day 1 - Day 3) 
In the third week, the same subjects followed a high-oxalate standardized diet for three 
consecutive days. The meals and liquid intakes were the same as for the standardized 
diet protocol (protocol 2), except that 10 mmol sodium oxalate dissolved in 200m I 
tapwater was also ingested at breakfast on each day (Holmes et al. 2005). On day 3, 
urine fractions were again collected and analysed as in protocol 1 and 2. 
3.3 Determination of gut permeability index using high performance anion 
exchange chromatography (HPAEC-PAD) 
Reagents and standard solutions 
Standard carbohydrates were used for the preparation of the calibrator and test 
solutions: D-MA (99+%) (Sigma-Aldrich, Germany), and LA (crystalline powdery (Medpro 
Pharmaceutica (Pty, Ltd, Bellville, South Africa). Low carbonate sodium hydroxide 50% 
(v/v) was obtained from Fluka, Deisenhofen, Germany and sodium oxalate (assay min 
99.0%) was purchased from Sigma-Aldrich, Germany. MilliQ water was obtained from 
MilliQ water purification system (Millipore, Berdford, USA). Stock analyte standard 
solution was prepared by dissolving the appropriate amount of each carbohydrate in 
MilliQ water to give a final concentration of 157 ppm for MA and 132 ppm for LA. This 
stock solution was stored at -20°C until analysis, when it was diluted to produce working 
standard solutions at different concentrations as shown in appendix CD/Chapter 
3/concentrations of working standards. 
HPAEC-PAD sample analysis 
Stored samples were defrosted and pooled before analysis (Monteleone et al. 2004). 
Briefly, 1 ml aliquot was taken from each pre-test sample from all subjects and pooled 
according to race group. The 5hr test samples of protocol 1 as well as samples from 
protocol 2 and protocol 3 were also pooled in a similar manner. 
The pooled samples were then diluted (5x) with MiIIiQ water. Diluted samples were then 
filtered through 0.45 IJm membranes (Target, Cape Town, South Africa) and C18 
99 Chapter Three gut permeability & oxalate handling 
reverse phase solid phase extraction cartridges (Isolute, Biotage, Virginia, USA) to 
remove proteins. Samples were then analysed by HPAEC-PAD for determination of the 
recoveries percentages of LA and MA as described below. 
Carbohydrate profiling was performed on a Dionex BioLC ion chromatograph system 
(Dionex Sunnyvale, CA, USA) equipped with an AS50 autosampler (Rheodyne rotary 
injection valve with a 25 pI PEEK sample loop), ED50 pulsed-amperometric 
electrochemical detector, LC30 oven and GS50 pump (Dionex). The detector cell 
incorporated a gold working electrode and a pH Ag/AgCI reference electrode. To control 
the complete system and to realize acquisition and processing of chromatographic data, 
a personal computer equipped with the Chromeleon® chromatography management 
system was used. 
Profiling of MA and LA was achieved using a CarboPac MA1 column (250 mm X 4 
mm,l.D., Dionex) coupled with a CarboPac MA1 guard column (50 mm X 4 mm, 1.0., 
Dionex). Isocratic elution with 300 mM NaOH at a flow rate of O.4ml/min was employed 
for separation of the analytes. This mobile phase was degassed with nitrogen and then 
continuously purged with helium during elution. Quantification was achieved from peak 
areas calculated from LA and MA standard curves (figures 3.5a and 3.5b). The use of an 
available internal standard (arabinose) was investigated but unfortunately it overlapped 
with the MA peak. Each pooled urine fraction was analysed in triplicate. 
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Figure 3.5a Standard curve for LA determinations Figure 3.5b Standard curve for MA determinations 
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Urine reconstitution, treatment and physicochemical properties 
As stated earlier, in all three protocols, 24hr urine samples were reconstituted from the 
urine fractions (pre-test, 5hr test and 18 hr post-test) from each subject. Each 24hr urine 
sample was tested for haematuria and nitrite using urinalysis test strips (Medi Test 
Combi 5N, Macherey-Nagel; DOren, Germany). None of the samples tested positive for 
either blood or infection. Urine pH (PH 211 microprocessor pH meter, Hanna 
Instruments, Cape Town, South Africa) and volume were routinely measured. Aliquots 
were filtered through a 0.75 IJm filter (Macherey-Nagel, DOren, Germany) to remove 
cellular debris and proteinaceous material. The urine samples were analysed as 
described in Chapter 2 (section 2.2). Relative supersaturation (RS) values of calcium 
oxalate (COM) were computed using EQUIL 1.5 computer software programme 
(Ackermann et al. 1989) while the Tiselius risk index (Tiselius 1982) was calculated for 
each urine sample as described in Chapter 1 (section 1.3). 
Statistical analysis 
Statistical comparison of mean dietary intake was achieved using one-way analysis of 
variance (ANOVA) while data from 24hr urine samples were analyzed using repeated 
measures ANOVA. Both analyses were computed using STATISTICA version 8.0. Data 
were considered statistically significant if p~0.05. 
3.4 Results 
Dietary analysis 
In week 1 (protocol 1), subjects were instructed to consume their regular diet for three 
consecutive days and keep 3x 24hr dietary food records. The subjects' regular home-diet food 
intake was assessed using a FoodFinder 2 computer software programme (Langen hoven et al. 
1991). Comparison of mean nutrient intakes for black and white subjects when they were on 
their regular diet is given in table 3.4 as well as those of the standardized diet. 
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Table 3.4 Comparisons of the mean dietary intakes (SE) of regular diets of black and white 
subjects and standardized diet 
Nutrients Blacks (B) Whites Standard BvsW 
(W) diet p-values 
8MI (kg/m;!) 24.28(0.89) 25.74(0.89) -- 0.2627 
Energy (kJ) 10729 (1144) 15733(699) 11060 0.0015* 
Moisture (g/day) 2122(207) 3137(296) 1204 0.0095* 
Total protein (g/day) 82.20(5.59) 123.33(8.63) 82.9 0.0008* 
Total fat (g/day) 102.36(9.75) 124.80(6.92) 79.6 0.0770 
Carbohydrate (g/day) 320(34.11) 394(39.60) 357.7 0.1724 
Fibre (g/day) 26.95(3.39) 31.48(3.61) 36.8 0.3725 
Total sugars (g/day) 32.06(3.64) 66.53(53) 104.6 0.0008* 
Oxalate (mg/day) 328(46.77) 142(12.36) 55 0.0012* 
Calcium (mg/day) 708(83) 1182(70) 923 0.0004* 
Magnesium mg/day) 348(8) 513(33) 391 0.0001* 
Phosphate (mg/day) 1360(117) 2187(175) 1377 0.0010* 
Potassium mg/day) 2764(269) 4407(386) 2687 0.0026* 
Sodium (mg/day) 3011(387) 4242(452) 2773 0.0820 
Vitamin A (pg/day) 1263(175) 1575(118) 1065 0.1550 
Vitamin 86 mg/day) 2.27(0.30) 3.14(0.36) 2.58 0.0794 
Vitamin C (mg/day) 135(29) 106(13) 99 0.3728 
Vitamin D (pg/day) 6.24(0.72) 5.78(0.54) 3.23 0.6320 
Vitamin E (mglday) 12.29(1.16) 13.64(1.08) 7.04 0.4204 
.. 
*S/gniflcance at p;::.O. 05 
Comment 
Dietary analysis of mean intake of nutrients of black and white subjects on their regular 
diet revealed that dietary oxalate was significantly higher in black subjects (p=0.0012) 
while total protein (p=0.OOOB), total sugar (p=O.OOOB) as well as calcium (p=0. 0004) , 
magnesium (p=0.OO01), phosphate (p=0.0010) and potassium (p<0.0026) were 
significantly lower. 
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Analysis of gtJt permeability index 
Data obtained from HPAEC-PAD chromatograms for determination of gut penneability 
indices in black and white subjects following the three protocols are given below. 
HPAEC-PAD analysis of standard solution 
A standard mixture of LA (132 ppm) and MA (157 ppm) was eluted isocraticaUy with an 
alkaline mobile phase (300 mM NaOH) , the resultant HPAEC-PAD chromatogram is 
shown in figure 3.6. 
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Figure 3.6 Typical HPAEC-PAD chromalogram o( a standard mixture of MA (157 pp m! and LA (13'2 ppm, 
(The ,~hroma lograph;c COfl<N IOOS for rms ana aM samples analysed are as given In SectiOl1 3 3 of 
/fus Chapter). 
Comment 
As revealed in this representative chromatogram of the standard solution. the two 
carbohydrate sugars LA and MA are well-resolved. with their respective peaks and 
retention times being displayed . It IS noted that there appears to be a much lower 
electrochemical detector response for LA than MA (Fleming et af 1990. Kynaston el al 
1993. Barboza at al 1999) as also evident in the relative small peak of LA in the 
chromatogram. As expected. the monosaccharide MA was eluted first (- 16min) . while 
the disaccharide LA exhibited a longer retention time (-30min ). This maximum 
separation of the peaks under the chromatographic conditions described was deemed to 
have been achieved in a reasonable lime. As such, this isocralic elution (with the 
indicated alkaline mobile phase) was employed for analysis of all samples. The 
concentrations of the working standard solutions used for preparation of the calibration 
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curve are indicated in the appendix (see appendix COIChapter 31concentrations of 
working standard solutions). 
Typical HPAEC-PAD chromatograms obtained from urines of black and white subjects 
for protocol 1 (regular diet) are given below while the chromatograms obtained from 
analysIs of the pooled urine fractions (pre-test and 5hr test samples) for all three 
protocols from black and white subjects are given in the appendix (see appendix COl 
Chapter 3IHPAEC-PAD chromatograms). The samples were pooled as done by 
Monteleone et a/. 2004, due to financial constraints. 
Typical HPAEC-PAD chromatograms from samples of black subjects 
Typical chromatograms obtained from pre-test and 5hr pooled urine fractions from black 
subjects for Protocol 1 (regular diet) are shown in figures 3.7 and 3.8, respectively. The 
remaining chromatograms from urine fractions from this group for protocol 2 
(standardized diet) and protocol 3 (high-oxalate standardized diet) are given in the 
appendix as indicated above. 
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Figure 3_7 HPAEC-PAD cl1romatogram from pooled pre-lest samples from black subjects before LA 
and MA oral load while on protocol 1 (PI81=protocoll. black subjects, pooled pre-lest sample) 
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Figure 3.8 HPAEC-PAD chromatogram from pooled 5hr tsst samples from black subjects after 5g LA 
and 2g MA ora/load while on prorocoI f (P185=proloco/ f , black subfttCts, pooJed 5hr test sample) 
Typical HPAEC-PAD chromatograms of samples from white subjects 
Typica l chromatograms obtained from pre-test and 5hr pooled urine fractions from white 
subjects for protocol 1 are shown in figures 3.9 and 3.10, respectively. AU other 
chromatograms from pooled urine fractions from this race group for protocol 2 and 3 are 
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Figure 3.9 HPAEC-PI1D chromatoglam from pooled pre·test samples from -Mllte subjects beforo LA 
and MA ora/load while all protoeol I(P IWI =-prOlocof I . wh ile SUbjeCts. pOOled pre-1es/ sample) 









• I I 
Ii ' I 
,I I /"'" .' , 
t----->' .,.j ~, / - '-~-----------
100 ,..- .. ~ , ...... I 
00 5 0 10 0 15.0 20.0 25_0 
2 · 1~1ose . 30.217 ~ 
I I ii 
300 350 40 0 
Figure 3.10 HPAEC-PAD Chromatogram from 5hr pooled lest samples from white subjects aftar 5g LA 
and 2g MA ora/load while on protocol1(P1W5=pmtoco/1, while subjects, 5l1r pooled tast sample) 
Comment 
The general HPAEC-PAD chromatograms for each sample from the pooled urine 
fractions from black and white subjects indicate a large eITor for LA as small values were 
obtained. This might introduce an error in the ratio (small numberlbig number) . It 
appears that the pulsed·amperometric electrochemical detector used might e insensitive 
to LA since other studies have also shown a lower pulsed-amperometric electrochemical 
detector response for LA (Aeming at aI. 1990, Kynaston at s/. 1993. Barboza at aI. 
1999). Perhaps a more sensitive analytical technique is required to detect urinary sugar 
excretions in individual subjects. It is also worth pointing out that each analysis was 
performed in triplicate. The chromatogams from both race groups show few peaks and 
the labetted analyte peaks (LA and MA) are dearly recognizable. Similar pattems are 
apparent. For example, in protocol 1, at first glance the pre-test pooled urine fractions 
from both groups show less MA excretion than the 5hr test samples obtained after the 
oral load (MA and LA test solution). It also appears as if LA excretion for this protocol 
was not affected by the oral load as it does not seem to be different when comparing the 
pre-test and 5hr excretions in the two groups. 
Percentage recoveries of LA, MA and the LA "cJMA % ratios 
The actual recoveries of LA and MA computed from all the pooled urine fractions using 
peak areas on Chromeleon® software and urine volumes are given tn table 3.5. 
Volumes for individual samples for all three protocols are given in appendix CD/Chapter 
3/urine volumes. 
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Table 3.5 Urine volumes and concentrations of LA and MA from pooled 5hr test samples 
from urines of black and white subjects collected on day 3 of each protocol 
Blacks Whites 
Concentration Concentration 
Protocol volume (~glml) volume (~glml) 
(ml) LA MA (ml) LA MA 
P1 (regular diet) 4180 4.00 399.50 4455 3.00 503.00 
P2 (standardized diet) 6401 9.00 358.00 5740 7.50 358.00 
P3 (high-oxalate 6085 2.10 137.05 6280 1.00 123.00 
standardized diet) 
Comment 
The LA and MA concentration values (table 3.5) obtained from peak areas were used to 
calculate the recoveries of LA and MA after taking into consideration the total combined 
amount of ingested analytes and the total combined volumes (table 3.5). The combined 
total volume of the pooled urine fractions was also determined in the same way. The 
urinary recoveries (~g) of LA and MA were determined as ~g/ml X volume (ml) 
(Duerksen et al. 2005, Lostia et al. 2008). The respective percentage recoveries of the 
ingested dose of LA and MA were then calculated. 
For calculating percentage recoveries of LA and MA in the pooled 5hr test urine fractions 
from the two race groups, the combined total amount of test solution ingested by 
subjects from each race group was taken into account. For example, for MA, 2g MA was 
ingested by each of the 10 subjects per group contributing to the pooled urine fractions, 
therefore 20g MA was taken as the ingested amount for the calculation of %MA 
recoveries. 
Results are expressed in two ways. Firstly, they are expressed as the percentage 
recoveries of the ingested dose of LA and MA present in the pooled 5hr test urine 
fractions. Secondly, they are expressed as the percentage excretion LA%/MA% ratio (an 
accurate and reliable indicator of gut permeability) (Catassi et al. 1997, Generoso et al. 
2003, Bosi et al. 2006) and are given in table 3.6 to table 3.10. No attempt was made to 
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correct for the small amount of endogenously produced MA appearing in the urine as in 
the studies by Northop et a/. 1990 and Goren et a/. 1995. Hypothesis tests (p-va/ues) are 
not possible in this case because urine samples were pooled for each race group so the 
data consist of a single observation in each group (Underhill and Bradfield 2001). 
Table 3.6 Percentage recoveries of LA, MA and LAlMA ratios from pooled 5hr test urine 
fractions from urines of black subjects for all three protocols (P1, P2 and P3) 
%LA %MA LA%IMA% 
Protocol 1 0.03 8.3 0.004 
Protocol 2 0.12 11.4 0.010 
Protocol 3 0.03 4.2 0.007 
Table 3.7 Percentage recoveries of LA, MA and LAlMA ratio from pooled 5hr test urine 
fractions from urines of white subjects for all three protocols (P1, P2 and P3) 
%LA %MA LA%/MA% 
Protocol 1 0.03 11.2 0.003 
Protocol 2 0.09 10.3 0.009 
Protocol 3 0.01 3.9 0.003 
Table 3.8 Comparisons of the percentage recoveries of LA, MA and LAlMA ratios from pooled 
5hr test urine fractions from urines of black and white subjects for protocol 1 (regular 
diet) 
% Recoveries Blacks Whites 
of probes 
%LA 0.03 0.03 
%MA 8.3 11.2 
LA%/MA% 0.004 0.003 
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Table 3.9 Comparisons of the percentage recoveries of LA, MA and UVMA ratios from pooled 
Shr test urine fractions from urines of black and white subjects for protocol 2 
(standardized diet) 
% Recoveries Blacks Whites 
of probes 
%LA 0.12 0.09 
%MA 11.4 10.3 
LA%/MA% 0.010 0.009 
Table 3.10 Comparisons of the percentage recoveries of LA, MA and UVMA ratios from pooled 
Shr test urine fractions from urines of black and white subjects for protocol 3 (high-
oxalate standardized diet) 
% Recoveries Blacks Whites 
of probes 
%LA 0.03 0.01 
%MA 4.2 3.9 
LA%/MA% 0.007 0.003 
Comment 
The percentage recoveries of urinary MA excretion in all three protocols ranged from 
4.2-11.4 % of the ingested dose in black subjects while in white subjects the range was 
similar (3.9-11.2%). Low percent recovery ranges of urinary LA were observed in the two 
race groups, with 0.03-0.12% of the ingested dose recovered for black subjects while in 
white subjects the recovery range was 0.01-0.09 %. 
Data analysis of gut permeability index in the two race groups reveal that in all three 
protocols, the LA%/MA% ratio (an index of gut permeability) was within normal reference 
intervals (range of present study 0.003-0.010 vs range from literature values 0.006-
0.030). In protocol 1, following regular diet, the ratio was similar between the two groups 
(0.004 vs 0.003, for blacks and whites, respectively). Administration of a standardized 
diet did not have a noticeable effect on the gut permeability as it remained similar in both 
groups (0.010 vs 0.009) for blacks and whites respectively, albeit there was a slight 
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increase in MA excretion in the black subjects, it was accompanied by a slight increase 
in LA excretion, hence the ratio did not vary. On the other hand, administration of a high-
oxalate standardized diet in protocol 3, led to a reduction of more than 50% in MA 
excretion in black and white subjects. However, the gut permeability index was still 
within the normal range in both groups, due to the very low recoveries of LA. In addition, 
the gut permeability index for this protocol was slightly higher in black subjects than 
white subjects (0.007 vs 0.003, respectively). 
Analysis of reconstituted 24hr urines 
Comparisons of urinary parameters and computed risk indices for black and white 
subjects following protocol 1 (regular diet), protocol 2 (standardized diet) and protocol 3 
(high-oxalate standardized diet) are given in figures 3.11 to 3.21. 
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Figure 3.21 Comparisons of mean Tiselius risk index 
Comment 
gut permeability & oxalate handlmg 
It has been stated earlier in chapter one that diel plays a crucial role In the pathogenesIS 
of calcium-containing kidney stones and that It has been shown to have a key role in 
determining urine chemistry and as a consequence, can influence the risk of stone 
formation (Rodgers and Lewandowski 2002, Taylor and Curhan 2004). Indeed, the 
comparisons of the mean 24hr urinary composition data obtained from black and white 
subjects in present study, indicate as shown in the figures 3.11 to 3.2 1, that the 
administration of the three protocols Pl (regular diet) . P2 (standardized diet) and P3 
(high-oxalate standardized diet) induced remarkable changes (both favourable and 
unfaVO/.Jreble) to Ihe most important urinary risk factors for slone formation in both 
groups (although to different extents in some instan~s) . 
Inter alia , in black subjects, the urinary parameters that increased sigmficantly is oxalate 
in P3 (p=O.0021) while an increase in citrate was approaching significance in P2 and 
reached significance in P3 (p =0.0607 and p<O.OOO1, respectively). In white subjects, 
although potassium showed a decreasing trend from P1 to P3, the decrease only 
reached statistical significance in P3 (p=0.0428). 
When making comparisons of the urine parameters in black and white subjects for each 
protocol , experimental data further showed that , citrate and oxalate were significantly 
higher in blacks than in whites in P1 and P3 (p=0.0206 and 0.0046, respectively). 
Urinary calcium. sodium and magnesium were sign ificantly higher in whites than In 
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blacks for protocol 1 (p=O.0021, p=O.0246 and p=O.0253, respectively). It is also noted 
that although the urinary pH showed increasing trends from P1 to P3 in both groups, it 
only reached statistical significance in the white group, in P3 (p=O.0287). 
With regard to the relative supersaturation of calcium oxalate (COM) values (computed 
from al/ the urinary parameters shown in the figures above), although there were no 
significant differences when comparing values obtained from black and white subjects 
for this risk index, there was a significant decrease from P1 to P2 for black subjects 
(p=O.0179). The Tiselius risk index (computed from urinary calcium, magnesium, citrate, 
oxalate and creatinine only) was significantly higher in black subjects for P3 (p=O.0003) 
while it did not change significantly in white subjects (p=O.2281), although it showed a 
similar trend (an increase in P3). 
3.5 Discussion 
In this chapter, determination of the gut permeability index in black and white South 
African subjects using the LA-MA absorption test, has been described. Discussion of the 
study described in this Chapter will commence with a critical assessment of the 
technique used for evaluating permeability. The choice of analysis of permeability of the 
two sugars using the HPAEC-PAD technique, proved to be a. relatively good option as it 
allowed both analytes (LA and MA) to be determined even in relatively small amounts 
(for example, 1.0 Ilg/ml obtained for the recoveries of LA from the pooled 5hr test 
sample from white subjects in protocol 3). Moreover, all the peaks were well-resolved, 
with elution of both analytes achieved in a reasonable time (-30min). 
The use of the alkaline mobile phase (e.g NaOH) is a critical factor in analysis of 
carbohydrates by HPAEC-PAD. This is mainly because most carbohydrates are weak 
acids (with pKa values in the range 12-14), and at high pH values, their hydroxyl groups 
are consequently partially or totally transformed into oxyanions, which enable this class 
of compounds to be chromatographed as anions (Corradini et a/. 1997, Andersen and 
S0rensen 2000). Conversely, the use of such high pH eluents, might also serve as a 
drawback as it may cause carbonate, a divalent anion at pH 12, to bind strongly to the 
columns and interfere with carbohydrates binding, causing a drastic decrease in column 
selectivity and a loss of resolution and efficiency (Cataldi et al. 1998). Nevertheless, the 
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eluent used in the present study was relatively carbonate-free as it was first purged with 
nitrogen and then continually degassed with helium during elution to prevent absorption 
of atmospheric carbon dioxide and subsequent production of carbonate, which would act 
as a displacing ion and shorten retention times. 
In addition, the pulsed-amperometry detector used in HPAEC-PAD technique, allows for 
detection of only those compounds containing functional groups oxidizable at the 
detection voltage employed (Generoso et a/. 2003, Casabuono et a/. 2005). Thus, 
neutral and cationic samples were eluted in the void volume of the column. However, 
noting that urine is a complex matrix sample, it is comforting that, even if such species 
were oxidizable, they did not interfere with the analysis of the carbohydrate components 
of interest (LA and MA) as seen in all the chromatograms which were obtained (see 
appendix C~/Chapter 3IHPAEC-PAO chromatograms). 
The interference of the available internal standard (arabinose) with the MA peak (MA) 
(chromatogram not shown) culminated in it being discarded. However, in order to 
overcome this limitation, each pooled sample was analysed in triplicate under similar 
conditions. As a result, analysis of results can be regarded with some degree of 
confidence. 
Much of the published work on permeability testing has been done on diseases (e.g 
pediatrics, coeliac disease, Crohn's disease, chronic diarrhoea and malnutrition) that 
affect gut permeability. Although early studies have linked intestinal diseases to renal 
colic (Dowling et al. 1971, Admirand 1972, Smith et al. 1972, Stauffer 1977, Dobbins 
1985), laboratory data on gut permeability tests with respect to kidney stone disease 
appear to be lacking. Thus, findings in the present study could not be compared with any 
published reference values. 
However, as stated earlier, the results compare favourably with other studies 
investigating gut permeability in other diseases (e.g pediatrics, coeliac disease, Crohn's 
disease, chronic diarrhoea and malnutrition) as well as in healthy subjects as described 
in this chapter (introduction) (Wheeler et al. 1978, Menzies et al. 1979, Ford et al. 1985, 
Elia et al. 1987, Juby et al. 1989, Sullivan et al. 1992, Peters et al. 1994, Iqbal et al. 
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1996, Catassi et al. 1997, Marsilio et al. 1998, Kukuruzovic et al. 1999, Haase et al. 
2000, Generoso et al. 2003, Liu et al. 2004, Dastych et al. 2008). 
Although analysis of percentage recoveries of the analytes in the present study was 
performed in pooled test samples as done by Monteleone and co-workers (2004), it is 
conceded that individual variability was lost. For example, in a study by Iqbal and co-
workers (1996), it was also reported that 33% Indians and 45% Afro-Caribbeans had 
values outside the normal white range while four otherwise healthy patients (three Afro-
Caribbens and one Indian) fell within the coeliac patients' range. 
In the present study, the levels of percentage recoveries of urinary LA and MA have 
been reported and gut permeability index (LA o/alMA % ratio) was determined in a stone-
prone population and a relatively stone-free population following administration of 3 
protocols, protocol 1 (regular diet), protocol 2 (standardized diet), and protocol 3 (high-
oxalate standardized diet). In addition, urinary parameters have also been measured 
including urinary oxalate excretion, a major risk factor for kidney stone disease in the two 
race groups and risk indices for stone formation were computed. 
As stated earlier, the hypothesis in the present study is that blacks have a better 
intestinal integrity and therefore better intestinal control mechanisms that allows for less 
oxalate to be absorbed when challenged by a high dose of oxalate. Whereas, in whites, 
the integrity of the gut wall could be lowered (made more permeable) and thus passive 
intestinal absorption of oxalate could occur when challenged by a high dose of oxalate. 
The results obtained in the present study are intriguing. In all three protocols consistently 
low percentage recoveries of LA were observed in both groups (0.01-0.15%) although 
this was within the aforementioned normal reference interval range, the reason for this 
observation is unclear. It appears that the pulsed-amperometric electrochemical detector 
used might be insensitive to LA as analysis was done in triplicate. It is also possible that 
both premucosal, mucosal and postmucosal factors could be responsible for the low 
recoveries of LA. In a study by Monteleone and co-workers (2004), in which intestinal 
permeability in patients with aneroxia nervosa was investigated, reduced recoveries of 
LA was ascribed to changes in the anatomophysiology of intestinal mucosa leading to a 
decreased passage of sugar into systemic circulation. 
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For apparently healthy subjects, it is not far-fetched to speculate that this could also 
occur through bacterial degradation of LA (colonic or in urine) (Goren et al. 1995, 
Soderholm et al. 1999, Farhadi et al. 2008, Vilela et al. 2008). However, this seems 
unlikely as errors such as bacterial degradation of the sugars should affect both of them 
equally (Vilela et al. 2008), casting doubt about this possibility. Although there are no 
data available on renal clearance of LA, it appears as if this clearance is dependent on 
the quantity of LA present in the circulation as shown in a study by van Nieuwenhoven 
and co-workers (2000). who observed a lower recovery of LA at 5hr after a higher 
quantity of LA ingested in a dose-dependency study. 
Furthermore, according to Fasano (2001), the paracellular route, through which LA is 
thought to permeate, is the dominant pathway for passive solute flow across the 
intestinal epithelial barrier, and its permeability depends on the regulation of intercellular 
tight junctions, also known as the zonula occludens. In recent years, much has been 
discovered about the structure, function and regulation of tight junctions although the 
precise mechanism(s) through which they operate is still incompletely understood. 
Nevertheless, most authors agree that LA permeates the mucosa via the para cellular 
pathway (through the tight junctions) (Catassi et al. 1997, Marsilio et al. 1998, 
Kukuruzovic et al. 1999, Haase et al. 2000. Generoso et al. 2003, Liu et al. 2004, 
Dastych et al. 2008). Thus, it is conceivable that the low absorption of LA observed 
could be indicative of an indication of the integrity of the gut mucosa in both groups, 
which might have led to the reduced passage of this sugar probe through the tight 
junctions. 
Data from HPAEC-PAD chromatograms revealed interesting trends with regard to MA 
recoveries in the 5hr test samples from the two race groups. In fact, the most prominent 
abnormality observed in this study, along with the augmented urinary oxalate excretion 
in black subjects, was the reduction of mannitol permeability in both groups following the 
administration of a high-oxalate standardized diet. In addition, the trend of this reduction 
is rather closely similar in both groups. For example, in black subjects, the percentage 
recoveries of MA was reduced from 11.4% in the standardized diet protocol to 4.2% in 
the high-oxalate standardized diet, while in white subjects the reduction was analogous 
from 10.3% to 3.9%. Although the reduction of MA recoveries was extreme (more than 
50%) in both groups, it was still within the aforementioned normal reference intervals. 
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It has been theorized that MA diffuses through small water-filled pores in the enterocyte 
cell membrane, reflecting total transcellular transport of basal surface area. (8ao et al. 
1996). It is commonly assumed that reduced MA percentage reflects the reduction in the 
total surface area of the small intestine caused by villous atrophy. Moreover, the present 
findings of reduced MA recoveries in both groups in protocol 3 seem to be in agreement 
with studies that have shown reduced MA permeability in patients with active celiac 
disease and other diseases that cause villous hypotrophy as a result of reduced 
absorptive area (Gatassi et al. 1997, Vilela et al. 2007). According to Andre and co-
workers (1988), permeation of MA is generally low except in patients free from 
localisation of Grohn's disease in the small bowel. This is in line with the concept that 
MA absorption is mainly transcellular and located in the small bowel. It is further posited 
that the low permeability in Grohn's disease could be a consequence of either intestinal 
hurry or of a smaller surface of absorption possibly related to a reduction in the mean 
cellular pore size. 
With respect to the influence of diet on permeability between the two race groups, it was 
observed that in week 1, protocol 1 while following their respective regular diet, there 
were no differences in the gut permeability index in the two groups as shown by similar 
LA%IMA% ratios (0.004 vs 0.003, for blacks and whites respectively), in addition, there 
was also no variation in the gut permeability index in week 2, protocol 2, when both 
subjects were on a similar, strict and controlled standardized diet (0.010 vs 0.009, for 
blacks and whites respectively). However, after the administration of the high-oxalate 
standardized diet in week 3, protocol 3, there was a marked reduction of MA (more than 
50%) in both groups and the gut permeability index was slightly higher in black subjects 
than in white subjects (0.007 vs 0.003, respectively). Statistical significance could not be 
determined for these observations (see page 107). Nonetheless, the LA%/MA% ratios 
were still within the normal range due to the very low LA excretion values obtained. 
Thus, the present results are noteworthy in this additional respect that data analysis 
clearly revealed that the gut permeability index in both South African black and white 
race groups was within the normal range in all three protocols (range 0.003-0.010 vs 
0.006-0.030, range of present study vs range from literature values respectively). 
Nonetheless, taken together, the cited data obtained in the present study in protocol 3 
(i.e reduced MA and low LA percent recoveries) imply an indication of a defect in the 
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observation in protocol 3, the present author might tentatively conclude that there was 
an induced general malabsorption of nutrients after the high-oxalate standardized diet in 
this regard. 
It is feasible that the differences observed after the high-oxalate standardized diet can 
be attributable to the different renal handling mechanisms of oxalate in the two race 
groups. This is in consideration of the fact that, in protocol 3 of this study, experimental 
data showed that after oral oxalate loads urinary oxalate was significantly higher in black 
subjects compared to white subjects (p=O.0046), indicating an increased risk of stone 
formation in the black subjects. This was further confirmed and manifested in the 
observed significantly higher Tiselius risk index for this group which reached statistical 
significance in P3 (p=O.0003) as opposed to white subjects who did not show a 
sjgnificant increase in this risk index (p=O.22B1). 
This is rather surprising considering the reported low incidence of stone formation in the 
black population. Although in one hand it confirms the findings by Lewandowski and co-
workers (2001) who observed higher urinary oxalate levels in black subjects compared 
to white subjects after an oxalate-rich meal. On the other hand, it not only contradicts the 
findings in recent studies (Rodgers and Lewandowski 2002, Lewandowski et al. 2004a, 
Lewandowski et al. 2004b) but it also disproves the hypothesis mentioned earlier in this 
chapter. 
It is noteworthy that in Lewandowski study (2001), observations were based on oxalate 
intake from spinach, it is uncertain whether the results observed with a spinach-derived 
oxalate load would compare with those observed with sodium oxalate due to poorly 
defined bioavailability of oxalate in spinach. It is also possible that the oxalate contained 
in food may be handled differently from that of a crystalline salt (Holmes et al. 2005). 
Factors that may modulate the absorption of oxalate include co-ingestion of calcium and 
magnesium, the presence of oxalate degrading bacteria and inherent absorption 
characteristics (Holmes and Assimos 2004). It has been postulated that lower dietary 
calcium (in blacks) could cause reduced complexation with oxalate in the gastrointestinal 
tract leading to increased absorption and hence higher urinary oxalate (Messa et al. 
1997, Lewandowski et al. 2005) while a previous study had demonstrated that blacks 
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1997, Lewandowski et al. 2005) while a previous study had demonstrated that blacks 
have significantly more oxalate-degrading bacteria including O. formigenes and greater 
oxalate-degrading capability than white subjects (Lewandowski and Rodgers 2004a). 
However, in the present study, when both groups were following high-oxalate 
standardized diet with normal calcium and similar magnesium intake, it may be 
speculated that the data show that blacks handled oxalate more transiently than white 
subjects. This striking and rapid increase (transient/temporary) in the urinary oxalate 
excretion after oral oxalate load, proves the absorption of oxalate in the upper 
gastrointestinal tract and agrees with the investigation of Balcke et al. 1989. 
Although the reasons for this observation are not clear, transient hyperoxaluria has been 
observed in a number of studies after oxalate loads (Marshall et al. 1972, Barilla et al. 
1978, Finch et al. 1981, Balcke et al. 1989, Nguyen et al. 1994, Hess et al. 1998, 
Liebman and Costa 2000, Holmes et al. 2001). In most studies, the transient 
hyperoxaluria that occurred (increases of about 8-289%) was equivalent to that 
observed chronically in individuals with primary hyperoxaluria where such conditions can 
cause pathological changes (Jaeger and Robertson 2004). Nonetheless, since Holmes 
and co-workers (2005) did not observe renal injury (urinary N-acetyl-j3-glucosaminidase 
(NAG) and y-glutamyl transpeptide (GGT) or oxidative stress (urinary isoprostanes) after 
oxalate loads of up to 8mmol sodium oxalate in normal individuals, these markers were 
not investigated in this study. 
Apart from excessive intakes of oxalate, increased urinary oxalate excretion could 
originate from its precursors (ascorbic acid and glycolate) or from increased endogenous 
synthesis as in primary hyperoxaluria (Finch et al. 1981, Jaeger and Robertson 2004). It 
is generally accepted that oxalate absorbed from the diet is almost all excreted from the 
body by the kidney. In 2005, Holmes and co-workers concluded that oxalate is rapidly 
absorbed and cleared by the kidney by filtration and secretion following an oral oxalate 
load. If this is indeed correct as the present author believe, then it seems credible that 
this renal oxalate secretion process, which has a significant role in the renal handling of 
an oral oxalate load, occurs differently in the two race groups. 
Nevertheless, in addition to the aforementioned differences in urinary oxalate excretion 
in the two race groups, an increase in urinary citrate excretion reached Significance only 
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in black subjects (p<O.0001) in protocol 3. Although such an increase in urinary citrate 
after oral oxalate loads has been reported before in the two groups, its mechanism is still 
unexplained in literature (Lewandowski et al. 2001). 
The available evidence argues against the hypothesis which motivated this study, 
namely that blacks have a better intestinal integrity and therefore better intestinal control 
mechanisms which allow for less oxalate to be absorbed when challenged by a high 
dose of oxalate while in whites the integrity of the gut wall might be lowered (made more 
permeable) and thus passive intestinal absorption of oxalate could occur when 
challenged by a high dose of oxalate. Nonetheless, of particular interest is that despite 
both race groups following similar and strictly controlled protocols, some important 
differences with regard to gut permeability index and urinary stone risk factors were 
observed in the two race groups. This lends auxiliary credence to the notion that 
different renal handling mechanisms of lithogenic (and antilithogenic) substances occur 
in these groups and that these might contribute to the differences in stone incidences in 
the two groups. 
To explore this idea further, anti-lithogenic substances (vitamin E and fish oil) were 
administered to both groups singly and in combination. These studies are described in 
Chapters 4 and 5 of this thesis. 
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Chapter Four 
Investigation of the effects of vitamin E ingestion on 
lipid peroxidation and urinary kidney stone risk factors 
in black and white South African subjects 
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4.1 Introduction 
Vitamin E is a mixture of 0-, ~-, l5-, and v-tocopherol and tocotrienols, differing in the 
methyl substitutions on the chromanoxyl ring, and the saturation of the phytyl tail. The 
most extensively studied of these is 0- tocopherol (figure 4. 1) because it has the highest 
biological activity and possesses potent antioxidant activity (Lodge et al. 2000). 
Figure 4.1 Chemical structure of vitamin E (a-tocopherof) (Brigelius-Flohe and Traber 1999) 
A well-established chemical property of vitamin E is that it is an antioxidant, which has 
been shown to protect important compounds, including vitamin A, from degradation in 
the laboratory. It probably also serves this function in organisms (Campbell 1991, Sakly 
et al. 2003). It has been reported that the interaction of vitamin E with membranes 
enhances its effectiveness as an antioxidant (Brigelius-Flohe and Traber 1999, Brigelius-
Flohe 2003, Frank 2005, Weinberg 2005, Sen et al. 2006). 
As with other fat-soluble vitamins, the absorption of tocopherols is dependent on the 
ability to digest and absorb fat. Previous studies have centred on the physical form in 
which it reaches the intestine, its location within the mucosal cells, the efficiency of 
absorption, and the effect of dietary fat unsaturation on absorption or intestinal 
destruction (Marks 1975, Munson and Falusy 1976, Blatt et al. 2001). 
It is widely accepted that free radicals are highly reactive molecules that damC\ge cells 
throughout the body and that free radical-mediated oxidative stress is implicated in the 
genesis and exacerbation of degenerative diseases including urolithiasis (Brown et al. 
1994, Seven et al. 1996, Selvam and Kalaiselvi 2001, Zhao et al. 2004). 
129 Chapter Four vitamin E & urolithiasis 
Many researchers believe that supplementing with antioxidants (e.g. vitamin E) can 
dramatically reduce free radical damage, prevent and delay the onset of chronic 
degenerative diseases and possibly extend lifespan (Zhao et al. 2004). In fact, vitamin E 
has been shown to be involved in free radical physiology and antioxidant defense 
mechanisms (van Acker et al. 1993, Pope et al. 2000). Vitamin E is able to prevent free 
radical formation or terminate their reaction and is therefore, essential to protect 
molecules and biological systems from oxidative damage (Selvam 2002). 
Lipid peroxidation (LPO) products such as thiobarbituric reactive agents (TSARS) and 
malondialdehyde (MDA) and antioxidant enzymes can be measured in urine and blood 
as markers of cellular injury (Huang et a/. 2003, Khan 2005). Previous studies have 
shown that CaOx stone formers have elevated plasma TSARS (Anuradha et al. 1988, 
Ravichandran and Selvam 1990, Anbazhagan et a/. 1999) and elevated urinary N-
acetyl-l3-glucosaminidase (NAG) (Huang et a/. 2003). This is a tubular enzyme found 
primarily in the proximal tubular cells of the kidney, which is one of the most sensitive 
marker enzymes for renal tubular injury (Green et al. 2005, Khan 2005, Tungsanga et al. 
2005). In the study by Huang and co-workers (2003), it was shown that NAG of stone 
formers was positively and significantly correlated with their urinary oxalate and calcium. 
Measurement of these markers is therefore a useful indicator of stone risk profiles. 
Administration of vitamin E rapidly restored plasma antioxidant levels and reduced 
urinary excretion of oxalate and calcium in kidney stone patients (Anbazhagan et a/. 
1999). In another study involving hypertensive and hyperoxaluric patients, 
supplementation with vitamin E decreased LPO products and increased antioxidant 
enzymes and vitamin E in plasma (Sumitra et al. 2005). It also restored the biochemical 
and kinetic properties of urinary Tamm-Horsfall glycoprotein, which is a well known 
inhibitor of calcium oxalate crystallization. In addition, a recent study involving urogenital 
tuberculosis patients showed that administration of vitamin E enhanced the antioxidant 
status of plasma thereby preventing membrane injury and consequently, the risk of 
stone formation (Srinivasan et a/. 2004a). 
The potential role of free radicals, reactive oxygen species and antioxidants in the 
aetiology of chronic diseases has stimUlated extensive research (Knight 1998, 
Santanam et a/. 1998, Toyokuni 1999, Trevisan et a/. 2001). According to Khan (2005), 
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recent studies have provided evidence for the development of oxidative stress in the 
kidneys of stone patients. 
As part of the motivation and rationale of the present thesis, an investigation of effects of 
vitamin E ingestion on the biomarkers of oxidative stress in South Africa's stone-prone 
and relatively stone-free population groups was undertaken. Details of this study are 
described in this Chapter. 
4.2 Subjects and Methods 
Study population (Inclusion criteria) 
Healthy South African black (n=5) and white (n=5) male subjects were recruited from the 
student cohort of the University of Cape Town via advertisement in the university notice 
boards. The number of subjects corresponds to that of similar studies (Burton et a/. 
1998, Couderc et al. 1998, Meagher et al. 2001, Traber et al. 2001, Rabovsky et al. 
2006). The age range of subjects was 18-30 years in each group. 
Exclusion criteria 
Subjects were excluded if: 
• they were on any medication or taking supplements that might affect vitamin E 
metabolism e.g. warfarin, dalteparin sodium, enoxaparin sodium 
• they had high blood pressure and/or diabetes 
• they had a family history of renal or kidney stone disease 
Study design 
Subjects were required to ingest one vitamin E capsule (dl-a-tocopheryl acetate, 400 IV) 
per day every day immediately after supper for 60 days (Meagher et al. 2001, Srinivasan 
et a/. 2004a, Srinivasan et a/. 2004b, Sivrioglu et al. 2007). The vitamin E capsules were 
manufactured by Vitalfarm (pty) Ltd, Cape Town, South Africa. 
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Venous blood samples (Sml) were collected in EDTA tubes by a qualified phlebotomist 
from each subject on day 0 (baseline) and on day 60 (post-supplementation), following 
an overnight fast (-12hrs). Blood samples were kept in the dark and on ice until 
centrifugation. Plasma samples were prepared within 1 hr of blood collection by 
centrifugation (3000 rpm for 10 min) (Horoz et al. 2005, Rabovsky et al. 2006) using 
Labofuge 200, Heraeus Sepatech, Germany. Plasma vitamin E was determined using 
high performance liquid chromatography (HPLC) method. Urinary and plasma TBARS 
were measured using commercially available assay kits (OXI-TEK TBARS Assay Kit, 
ZeptoMetrix, Buffalo, New York, USA). Details of both analyses are provided below. 
24hr urine samples were also collected on the day in which blood samples were drawn 
for measurement of urinary parameters as described in Chapter 2, Section 2.2. 
Subjects were instructed to continue taking their free and unrestricted regular diet for the 
duration of the study (Turley et al. 1998, Wander and Du 2000, Higdon et al. 2001) so 
that their habitual intake of macronutrients was maintained throughout the study period. 
24hr dietary food records were also collected on the days in which blood and urine 
samples were drawn (see appendix CO/chapter 4124hr dietary food record). The 
subjects' dietary food intake was assessed using a FoodFinder 2 computer software 
programme (Langen hoven et al. 1991) (see appendix C~/Chapter 4/dietary analysis). 
4.3 Determination of plasma vitamin E (HPLC) 
Plasma vitamin E (a-tocopherol) levels were analyzed by the African Micronutrient 
Research Group, Stellenbosch University, using the procedure based on that described 
by Catignani and Bieri (1983). The test procedure is aimed at the quantitation of Vitamin 
A and E levels in human plasma or serum samples. In this method, serum or plasma are 
first deproteinised by precipitation following which the fat soluble components, including 
vitamin A and vitamin E, are extracted with hexane. After evaporation of the hexane, the 
residue is dissolved in methanol and aliquots used for quantitative determination by high 
performance liquid chromatography (HPLC). 
HPLC analysis was conducted on a Waters solvent delivery system consisting of two 
solvent pumps (model M45) and a gradient controller (model 680), Waters model 717 
plus autosampler and a Linear Programmable UV-VIS Detector (Model SSI 525). 
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Analytes were separated on a Supelco LC-18, 250mm x 4,6mm, 5IJm analytical column 
together with a Supelcosil™ LC-18 guard pack. Recording and analysis of data were 
done on EZChrom Elite/Client Server (ver 2.3) Chromatography Data System (Scientific 
Software Inc., USA) under Windows 95. 
4.4 Determination of urinary and plasma TBARS 
Urinary and plasma lipid peroxide thiobarbituric acid reactive substances (TBARS) were 
measured as MDA equivalents using commercially available kit (OXI-TEK TBARS Assay 
Kit, ZeptoMetrix, Buffalo, New York, USA) (Kwon and Watts 1964). In this assay, 
malondialdehyde (MDA) forms a 1:2 adduct with thiobarbituric acid (TBA) to form an 
MDA-TBA adduct as shown in the reaction scheme (figure 4.2), which can be measured 










• ~ N 
OH OH 
MDA-TBA Adduct 
Figure 4.2 Reaction scheme of MDA with TBA 
Preparation of solutions 
The following solutions were provided with the kit: TBA (4 vials) containing 0.53 grams 
TBA, TBARS diluent 1 (4x50 ml) containing acetic acid, TBARS diluent 2 (4x50 ml) 
containing sodium hydroxide, MDA standard (20 ml) containing 100 nmollml 
malondialdehyde Bis (dimethyl acetal), MDA diluent (100 ml) containing sterile deionized 
water and sodium dodecyl sulphate (SDS) solution (30 ml). 
A TBAlBuffer reagent was prepared as follows: TBA was added to a mixing vessel 
containing half a bottle of TBARS diluent 1. The vial was mixed with the remaining half of 
+ 2H2O 
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TBARS diluent 1 and added to the mixing vessel. A full bottle of TBARS diluent 2 was 
then added while mixing until the TBA was completely dissolved. 
Assay procedure 
A series of five standards in MOA standard diluent was prepared using the dilution 
scheme as shown in table 4.1. The MOA standard was used undiluted for the 100 
nmollml concentration. All reagents were allowed to reach room temperature before use. 
Samples or standards (100 1-11) were then pipetted into properly labeled tube. 1001-11 SOS 
solution was added to each tube with mixing. 2.5 ml TBAlBuffer reagent was added 
forcefully down the side of each tube, which was then covered with glass marbles 
(provided with the kit) and incubated at 95°C for 60 minutes. The samples or standards 
were then cooled to room temperature in an ice bath for 10 min. The mixtures were then 
centrifuged (Labofuge 200, Heraeus Sepatech, Germany) at 3000 rpm for 15 min. The 
supernatants were removed from samples for analysis and absorbances were read at 
532 nm using a spectrophotometer (Spectronic Unicam Helios, Cambridge, England). All 
assays were performed in duplicate. Mean data obtained from absorbance readings of 
standard solutions (table 4.1) were used to prepare a calibration curve as shown in 
figure 4.3 and are expressed as MDA equivalents (nmollmf) (Kwon and Watts 1964). 
The calibration curve was then used to calculate the respective concentrations of urine 
and plasma TBARS (as MDA equivalents) (section 4.6). 
Table 4.1 Dilution scheme for preparations of MDA standards 
Standard MDA MDA MDA Mean 
(nmol/ml) (pi) diluent (pi) Absorbance 
(532 nm) 
0 0 0 1000 0 
1 12.5 125 875 0.0755 
2 25 250 750 0.1525 
3 50 500 500 0.2565 
4 100 1000 0 0.5390 
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Figure 4.3 The standard curve for TBARS determinations (MDA nmol/ml) 
4.5 Urine analysis 
24hr urine samples were collected on day 0 (baseline) and on day 60, following vitamin 
E supplementation. Urinary parameters were measured as described in Chapter 2, 
Section 2.2 of this thesis. 
4.6 Statistical analysis 
Data were statistically analysed using repeated measures AN OVA, STATISTICA version 
8.0. Data were considered statistically significant if p~0.05. 
4.7 Results 
Dietary analysis 
Comparison of the mean nutrient intakes derived from the 24hr dietary records from 
black and white subjects are given in table 4.2 while the summary of changes is given in 
table 4.3. The raw data are presented in appendix CD/Chapter 4/Dietary analysis. 
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Table 4.2 Comparisons of mean dietary intakes (SE) of black and white subjects before 
and following vitamin E ingestion (60 days) 
Black (B) White(W) 
Nutrients OayO Oay60 p- OayO Oay60 p-valuea 
values 
BMI (kg/m") 25.30(0.98) -- -- 25.81 (0.98) -- --
Energy 8720 8922 0.7360 13815 14133 0.5970 
(kJ) (1623) (1270) (1622) (1270) 
Moisture 1870 1729 0.3150 3287 3303 0.9072 
I (gIday) (392) (469) (392) (469) 
• Total Protein (g/day) 86(5.4) 87(6.2) 0.8190 121(5.4) 116(6.2) 0.2630 
~ 
0.7659 111(15) 109(15) 
1=2262' I 0.5141 339(25) 350(21) 0.6074 
I Fibre 25.10 0.2444 27.00 29.37 0.2635 
(glday) (3.45) (4.03) (3.45) (4.03) 
Total Sugar 36.91 38.56 0.4453 60.44 60.75 0.8851 
(glday) (7.89) (8.33) (7.89) (8.33) 
Oxalate (mg/day) 262(47) 251(41) 0.1399 119(47) 120(41) 0.7903 
• Calcium (mg/day) 659(69) 683(55) 0.6062 1151(69) 1088(55) 0.1907 
Magnesium (mglday) 
~ 
280(13) 0.6236 381(20) 372(13) 0.4809 
Phosphate 1670 0.1099 1999 1997 0.7941 
(mglday) (286) (253) (286) (253) 
Potassium (mglday) 2835(491) 2846(493) 0.8447 3550(491) 3497(493) 0.3661 
Sodium (mg/day) 2769(626) 2738(634) 0.6613 3641(626) 3609(634) 0.6518 
Vitamin A 1031 1050 0.5381 1157 1140 0.5870 
(RE/day) (197) (198) (197) (198) 
Vitamin B6 2.56 2.44 0.4170 2.83 2.80 0.8650 
(mglday) (0.39) (0.35) (0.39) (0.35) 
Vitamin C (mg/day) 121(24) 122(23) 0.7629 105(24) 103(23) 0.6286 
Vitamin D 3.32 3.30 0.4740 4.00 4.00 0.9454 
(pg/day) (1.09) (1.10) (1.09) (1.10) 
Vitamin E 9.88 8.97 0.3024 11.88 10.92 0.2824 
(pg/day) (1.20) (0.95) (1.20) (0.95) 
.. 
*SlgniflCance at p~O. 05, **approachlng SIgnificance 
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Table 4.3 Summary of comparisons of mean dietary intaKes between the two race groups 
Nutrients Comparison 
Day 0 Day 60 
Energy· B<W B<W 
Moisture" 8 <W B<W 
Total protein' B<W B<W 
Oxalate B>W B>W' 
Calcium' B<W 8<W 
Magnesium" B<W B<W 
.. 
• Significantly different p~ 05, ~ approachmg significance 
Comment 
Comparison of mean dietary intakes between the two race groups for moisture, energy .. 
total protein, calcium and magnesium followed the sequence B<W, the only exceptions 
were mean intake of oxalate which followed the sequence B>W. 
Plasma vitamin E 
Plasma vitamin E was determined as described in section 4.3 of this Chapter and is 
expressed as its most active form a-tocopherol (Bngelius-Fohle and Traber 1999). 
Comparisons of the relative levels of plasma Ct.-tocopherol obtained in both race groups 
































Day 0 Dav 60 
Time (daYI "p=O.0689 vs basellnc 
"p=C.OD47 vs baseline 
• Significance at p<O" 05, ·'approaching significance 
Figure 4.4 Comparisons of mean plasma a-tocopherol of black. and white subjects 
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Comment 
At baseline. no significant differences were observed in mean plasma a-tocopherol 
values between black and white subjects (p=0.8272). Following supplementation. a 
favourable increase (from 9.48 ± 1.09 to 15.14 ± 1.83 mglL) was observed for black 
subjects which approached significance (p=0 0689). However. a significant and 
favourable increase (from 10.22 ± 0.77 to 20.72 ± 4.13 mglL) was observed in white 
subjects (p=O.OO47). No significant differences were observed when comparing plasma 
a-tocopherol levels in the two groups at day 60 (p=0. 1153). 
Urinary TBARS 
Mean urinary TBARS expressed as MDA equivalents (j.Jmol/ 9 creatinine) (Jacob et a/. 
2003. Goulart et a/. 2005) were determined from the calibration curve shown in (figure 
4.4). Comparisons of the relative levels in black and white subjects at baseline and after 
vitamin E ingestion (60 days) are given in figure 4.5 below. 
Day 0 




Figure 4.5 Comparisons of mean urinary TBARS of black and white subjects 
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Comment 
No significant changes or differences were observed when making within-groups or 
inter-group comparisons for this parameter before or following vttamin E ingestion (60 
days). 
Plasma TBARS 
Mean plasma TSARS expressed as MDA equivalents (nmollmf) (Kwon and Watts 1964. 
Ide et a/. 2002) were determined from the calibration curve shown in (figure 4.3). 
Comparisons of the relative levels in black and white subjects at baseline and after 
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Figure 4.6 Compansons of mean plasma TSARS of black and while subjects 
Comment 
At baseline, no significant differences were observed in mean plasma TBARS (MDA 
equivalents) between black and white subjects (p=0.2782). Following vitamin E ingestion 
for 60 days, data showed that relative plasma TBARS (MDA equivalents) values were 
slightly reduced In blacks (from 2.42±OA8 to 1. 96±O. 23 nmollml) as well as in whites 
(from 1.B2±0.4B to 1.57±0.23 nmollml). These slight changes/reductions were not 
statistically significant in both groups (p=o. 1789 in blacks and 0. 4449 in whites). No 
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significant differences were observed when comparing the relative levels in the two 
groups at day 60 (p=0.4685). It appears as if plasma TBARS (MDA equivalents) values 
were slightly higher in blacks than whites on both days albeit the differences were not 
statistically significant (p>O.05). 
Urine analysis 
Comparison of mean 24hr urine data from the two race groups before and following 
vitamin E ingestion is given in table 4.4 while the summary of changes in parameters 
investigated in this study following vitamin E ingestion is given in table 4.5. The raw data 
from each subject are presented in appendix CD/Chapter 4/urinary analysis. 
Comparison of mean urinary parameters between the two race groups showed that, 
urinary calcium was significantly higher in whites than in blacks at baseline (day 0) and 
at day 60 (p=O.0170 and p=O.0386, respectively). Magnesium was slightly higher in 
whites at baseline, approaching significance (p=O.0609). Following vitamin E ingestion 
for 60 days, the only urinary parameter that changed significantly was citrate excretion, 
which was elevated in both groups (p=O.0017 for blacks and p=O.0001 for whites). No 
other changes were observed. 
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Table 4.4 Comparisons of mean 24hr urine parameters (SE) from urines of black and white 
subjects before and following vitamin E ingestion (60 days) 
Black (B) White (W) B YS W, p-values 
Parameter Day 0 Day 60 p-values Day 0 Day 60 p-values Day 0 Day 60 
pH 6.70 6.77 0.5660 6.29 6.35 0.6374 0.1042 0.0957 
(0.19) (0.12) (0.19) (0.12) 
Volume 1588 1719 0.2084 1453 1596 0.1736 0.4449 0.4854 
(mIl24hr) (123) (117) (123) (117) 
Citrate 2.71 4.94 0.0017* 1.96 5.27 0.0001* 0.2905 0.6369 
(mmoIl24hr) (0.40) (0.55) (0.40) (0.55) 
Oxalate 0.21 0.24 0.5608 0.23 0.28 0.2431 0.6384 0.2394 
(mmoI124hr) (0.03) (0.03) (0.03) (0.03) 
Calcium 2.22 2.72 0.2506 4.43 4.56 0.7432 0.0170* 0.0386* 
(mmoIl24hr) (0.62) (0.47) (0.62) (0.47) 
Magnesium 2.02 2.01 0.9738 3.11 2.99 0.8030 0.0609* 0.0873 
(mmoIl24hr) (0.41 ) (0.35) (0.41 ) (0.35) 
Sodium 222.2 273.16 0.2256 208.52 213.86 0.8940 0.8548 0.4342 
(mmoI124hr) (60) (41 ) (60) (41 ) 
Potassium 47.56 58.10 0.1617 55.06 68.76 0.0800 0.7406 0.6391 
(mmoll24hr) (16) (15) (16) (15) 
Urate 2.68 3.32 0.2098 4.08 4.28 0.6813 0.1015 0.2464 
(mmoIl24hr) (0.62) (0.48) (0.62) (0.48) 
Creatinine 14.64 15.08 0.4869 16.90 17.08 0.7732 0.2306 0.2845 
(mmoIl24hr) (1.34) ( 1.14) (1.34) (1.14) 
Phosphate 20.98 27.88 0.3802 31.16 38.80 0.3338 0.1609 0.1344 
(mmoIl24hr) (5.30) (4.45) (5.30) (4.45) 
RS CaOx (COM) 5.31 5.34 0.9233 6.88 6.76 0.6971 0.0243* 0.0375* 
(0.46) (0.38) (0.46) (0.38) 
RS brushite 7.16E-9 7.13E-9 0.9669 3.37E-9 3.72E-9 0.6140 0.0270* 0.0422* 
(1.13E-9) (9.25E-10) (1.13E-9) (9.25E-
10) 
RS uric acid 1.60 1.13 0.3462 3.25 2.85 0.4134 0.1814 0.1665 
(0.96) (0.64) (0.96) (0.64) 
Tiselius risk index 157(47) 176(17) 0.7240 227(47) 236(17) 0.8613 0.1772 0.2416 
.. 
*Slgniflcance at p~O. 05 
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Table 4.5 Summary of changes in parameters following vitamin E ingestion (60 days) 
Parameter Blacks Whites 
Plasma a-tocopherol i * i * 
Urinary TSARS -- --
Plasma TSARS -- --
Calcium -- --
Citrate 
i i * * 
Oxalate -- --
RS CaOx (COM), -- --
brushite, uric acid 
Tiselius Risk Index -- --
.. 
*Slgniflcance at p~0.05 
4.8 Discussion 
It is well-recognized that vitamin E is the major lipid soluble antioxidant in humans and 
thus plays the largest role in protecting cell membranes (Emmert and Kirchner 1999). 
Although the antioxidant defence system includes endogenous components and 
exogenous antioxidants which may be obtained by dietary intake, diet alone is not 
enough to provide the required amount of antioxidants such as vitamin E that minimize 
or prevent deleterious actions of free radicals that may induce oxidative stress (Jain et 
at. 1998, Panza et aJ. 2008). Therefore supplementation becomes necessary. In fact, it is 
the only feasible way to acquire large doses of vitamin E. For example, it would take 
1000 almonds, containing 33472 J and 658 g of fat, to provide 400 IU of vitamin E 
(Butler 1997), which was readily provided in the present study through supplementation 
of one capsule per day. 
It is recommended that 2 or more markers be used for accurate and consistent 
evaluation of oxidative stress in humans (Niki et at. 2005). In 2002, Block and co-
workers, suggested that investigators of causal mechanisms or the association between 
oxidative stress and disease, should collect data on one or both lipid peroxidation 
markers (eg TBARS and/or MDA or tsoprostanes) while other studies have used plasma 
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vitamin E as an additional measure (Selvam and Ravichandran 1993, Srinivasan et at. 
2004a, Srinivasan et a/. 2004b). 
In the present study, plasma vitamin E and lipid hydroperoxide TSARS (as MDA 
equivalents) in urine and in plasma (indeces of oxidative stress) as well as urinary risk 
factors were investigated in both race groups. At baseline, there were no significant 
differences between the two groups with respect to plasma a-tocopherol (p=0.B272). 
Supplementation with vitamin E for 60 days significantly elevated the relative levels of 
plasma a-tocopherol in both groups (p=0.06B9 for blacks and p=0.0047 for whites) but to 
different degrees. Inter-group comparisons of postsupplementation levels showed that 
the effect was slightly higher in the white group albeit not significant (p=0. 1153). Studies 
usually associate decreased plasma a-tocopherol with increased susceptibility to lipid 
peroxidation and increased plasma a-tocopherol levels with prevention of membrane 
injury and consequently, the risk of stone formation (Belcher et at. 1993, Srinivisan et at. 
2004b). This significant and favourable increase in levels of plasma a-tocopherol in both 
groups is in good agreement with previous studies that have shown enhancement of 
antioxidant status of plasma following vitamin E ingestion (Selvam and Ravichandran 
1993, Srinivasan et a/. 2004a, Srinivasan et at. 2004b). 
As mentioned earlier, the increasing evidence of the involvement of lipid peroxidation in 
various disorders and diseases has prompted most investigators to examine TSARS (as 
MDA equivalents) as it is a byproducts of lipid peroxidation (Clarkson and Thompson 
2000, Niki et at. 2005). According to McCall and Frei (1999), lipid peroxidation studies 
with precise endpoints such as specific classes of lipid peroxides (TBARS andlor MDA) 
are likely to be of considerable value. 
In the present analysis, data showed that vitamin E (400IU) ingestion for 60 days did not 
significantly change urinary TSARS (MDA equivalents) values in either race groups 
(p=0.7772 in blacks and p=1.0000). Although, this is in contrast with a study by Cadenas 
and co-workers (1996) who observed a 27% decrease in urinary TSARS after vitamin E 
ingestion (100mg, 30 days) in healthy subjects, it is in agreement with observations by 
Kosugi and co-workers (1995) who also reported no change in this parameter after 
administering vitamin E (300 mg, 50 days). 
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With regard to plasma TBARS (MDA equivalents) values, there were no changes in this 
parameter in either race group (p=0. 1789 in blacks and p=0.4449 in whites) following 
vitamin E ingestion (400IU, 60 days). Although a slight reduction occurred in both 
groups, it was not statistically significant. This is in agreement with a study by Mol and 
co-workers (1997) in which no consistent or significant change was observed in this 
parameter following vitamin E ingestion (600IU, 4 weeks) while it contradicts that of 
Sakuma and co-workers (1997) who observed a significant decrease in plasma TBARS 
following vitamin E ingestion (300mg, 4 weeks). 
In general, in the present study, blacks tended towards having slightly higher plasma 
TBARS values than whites albeit not statistically significant (p=0.2782 at baseline) and 
(p=0.4685 post-supplementation). Although Block and co-workers (2002) has also 
reported higher values of this parameter in healthy African American as opposed to their 
white compatriots, this is surprising in view of the lower stone incidence in black 
subjects. On the other hand it might help explain the greater effect of vitamin E in raising 
plasma a-tocopherol levels in whites as opposed to their black compatriots as this 
biomarker also serve as a sensitive functional assessment of vitamin E status in 
biological fluids (Drury et al. 1997). 
The results of other prospective controlled human trials of the effects of vitamin E on 
lipid peroxides such as TBARS (MDA equivalents) are contradictory. Studies show either 
a reduction (normalization) of TBARS and/or MDA in kidney stone patients with 
hyperoxaluria (Anbazhagan et al. 1999) as well as in healthy males (Kanter et al. 1993, 
Meydani et al. 1993, Rokitzki et al. 1994, Cadenas et al. 1996, Sakuma et al. 1997), an 
increase in healthy males (Sacheck et al. 2003) or no effect in healthy subjects (Kosugi 
et al. 1995, Mol et al. 1997, McBride et al. 1998, Huang et al. 2002) as well as in healthy 
smokers (Mol et al. 1997) in both urine and plasma samples. 
Although the TBARS assay (as MDA equivalents) is the most widely used to determine 
lipid peroxidation (Armstrong and Browne 1994, Ide et al. 2002), its determinations may 
not fully reflect the real situation. In fact, the present author is aware that, when this 
technique is used on human fluids, false-positives may be produced as stated by 
Clarkson and Thompson (2000). For example, aldehydes other than MDA may also 
react with thiobarbituric acid to produce compounds such as iron (II), heme proteins and 
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purines that absorb ultraviolet-visible light within the same wavelength (532 nm) as MDA 
(Mukai and Goldstein 1976, Esterbauer et al. 1989, Duthie 1991, Frankel 1991, Block et 
al. 2002). The decomposition of lipid peroxides during the test itself may also mask the 
actual MDA concentration before testing (Green et al. 2005, Dragsted 2008).This test is 
therefore considered to be a general indicator of oxidative stress only, rather than a 
specific marker of lipid peroxidation (Armstrong and Browne 1994, Trevisan et al. 2001). 
Regarding urine chemistry contradictory reports exist about the effect of vitamin E 
ingestion. In rat model studies, one study reported that vitamin E prevented 
hyperoxaluria (Kumar and Selvam 2003) while in another study hyperoxaluria and 
tubular enzymuria were not completely prevented (Huang et al. 2006). It is worth 
mentioning that, in the former study, vitamin E was administered in tandem with 
selenium. Perhaps an explanation for this anomaly is provided by Green and co-workers 
(2005), who observed that lipid peroxidation is not the underlying cause of renal injury in 
hyperoxaluric rats. 
In human studies, a reduction of urinary calcium and oxalate in kidney stone patients 
with hyperoxaluria (Anbazhagan et al. 1999) and in urogenital tuberculosis patients 
(Srinivasan et al. 2004a, Srinivasan et al. 2004b) has been reported following vitamin E 
ingestion. In contrast, in the present study, no changes were observed in urinary calcium 
(p=0.2506 in blacks and p=O. 7432 in whites) and oxalate (p=0.5608 in blacks and 
p=2431 in whites) following supplementation in both groups. It is noted that, although 
urinary calcium was significantly higher in whites than blacks on day 60 (p=0.0386), this 
difference was not attributed to vitamin E ingestion as it was also significantly higher at 
baseline (day 0) (p=0.0170). 
The causes of differential effectiveness of vitamin E in epidemiological, clinical and 
experimental studies are not clearly defined in literature (Rimm et al. 1993, Stampfer et 
al. 1993, Sakly et al. 2003, Huang et al. 2006, Thabet and Chan 2006). Some authors 
have speculated that it might be related to many variables such as nature and dosage of 
vitamin E, timing of therapy, stage of various diseases including stone formation, age of 
patients and degree of renal insufficiency among other factors (McCall and Frei 1999, 
Sacheck et al. 2003). 
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Although no changes in urinary calcium and oxalate were observed in the present study, 
elevated urinary excretion of citrate following vitamin E ingestion was observed in both 
race groups (p=0.0017 for blacks and p=0.0001 for whites). Such an effect has been 
reported by other workers in kidney stone patients with hyperoxaluria (Anbazhagan et al. 
1999) and urogenital tuberculosis patients (Srinivasan et al. 2004a, Srinivasan et al. 
2004b). According to Khan (2005), urinary citrate is involved in maintaining endogenous 
antioxidants. However, of particular importance is that an increase in the excretion of 
urinary citrate is widely accepted as being highly favourable for reducing the risk of stone 
formation (Fleisch 1978, Pak 1994, Ryall 1997, Chow et al. 2004, Rodgers et al. 2005). 
It has also been suggested that increases in citraturia reduce the retention of calcium 
oxalate crystals by complexation with calcium ions, thereby lowering the rate of 
recurrence of stone formation (Anbazhagan et al. 1999). Further investigations as well 
as experiments examining the mechanism underlying the altered citrate excretion in the 
present study as well as in other studies (Anbazhagan et al. 1999, Srinivasan et al. 
2004a, Srinivasan et al. 2004b) are needed as it is a beneficial effect of the treatment 
which might decrease stone risk. 
Because citraturia increased in both groups, it seemed reasonable to anticipate a 
lowering of RS CaOx and RS brushite. However, no changes were observed in these 
parameters following vitamin E ingestion in either group. The reasons for these 
observations are not very lucid. It is probable that it may be related to other subtle 
changes in urine composition values, which were statistically too small to detect 
individually, but which had a collective influence on the RS values. No significant 
changes were observed in the computed Tiselius risk index for calcium oxalate stone 
formation following vitamin E ingestion in both race groups. 
In the present study, comparisons of mean dietary intakes between the two groups 
showed that moisture, energy, total protein, calcium and magnesium were significantly 
lower in blacks than in whites on both day 0 and day 60 (p<0.05) while oxalate was 
significantly higher in blacks than whites at day 0 (p=0. 0492) , but this difference only 
approached significance on day 60 (p=0.0646). It is noted that mean dietary intakes of 
vitamin E were not significantly different between the two groups at baseline (day 0) and 
at day 60. Thus the observed changes in the present study can be attributed to the 
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vitamin E supplement with some degree of confidence because the intake of all other 
nutrients did not change during the 60 day trial. 
Although this study is comparable to other studies that have involved similar small 
numbers of subjects (Burton et al. 1998, Couderc et al. 1998, Meagher et al. 2001, 
Traber et al. 2001, Rabovsky et al. 2006), it is recognized that it is a preliminary report 
only and that it may have precluded detection of subtle effects of vitamin E. Since the 
study was designed to detect changes of at least 10% in any parameters (as done by 
Meagher and ccrworkers 2001), the subtle changes were not detected. 
Studies have revealed that oxidative damage is more related to hyperoxaluria and 
crystalluria rather than to tissue crystal deposits and that the process of membrane 
damage is greatly increased with progressive crystal deposition (Thamilselvam et al. 
1999, Selvam 2002). Urinary N-acetyl-p-glucosaminidae (NAG) a lysosomal enzyme 
found primarily in the proximal tubular cells of the kidney, is one of the most sensitive 
marker enzymes for renal tubular injury (Green et al. 2005, Khan 2005, Tungsanga et al. 
2005). However, since no change or increase in urinary oxalate was observed in both 
race groups, NAG was not investigated in the present study as it has been reported that 
it is significantly and positively correlated with urinary oxalate (Khan et al. 1989, Winter 
et al. 1996, Huang et al. 2000, Perez-Blanco et al. 2000, Tungsanga et al. 2005). 
There is evidence that vitamin E is transported in plasma lipoproteins and is 
incorporated into lipid bilayers of biological membranes where it determines oxidative 
susceptibility (Drevon 1991, Brigelius-Fohle and Traber 1999). Thus, after its intestinal 
absorption, it is packaged into chylomicrons, which are secreted into the systemic 
circulation (Herrera and Barbas 2001, Wood et aJ. 2003). The literature abounds with 
basic science showing that vitamin E inhibits smooth muscle cell proliferation, platelet 
adhesion and ~ggregation and monocyte endothelial adhesion (Emmert and Kirchner 
1999, Sen et al. 2006, Blumberg and Frei 2007, Traber 2007). Thus, it is difficult to 
argue that the mechanistic actions of vitamin E are unknown. However, these effects are 
unrelated to the antioxidant activity of vitamin E (Zingg and Azzi 2004). 
As alluded to earlier in this Chapter (introduction), the antioxidant activity of vitamin E is 
attributed to its ability to react with free radicals. Vitamin E as one of hydroxyl radical 
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scavengers, is thought to abolish the accumulation of lipid peroxidation products such as 
TBARS and/or MDA in tissues under urolithic conditions (Selvam 2002). 
There is a paradox between the dramatic responses to vitamin E in animal studies and 
the lack of efficacy in some human studies (McCall and Frei 1999, Thabet and Chan 
2006). The currently available markers of oxidative damage seem to be unable to pick 
up antioxidant effects of supplementation with vitamin E after dietary intervention 
(Dragsted 2008). In fact, according to Huang and co-workers (2006), the use of 
antioxidant therapy to prevent renal stone formation is not yet established and its 
mechanism remains obscure. 
In summary, the present study appears to show a dual-role for vitamin E ingestion in the 
two race groups. On one hand, plasma a-tocopherol and urinary citrate were favourably 
and significantly elevated in both groups while on the other hand, urinary calcium, 
oxalate, relative supersaturation and Tiselius risk index as well as urinary and plasma 
TBARS (MDA equivalents) were not altered. Subtle differences in handling mechanisms 
of vitamin E in black and white subjects were apparent. Overall, vitamin E appeared to 
have minimal beneficial effects in the small group of black and white South African 
subjects, which supports the findings of previous studies on vitamin E ingestion in 
healthy subjects (Patrignani et al. 2000, Meagher et al. 2001, Block et al. 2008). 
However, the findings of favourable and significant increase in urinary excretion of citrate 
coupled with an increase of plasma a-tocopherol levels in both groups supports the 
protective role of vitamin E ingestion in calcium oxalate urolithiasis albeit it does not fully 
explain the differences in stone incidence in the two South African race groups. The 
limitations of this study were small number of subjects and lack of dietary control. 
Further research is warranted in large cohort studies before firm conclusions can be 
drawn. 
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Chapter Five 
Investigation of the effects of Omega 3 (n-3) fish oil 
ingestion alone and in tandem with vitamin E (d/-a-
tocophery/ acetate) on urinary kidney stone risk factors 
in black and white South African subjects 
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5.1 Introduction 
As mentioned earlier in the first chapter (General Introduction), fish oil ingestion has 
been reported to playa role in many degenerative diseases including kidney stone 
formation (Rothwell et al. 1993, Tulloch et aJ. 1994, Claassen et al. 1995, Kruger et al. 
1995, Kruger et al. 1998, Schlemmer et al. 1999, Kelly et aJ. 2003, Baggio and 
Budakovic 2005, Kruger and Schollumb 2005). 
The possibility that dietary fish oil ingestion may benefit stone patients has been studied 
in rats (Buck et al. 1991, Ali and Bashir 1994, Daly 1996, Baggio et al. 2002, Fernandez 
et al. 2004) and humans (Rothwell et al. 1993, Claassen et al. 1995, Kruger et al. 1995, 
Kruger et al. 1998, Schlemmer et al. 1999, Yasui et aJ. 2001, Kelly et al. 2003, Kruger 
and Schollumb 2005). Most experts agree that amelioration of kidney stone risk factors 
following fish oil ingestion might occur through reduction of urinary calcium and oxalate 
and enhancing protective mechanisms. These favourable changes in urinary calcium 
and oxalate following fish oil ingestion have been attributable to the incorporation of EPA 
in the diet, which can provide a substitute metabolic pathway and a unique way of 
correcting the biochemical abnormalities of idiopathic urolithiasis (Yasui et al. 2001). 
However, it is worth noting that, in the aforementioned study by Yasui and co-workers 
(2001), a significant reduction in urinary calcium was only observed in the hypercalciuric 
group but not in the normocalciuric group and that in another clinical study involving 18 
hypercalciuric recurrent stone patients, the reduction in urinary calcium was 
accompanied by decreases in the excretion of magnesium and citrate while oxalate 
excretion was unchanged, thereby indicating that overall, fish oil had a limited impact on 
the risk profile for recurrent urolithiasis (Rothwell et al. 1993). 
Of concern is that some investigators have observed increased lipid peroxidation after 
fish oil ingestion and have concluded that it may consequently increase the need for 
vitamin E supplementation (Harmon et al. 1966, Yamamoto et aJ. 1985, Meydani et aJ. 
1987, Bartoli et al. 1988, Chautan et al. 1990, Meydani et aJ. 1991, Nair et aJ. 1993, 
Wander et al. 1996, Wood et al. 2003). On the other hand, other studies did not find any 
evidence of lipid peroxidation and have concluded that there is no basis for additional 
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vitamin E after fish oil ingestion (Turley et al. 1998, Wander and Du 2000, Higdon et al. 
2001). 
In light of the aforementioned inconclusive studies, further research is deemed 
necessary to investigate the extent to which fish oil increases the necessity for 
antioxidant nutrients (Sanders and Hinds 1992). In addition, it is of special interest that 
vitamin E therapy may also be considered as a means of correcting deficient plasma 
antioxidant status in chronic kidney failure rrhabet and Chan 2006}. In fact, it is noted 
that in the previous study of this thesis (Chapter 4), the present author observed a 
favourable and significant increase in plasma a.-tocopherol in whites (p=0.0044) while in 
blacks, the favourable increase was approaching significance (p=0.0689) following 
vitamin E (400IU, 60 days) ingestion. 
Thus, an investigation of the effects of n-3 fish oil ingestion alone and in tandem with 
vitamin E in South Africa's stone-prone and relatively stone-free population groups on 
kidney stone risk factors was undertaken. Details of this study are described in this 
chapter. 
5.2 Subjects and methods 
Study population (Inclusion criteria) 
20 healthy South African black (n=10) and white (n=10) male subjects (age range 18-30 
years) were recruited from the student cohort of the University of Cape Town via 
advertisement in university notice boards. 
Exclusion criteria 
Subjects were excluded if they: 
• were on any medication or taking supplements that might affect vitamin E 
metabolism e.g. warfarin, dalteparin sodium, enoxaparin sodium 
• had high blood pressure and/or diabetes 
• had a family history of renal or kidney stone disease 
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Study design 
Protocol I: Fish oil and urolithiasis 
Healthy black (n=5) and white (n=5) subjects were required to ingest an n-3 fish oil 
capsule (salmon oil, 1000mg) providing 164 mg eicosapentaenoic acid (EPA) and 110 
mg docosahexaenoic acid (OHA) every day immediately after supper for 30 days 
(Baggio et al. 1996, Baggio et al. 2000, Sivrioglu et al. 2007). The fish oil capsules were 
obtained from Dis-chern Pharmacy (Pty) Ltd, Johannesburg, South Africa. They were 
provided in sealed opaque containers and did not contain any added vitamin E. Subjects 
were instructed to store the capsules in the refrigerator at 4 °C (Wander et al. 1996). 
Protocol 2: Fish oil, vitamin E and urolithiasis 
A second group of healthy black (n=5) and white (n=5) subjects were required to ingest 
the aforementioned n-3 fish oil capsule in tandem with a vitamin E capsule (dl-a-
tocopheryl acetate, 400/u capsule/day), every day immediately after supper for 30 days 
(Baggio et al. 1996, Baggio et al. 2000, Sivrioglu et al. 2007). The vitamin E capsules 
were manufactured by Vitalfarm (pty) Ltd, Cape Town, South Africa. 
Study protocol 
In both protocols I and 2, subjects were instructed to take their free and unrestricted 
regular diet for the duration of the study (Turley et al. 1998, Wander and Du 2000, 
Higdon et al. 2001) so that their habitual intake of macronutrients was maintained 
throughout the study period. 24hr dietary food records were collected on the days in 
which blood and urine samples were drawn (see appendix CD/Chapter 5124hr dietary 
food record). The subjects' dietary food intake was assessed using a FoodFinder 2 
computer software programme (Langen hoven et al. 1991) (see appendix CD/Chapter 
51dietary analysis). 
Following an overnight fast (-12hrs), two venous blood samples (5ml) were collected 
(EOTA tube and lithium heparin-tube) by a qualified phlebotomist from each subject on 
day 0 (baseline) and on day 30 (postsupplementation). Blood samples were kept in the 
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dark and on ice until centrifugation. Plasma samples were prepared within 1 hr of blood 
collection by centrifugation (3000 rpm for 10 min for EDTA samples and 3500 rpm for 10 
min for lithium heparin samples) (Horoz et al. 2005, Rabovsky et al. 2006) using 
Labofuge 200, Heraeus Sepatech, Germany. 
Samples collected in lithium heparin-tubes were used for analysis of plasma uric acid 
(described in section 5.5) and ferric reducing ability of plasma (FRAP) (described in 
section 5.6) while samples collected in EDTA-tube samples were used for analysis of 
plasma a-tocopherol (described in section 5.3) and malondialdehyde (MDA) (described 
in section 5.4). Assays from the lithium heparin-tube samples were measured within 2hrs 
of sample collection while aliquots of EDTA-plasma were frozen at -80 °C for the 
subsequent assays (batch-analysis) of the remaining analytes. 24hr urine samples were 
also collected on the days in which blood samples were drawn without preservatives and 
urine parameters were measured as described in Chapter 2 of this thesis (Section 2.2). 
5.3 Determination of plasma vitamin E 
Plasma a-tocopherol levels were determined as described in Chapter 4, Section 4.3 of 
this thesis. 
5.4 Determination of plasma malondialdehyde (MDA) 
Commercially available kits BIOXYTECHMDA-586 (Oxis Research, Poriland, USA) were 
used to measure plasma MDA (Gerard-Monnier et al. 1997). This method is based on 
the reaction of a chromogenic reagent, N-methyl-2-phenylindole (R1, NMPI), with MDA 
at 45 °C. The stoichiometry is such that one molecule of MDA reacts with 2 molecules of 
NMPI to yield a stable carbocyanine dye. 
Reagents 
The following reagents were provided with the kit: reagent 1 (R1), which contains N-
methyl-2-phenylindole in acetonitrile (3x18ml), reagent 2 (R2), which contains 
concentrated hydrochloric acid (HCI) (1 x16.5ml), MDA standard, which contains 1,1,3,3-
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tetramethoxypropane (TOMP) in Tris-HCI (1x1ml), butylated hydroxytoluene (BHT) in 
acetonitrile (1x2ml), methanol (1x30ml). 
Preparation of solutions 
The R1 solution was diluted before use, one volume (6ml) of 100% methanol was added 
to three volumes (18ml) of reagent R1. This solution is stable for 2 days at 4°C. The 
MDA standard was provided as tetramethoxypropane (TOMP) because MDA is not 
stable. The TMOP was hydrolyzed during the acid incubation step at 45°C, which 
generated MDA. The TOMP standard was provided as a 10 mM stock solution, which 
was diluted 1/500 (v/v) in MiIIiQ water to give a 20 jJM stock solution. This standard was 
diluted as shown in table 5.1. 
Mean data obtained from absorbance (586 nm) values of standard solutions (table 5.1) 
were used to prepare a calibration curve as shown in figure 5.1 and are expressed as 
(J1M) (Richard et a/. 1992, Vagi 1998). The calibration curve was then used to calculate 
the respective plasma free MDA concentrations (section 5.8). 
Table 5.1 Dilution scheme of TOMP standard for preparations of MDA standards 
Standard Volume of Volume of MDA Mean 
20 11M MiIIiQ water (11M) Absorbance 
standard (III) (586 nm) 
(III) 
0 0 200 0 0 
1 25 175 0.5 0.057 
2 50 150 1.0 0.148 
3 100 100 2.0 0.243 
4 150 50 3.0 0.356 
5 200 0 4.0 0.461 
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Assay procedure 
1 0 ~I probucol was added to each assay tube and 200 ~I sample or standard was added 
to the respective assay tubes. 640 ~I diluted R1 reagent was added to each tube. The 
assay tubes were vortexed briefly. 150 ~I R2 reagent was added to assay tubes, which 
were stoppered and mixed well by vortex. The tubes were then incubated at 45°C for 60 
min. Turbid samples were centrifuged at 10000 x g for 10 minutes using an eppendorf 
minispin microcentrifuge (Lab depot, inc, Georgia, USA) to obtain a clear supernatant, 
which was then transferred to a cuvette and the respective absorbances were measured 
at 586 nm using a spectrophotometer (Spectronic Unicam Helios, Cambridge, England). 
5.5 Determination of plasma uric acid 
Plasma uric acid concentration was measured by a timed-endpoint method using 
Synchron LX® systems kits (Beckman Coulter, Inc, Fullerton, CA) (Fossati et a/. 1980). 
In this method, uric acid is oxidized by uricase to produce allantoin and hydrogen 
peroxide (H20 2). The hydrogen peroxide reacts with 4-aminoantipyrine (4-AAP) and 3,5-
dichloro-2-hydroxybenzene sulfonate (DCHBS) in a reaction catalyzed by peroxidase to 
produce a coloured product (quinoneimine). 
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Reagents 
Each kit contains the following items: Two uric reagent cartridges (A and B) (2 x 300 
tests), 4-Aminoantipyrine (0.85 mmolll), 3.5 Dichloro-2-hydroxy-benzene sulfonate (3.4 
mmol/I), uricase (240 lUll) and horseradish peroxidase (961 lUll). 
Assay procedure 
No reagent preparation was required. The system automatically proportions the 
appropriate sample and reagent volumes into a cuvette. The volumes per test are 
plasma (12 pI), cartridge A (270 pI) and cartridge B (30 pl). The ratio used for uric acid 
was one part sample to 25 parts for plasma. The system monitors the change in 
absorbance at 520 nanometers, which is directly proportional to the concentration of 
analyte in the sample and was used by the Synchron LX® systems to perform all 
calculations internally to produce the final reported plasma uric acid concentration. 
5.6 Determination of plasma ferric reducing antioxidant power (FRAP) 
Colorimetric FRAP assay kits (PolyU Technology and Consultancy Co. Ltd, Hong Kong) 
were obtained from collaborators at the Hong Kong Polytechnic University (Prof Iris F 
Benzie). In this assay, the electron-donating antioxidants in the sample reduce a 
Fe3+/tripyridyltriazine complex, which is present in excess, to the blue coloured product. 
The increase of absorbance at 593 nm is proportional to the total ferric 
reducing/antioxidant power (FRAP value) (Benzie and Strain 1996, Choi et al. 2004, 
Rabovsky et al. 2006). 
Preparation of solutions 
Four bottles were provided with the kit. FRAP assay reagent A and B, FRAP acid diluent 
and FRAP buffer. 10ml FRAP assay acid diluent reagent was added to one bottle of 
FRAP assay reagent A and mixed thoroughly while 10 ml of MiIIiQ water was obtained 
from MilliQ water purification system (Millipore, Berdford, USA) and added to one bottle 
of FRAP reagent B. FRAP reagent A, FRAP reagent Band FRAP buffer were then 
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mixed in the ratio 1:1:10 to prepare the working FRAP assay reagent immediately before 
use. 
Assay procedure 
1 ml MilliQ water, was added to clean labeled test tubes (one for each standard, control 
and test samples) and placed in water bath at 37°C for 5min. 25 IJL of standard, control 
and test samples was added to each tube and mixed. 1 ml of the freshly prepared FRAP 
assay working reagent was pi petted , with mixing, to each test tube at timed intervals (-
20 seconds). After 15 minutes' incubation time, the absorbance was then read (593nm) 
against the reagent blank using a spectrophotometer (Spectronic Unicam Helios, 
Cambridge, England). The FRAP value f,J..lmollL) of controls or test samples were then 
calculated as follows: 
FRAP value = absorbance of test X FRAP value of calibrator (1000 IJmol/L) 
absorbance of calibrator 
5.7 Statistical analysis 
Data were analysed using repeated measures (AN OVA) Statistica 8.0. Results were 
considered statistically significant if p s 0.05. 
5.8 Results 
5.9 Protocol I: Fish oil and urolithiasis 
Dietary analysis 
Comparisons of the mean nutrient intakes derived from the 24hr dietary records from 
black and white subjects for protocol 1 are given in tables 5.2a and 5.2b while the 
summary of the comparisons is given in table 5.3. The raw data are presented in 
appendix CD/Chapter 5/Dietary analysis (protocol 1). 
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Table 5.2a Comparisons of mean dietary intakes (SE) of black and white subjects (protocol 1) 
Nutrients Blacks (B) Whites (W) B VB W. p-values I 
OayO Oay30 p- OayO Oay30 p- OayO Oay30 
values values 
8MI (kg/mL) 25.51(1.01) -- -- 26.07(1.01) -- -- 0.7045 --
8751(1727) 8955(1805) 0.7367 14143(1727) 14204(1on~\ ** 
I 
• Moisture(g/day) 1828(356) 1798(349) 0.7137 3030(397) 2950(349) 0.0419* 0.0490* i 
Total Protein 87.99 87.38 0.7653 136.29 134.96 0.5183 0.0300* 0.0319* 
(g/day) (13.24) (12.76) (13.23) (12.76) 
Carbohydrate 332.28 316.57 0.5615 369.37 360.72 i 0.7476 0.6560 0.5967 
(g/day) (53.67) (59.95) (53.67) (59.95) 
i Fibre (g/day) 27.98(2.43) (2.33) 0.6518 32.53(2.43) 32.58(2.33) 0.9635 0.2093 0.2535 
Total Sugar 28.31 27.89 0.8679 59.54 58.65 0.7245 0.0152* 0.0163* 
(g/day) (6.76) (7.76) (6.76) (7.76) 
i Oxalate 279.75 261.99 0.2847 128.85 123.54 0.7407 0.0903 0.1155 I 
I (mg/day) (55.80) (55.60) (55.80) (55.60) 
Calcium 729 710 0.4522 985 962 0.3662 0.0312* 0.0330* 
(mg/day) (62) (78) (62) (78) 
Magnesium 327 317 0.2530 407 399 0.4270 0.0745** 0.0647** 
(mg/day) (30) (25) (30) (25) 
Phosphate 1567 1427 0.2013 1750 1763 0.8977 0.5061 0.2338 
(mg/day) (179) (194) (179) (194) 
Potassium 2813 2833 0.6818 3749 3662 0.1048 0.0257* 0.0421· 
(mg/day) (247) (240) (247) (240) 
i Sodium 2750 2789 0.3600 3340 3274 0.1353 I 0.5805 0.6488 
mg/day) (724) (725) (724) (725) 
I Vitamin A 1257 1257 0.9952 1470 1452 0.6245 0.4996 0.5366 
(RE/day) (223) (202) (223) (202) 
Vitamin 86 2.21 2.32 0.5503 3.14 2.96 0.3040 0.0830 0.2101 
(mg/day) (0.34) (0.34) (0.34) (0.34) 
Vitamin C 102 100 0.6837 114 115 0.8466 0.7329 0.6684 
(mg/day) (22) (25) (22) (25) 
Vitamin D 4.73 4.75 0.7904 3.06 3.14 0.4224 0.2636 0.2785 
(pg/day) (0.99) (0.97) (0.99) (0.97) 
Vitamin E 11.83 11.62 0.8267 13.75 12.87 0.3668 0.2869 0.4832 
(mg/day) (1.36) (1.04) (1.36) (1.04) 
.. 
(*S/gniflCance at p'5:.0.05, "approachmg Significance) 
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Table 5.2b Comparisons of mean dietary intakes (SE) of fatty acids of black and white subjects 
(protocol 1) 
Blacks (B) Whites (W) B va W, P-values 
Nutrients Day 0 Day 30 p- Day 0 Day 30 p- Day 0 Day 30 
(glday) values values 
Total fat 96.33 91.96 0.1780 136.21 134.95 0.6812 0.1144 0.0925 
(16.08) (15.82) (16.08) (15.82) 
Saturated 15.00 15.68 0.3702 15.88 16.37 0.5118 0.8293 0.8654 
Fat (2.92) (2.64) (2.92) (2.64) 
MUFA 12.65 12.53 0.9104 15.73 14.55 0.2945 0.4720 0.6335 
(3.22) (2.52) (3.22) (2.520 
I PUFA 7.57 7.60 0.9693 11.32 10.67 0.3862 0.2965 0.3867 
(2.55) (2.200 (2.55) (2.200 
Comment 
There were no significant changes or differences in mean dietary intakes of fatty acids in 
both race groups before and following protocol 1 (tab/e 5.2b). 
Table 5.3 Summary of comparisons of mean dietary intakes between the two race groups 
(protocol 1) 
Nutrients Comparison 
Day 0 Day 30 
Energy** 8<W 8<W 
Moisture* 8<W 8<W 
Total protein* 8<W 8<W 
Total sugar* 8<W 8<W 
Calcium* 8<W 8<W 
Magnesium** 8<W 8<W 
Potassium* 8<W 8<W 
* Statistically significant p~O. 05, 
** Approaching significance 
166 Chapter Five fish oil, vitamin E & urolithiasis 
Comment 
Differences in the mean dietary intakes between the two groups on both day 0 and day 
30 followed similar sequence B<W (table 5.3). It is noted that the intake of oxalate in 
blacks and whites on both day 0 and day 30 was not statistically different. 
Urinary analysis (protocol 1) 
Comparison of mean 24hr urine data from the two race groups before and following 
protocol 1 is given in table 5.4 while comparison for mean plasma parameters are given 
in table 5.5. The raw data from each subject are presented in appendix CD/Chapter 
5/urinary analysis/plasma parameters (protocol 1). 
167 Chapter Five fish oil, vitamin E & urolithiasis 
Table 5.4 Comparisons of mean 24hr urine parameters (SE) from urines of black and white 
subjects (protocol 1) 
Urinary Blacks (B) Whites (W) B va W, p-values 
parameters Day 0 Day 30 p- Day 0 Day 30 p- Day 0 Day 30 
values values 
pH 5.92 6.03 0.4781 6.17 6.18 0.9495 0.3043 0.5403 
(0.16) (0.17) (0.16) (0.17) 
Volume 1474 1495 0.8078 1295 1446 0.1082 0.6036 0.8861 
(mli24h) (235) (235) (235) (235) 
Citrate 1.34 1.77 0.1208 1.54 1.93 0.1559 0.6068 0.6814 
(mmoIi24h) (0.29) (0.26) (0.29) (0.26) 
Oxalate 0.21 0.19 0.6664 0.25 0.24 0.7621 0.2686 0.2094 
(mmoli24h) (0.03) (0.02) (0.03) (0.02) 
Calcium 1.36 1.81 0.3984 3.79 2.79 0.0806 <0.0001* 0.0468* 
(mmoli24h) (0.40) (0.22) (0.40) (0.22) 
Magnesium 0.96 1.55 0.2672 3.11 2.94 0.7391 0.0002* 0.0040* 
(mmoli24h) (0.27) (0.28) (0.27) (0.28) 
Sodium 138 136 0.9260 152 184 0.2912 0.6051 0.0787** 
(mmoli24h) (21 ) (15) (21) (15) 
Potassium 54 45 0.5360 69 66 0.8022 0.2520 0.1296 
(mmoli24h) (11 ) (7) (11 ) (7) 
Urate 2.26 3.24 0.1714 3.30 3.44 0.8354 0.1657 0.7834 
(mmoli24h) (0.39) (0.60) (0.39) (0.60) 
Creatinine 13.84 14.34 0.5771 15.00 15.08 0.9282 0.3394 0.5380 
(mmoli24h) (0.80) (0.86) (0.80) (0.86) 
Phosphate 18.08 22.26 0.3290 26.80 30.78 0.3514 0.0857 0.0924 
I (mmoli24h) (3.41 ) (3.28) (3.41) (3.28) 
RS CaOx 7.46 7.13 0.3441 6.96 7.02 0.8641 0.2849 0.8098 
(COM) (0.24) (0.38) (0.24) (0.38) 
RS brushite 1.8E-9 2.6E-9 0.4417 4.3E-9 3.0E-9 0.2279 0.0434* 0.7549 
(0.6E-9) (1.0E-9) (0.6E-9) (1.0E-9) 
RS uric acid 5.69(0.85) 5.05(1.13) 0.4926 3.75(0.85) 4.10(1.13) 0.7053 0.1965 0.5163 
Tiselius 141 133 0.7236 256 190 0.1869 0.0201* 0.1850 
Risk Index (35) (21) (35) (21 ) 
.. 
*S/gniflcance at p5.0.05, -approachmg sIgnificance 
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Comment 
When making within-group and inter-group comparisons for urine parameters, data 
showed that there were no statistically significant changes or differences at baseline 
(day 0) and after ingestion of n-3 fish oil (day 30) within the two race groups. It is noted 
that urinary calcium and magnesium were significantly different in the two race groups at 
baseline (day 0), (p<0.OO01 for calcium and p=0.0002 for magnesium) and at day 30 
(p=0.0468 and p=0.0040, respectively). 
There were no significant changes relative to baseline values in RS CaOx (COM) 
(p=0.3441 for blacks and p=0.8641 for whites), RS brushite (p=0.4417 for blacks and 
p=0.2279 for whites) and RS uric acid (p=0.4926 for blacks and p=0.7053 for whites). 
Although RS brushite was significantly lower in blacks than in whites at baseline (day 0) 
(p=0.0434), there were no significant differences between the two race groups following 
protocol 1 (p=0.7549). With regard to relative Tiselius risk index values, there were no 
significant differences when making within-group comparisons (p=0.7236 for blacks and 
p=0.1869 for whites). However, inter-group comparisons showed that this parameter 
was significantly lower in blacks than whites at baseline (p=0.0201). Following protocol 
1, there were no significant differences between the two race groups for the latter 
parameter (p=0.1850). 
Analysis of plasma biochemistry profiles (protocol 1) 
Table 5.5 Comparisons of mean plasma parameters (SE) of black and white subjects 
Plasma Blacks (B) Whltes(W) B vs W, p-values 
parameters Day 0 Day 30 p- Day 0 Day 30 p- Day 0 Day 30 
values values 
a-tocopherol 8.68 8.88 0.6987 10.56 11.22 0.2219 0.0828 0.0372* 
(mg/L) (0.72) (0.66) (0.72) (0.66) 
FRAP 1359 1331 0.2623 1386 1355 0.3011 0.8558 0.8692 
(IlmollL) (101 ) (103) (101) (103) 
Uric acid 0.31 0.33 0.4014 0.37 0.37 0.7482 0.2298 0.4199 
(mmollL) (0.03) (0.04) (0.03) (0.04) 
FreeMDA 0.056 0.060 0.7109 0.054 0.058 0.7047 0.9127 0.9162 
(PM) (0.01 ) (0.02) (0.01) (0.02) 
.. 
*S/gniflcance at p~O. 05 
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Comment 
Experimental data showed that supplementation with n-3 fish oil for 30 days did not 
significantly change plasma a-tocopherol, FRAP, uric acid and free MDA in both race 
groups (p>O.05). When making inter-group comparisons, data showed that plasma a-
tocopherol was significantly higher in whites than in blacks at day 30 (p=O.0372). 
5.10 Protocol 2: Fish oil, vitamin E and urolithiasis 
Dietary analysis 
Comparisons of the mean nutrient intakes derived from the 24hr dietary records from 
black and white subjects for protocol 2 are given in tables 5.6a and 5.6b while the 
summary of the comparisons is given in table 5.7. The raw data are presented in 
appendix CD/Chapter 5/Dietary analysis (protocol 2). 
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Table 5.6a Comparisons of mean dietary intakes (SE) of black and white subjects (protocol 2) 
Blacks (B) Whites (W) B va W, p-values 
Nutrients Day 0 Day 30 p- Day 0 Day 30 p- Day 0 Day 30 
values values 
BMI (kg/mO<) 26.31(0.97) -- -- 26.68(0.97) -- -- 0.7922 --
Energy 10675 10780 0.9101 15944 16750 0.3962 0.0517** 0.0316* 
(kJ) (1670) (1667) (1670) (1667) 
Moisture (g/day) 1881(222) 1862(186) 0.7366 2781(222) 2681(186) 0.1077 0.0139* 0.0215* 
Total Protein 89.89 95.00 0.2370 116.33 117.51 0.7749 0.0300* 0.0564* 
(g/day) (7.76) (6.82) (7.76) (6.82) 
Carbohydrate 276 289 0.1086 315 304 0.1753 0.4989 0.7906 
(g/day) (40) (38) (40) (38) 
Fibre 29.29 27.85 0.6490 34.29 32.02 0.4788 0.5260 0.5953 
(g/day) (6.36) (4.13) (6.36) (4.13) 
Total Sugar 29.39 28.71 0.7560 78.65 77.45 0.5913 <0.0001* <0.0001* 
(g/day) (4.92) (5.16) (4.92) (5.16) 
Oxalate(mg/day) 248(35) 246(35) 0.6081 138(35) 143(35) 0.3476 0.0578** 0.0706** 
Calcium 745 728 0.1281 989 977 0.2580 0.0291* 0.0269* 
(mg/day) (67) (63) (67) (63) 
Magnesium 302 300 0.8841 419 404 0.2856 0.0027* 0.0057* 
(mg/day) (22) (20) (22) (20) 
Phosphate 1244 1183 0.3214 2019 2050 0.6125 0.0066* 0.0035* 
(mg/day) (169) (137) (169) (137) 
Potassium 1569 1537 0.5597 3236 3216 0.7178 0.0034* 0.0032* 
(mg/day) (272) (304) (272) (304) 
Sodium 2877 3013 0.0903 3215 3127 0.2499 0.6607 0.8821 
(mg/day) (525) (524) (525) (524) 
Vitamin A 1543 1509 0.3797 2407 2423 0.6629 0.1311 0.1128 
(RElday) (367) (360) (367) (360) 
I Vitamin B6 2.82 2.92 0.4701 3.59 3.43 0.2715 0.2679 0.4627 
(mg/day) (0.48) (0.45) (0.48) (0.45) 
Vitamin C (mglday) 96(40) 92(41) 0.4266 172(40) 175(41) 0.3894 0.2207 0.1879 
Vitamin D 4.21 4.16 0.3721 6.31 6.21 0.1060 0.1451 0.1532 
(l1g/day) (0.94) (0.91) (0.94) (0.91 ) 
Vitamin E 11.54 12.13 0.7139 11.37 13.10 0.2969 0.9417 0.6634 
(mg/day) (1.71 ) (1.37) (1.71 ) (1.37) 
.. . . 
(*Slgmftcance at P5.0.05, -approachmg sIgnifIcance) 
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Table 5.6b Comparisons of mean dietary intakes of fatty acids of black and white subjects 
(protocol 2) 
Nutrients Blacks (B) Whites (W) B va W, P-values 
(g/day) Day 0 Day 30 p- Day 0 Day 30 p- Day 0 Day 30 
values values 
Total fat 102.84 100.54 0.3197 118.42 117.35 0.6350 0.5813 0.5524 
(19.72) (18.60) (19.72) (18.60) 
Saturated 16.92 17.06 0.8828 17.94 17.21 0.4396 0.8064 0.9699 
Fat (2.78) (2.890 (2.77) 92.89) 
MUFA 14.33 13.76 0.3234 16.16 16.28 0.8408 0.5834 0.4549 
(2.190 (2.35) (2.19) (2.35) 
PUFA 8.57 8.82 0.7187 8.29 8.91 0.3780 0.9048 0.9721 
(1.630 (1.67) (1.63) (1.67) 
Comment 
There were no significant changes or differences in mean dietary intakes of fatty acids in 
both race groups before and following protocol 2 (table 5.6b). 





Total protein* 8<W 






* Significantly different p~0.05 
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Comment 
Comparisons of mean dietary intakes between the two groups for day 0 and day 30 
followed the sequence B<W (table 5.7), the only exception was oxalate which followed 
the sequence B>W. 
Urinary analysis (protocol 2) 
Comparisons of mean 24hr urine data from the two race groups before and following 
protocol 2 are given in table 5.8 while comparisons for mean plasma parameters are 
given in table 5.9. The raw data for individual subjects are presented in appendix 
CD/Chapter 5/urinary analysis/plasma parameters (protocol 2). The summary of 
changes in urinary and plasma parameters for both protocol 1 and 2 is given in table 
5.10. 
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Table 5.8 Comparisons of mean 24hr urine parameters (SE) from urines of black and white 
subjects (protocol 2) 
Urinary Blacks (B) Whites (W) B vs W, p-values 
parameters Day 0 Day 30 p- Day 0 Day 30 p- Day 0 Day 30 
values values 
pH 6.25 6.25 0.9775 6.11 6.24 0.3511 0.6462 0.9801 
(0.16) (0.27) (0.16) (0.27) 
Volume 1416 1521 0.3685 1398 1603 0.0998 0.9402 0.7334 
(mI124h) (144) (184) (144) (184) 
Citrate 2.20 2.41 0.6762 2.50 2.52 0.9649 0.6661 0.8730 
(mmoIl24h) (0.44) (0.51) (0.44) (0.51 ) 
Oxalate 0.24 0.20 0.0998 0.29 0.28 0.5919 0.2451 0.0738** 
(mmoIl24h) (0.03) (0.02) (0.03) (0.02) 
Calcium 2.01 1.61 0.2357 3.89 3.52 0.2668 0.0009* 0.0008* 
(mmoIl24h) (0.24) (0.36) (0.24) (0.36) 
Magnesium 1.34 1.45 0.7793 3.25 3.51 0.4877 0.0002* <0.0001* 
(mmoIl24h) (0.22) (0.31) (0.22) (0.31) 
Sodium 158 132 0.1545 166 156 0.5581 0.6342 0.1647 
(mmoIl24h) (13) (11 ) (13) (11 ) 
Potassium 53 38 0.1284 77 64(5) 0.1793 0.0095* 0.0057* 
(mmoIl24h) (6) (5) (6) 
Urate 2.70 2.22 0.1104 3.34 3.58 0.3956 0.4011 0.0935 
(mmoIl24h) (0.51) (0.52) (0.51) (0.52) 
Creatinine 14.04 13.44 0.4379 17.50 17.62 0.8744 0.1557 0.0941 
(mmoIl24h) (1.60) (1.55) (1.60) (1.55) 
Phosphate 18.48 16.72 0.7224 32.52 36.28 0.4544 0.0510* 0.0102* 
(mmoIl24h) (3.19) (5.70) (3.19) (5.70) 
RS CaOx 6.72 6.35 0.3671 7.20 6.90 0.4658 0.5557 0.4972 
(COM) (0.35) (0.70) (0.35) (0.70) 
RS brushite 3.72E-9 4.38E-9 0.4346 2.49E-9 3.31E-9 0.3411 0.5160 0.5689 
(9.1E-10) (1.6E-9) (9.1E-10) (1.6E-9) 
RS uric acid 3.66 3.78 0.8115 4.67 3.61 0.1282 0.5236 0.9172 
(0.97) (1.20) (0.97) (1.20) 
Tiselius Risk 190 140 0.0163* 228 198 0.1002 0.0429* 0.0047* 
Index (13) (11 ) (13) (11 ) 
.. . . 
*S/gniflcance at p~O. 05, **approachmg slgmflcance 
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Comment 
Comparisons of mean urine parameters between the two race groups showed that 
urinary calcium, magnesium, potassium and phosphate were significantly higher in 
whites than in blacks (p<0.05) at baseline (day 0) and after ingestion of n-3 fish oil and 
vitamin E (day 30). It is interesting to note that urinary oxalate tended to be lower in 
blacks at day 30 while no such trend occurred at baseline. 
There were no significant changes or differences in RS CaOx (COM), RS brushite and 
RS uric acid in the two race groups following protocol 2. However, Tiselius risk index 
values were significantly reduced in blacks following protocol 2 (p=0.0163) while there 
were no significant changes for this parameter in white subjects (p=0.1002). When 
making inter-group comparisons, data showed that the latter parameter was significantly 
lower in blacks than in whites at baseline (p=0.0429) as well as following protocol 2 
(p=0.0047). 
Analysis of plasma biochemistry profiles (protocol 2) 
Table 5.9 Comparisons of mean plasma parameters (SE) of black and white subjects 
(protocol 2) 
Plasma Blacks (B) Whites (W) B YS W, p-values 
parameters Day 0 ·Oay 30 p-values Day 0 Day 30 p-values Day 0 Day 30 
a-tocopherol 8.66 12.30 0.0196* 14.70 18.76 0.0144* 0.0855 0.0577* 
(mg/L) (0.76) (0.76) (1.83) (1.83) 
FRAP 1371 1409 0.2509 1392 1429 0.2607 0.8905 0.8951 
(Ilmo/IL) (105) (97) (105) (97) 
Uric acid 0.30 0.31 0.7679 0.33 0.34 0.4390 0.3848 0.2248 
(mmol/L) (0.02) (0.02) (0.02) (0.02) 
Free MDA 0.062 0.052 0.0905 0.054 0.046 0.1622 0.5357 0.6407 
<11M) (0.01 ) (0.01 ) (0.01) (0.01 ) 
.. 
*Slgniflcance at p;:.O. 05 
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Comment 
Supplementation with n-3 fish oil in tandem with vitamin E for 30 days significantly 
increased plasma a-tocopherol in both race groups (p=O.0196 for blacks and p=O.0144 
for whites). Whites also had a significantly higher plasma a-tocopherol than blacks on 
day 30 (p=O.0577). No other significant changes were observed. 
Summary of results (protocols I and 2) 
Table 5.10 Summary of changes in parameters following protocols 1 and 2 (30 days) 
Fish oil Fish oil + vitamin E 
Parameter (Protocol 1) (Protocol 2) 
Blacks Whites Blacks Whites 
Plasma 
a-tocopherol -- - t * t * 
FRAP -- - -- -
Uric acid -- - -- -
Free MDA -- - -- -
Urine 
Calcium -- - -- -
Oxalate -- - -- -
RS CaOx (COM) -- - -- -
RS brushite -- - -- -
RS uric acid -- - -- -
Tiselius risk index -- - ~* ~ 
NS 
. . .. 
*S/gniflcance at p~0.05, NS not statIstIcally SIgnifIcant 
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5.11 Discussion 
A substantial body of literature suggests that n-3 fish oil ingestion regulates lipid 
metabolism as they are incorporated into cell membranes where they can influence 
membrane functions and enhance susceptibility to peroxidation due to a high degree of 
insaturation (Mills et a/. 1995, Calder 2003, Accinni et al. 2006). Following fish oil 
ingestion, lipid peroxidation is thought to proceed by radical mediated abstraction of a 
hydrogen atom from a methylene carbon on a PUFA (EPA and DHA) or PUFA side 
chain (Yagi 1987, Dreher and Junod 1996, McCall and Frei 1999, Saygili et at. 2003). 
The resulting carbon-centred radical may then undergo molecular rearrangement 
followed by interaction with molecular oxygen to form a peroxyl radical, which then 
culminates in oxidative injury (Chow 1991, Mazor et al. 1997, Wander and Du 2000). 
The latter action is a pathogenic factor in a variety of diseases including stone formation 
(Halliwell 1987, Thamilselvam et al. 2003). According to Ricciarelli and co-workers 
(2000), this drawback can be theoretically minimized by antioxidants such as vitamin E. 
In fact, as mentioned in the previous chapter of this thesis, the best known function of 
vitamin E relates to its capacity to scavenge reactive oxygenated species, thus acting as 
a chain-breaking antioxidant inhibiting lipid peroxidation, a predisposing factor for renal 
stone formation (Sundl et a/. 2007). 
In the present chapter, antioxidant status, lipid peroxidation as well as urinary risk factors 
for stone formation were evaluated in South African black and white subjects before and 
following ingestion of fish oil alone (protocol 1) as well as fish oil in tandem with vitamin 
E (protocol 2). 
Data showed that plasma a-tocopherol levels were not significantly affected by n-3 fish 
oil ingestion for 30 days (protocol 1) in both race groups. This supports the findings by 
Luostarinen and co-workers (1995), who observed no change in this parameter following 
protocol 1 (8.6g n-3 FA, 30 mllday, 4 weeks) in mildly hypertriglyceridemic males. In 
contrast, in a study by Shapiro and co-workers (1991) an increase in plasma a-
tocopherol was observed following protocol 1 (MaxEPA, 18g1day, 6 weeks) in 
normolipidemic males while Nair and co-workers (1993), reported a decrease in this 
parameter following protocol 1 (15 glday fish oil, 10 weeks) in healthy males. 
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On the other hand, in the present study, plasma a-tocophero/levels were favourably and 
significantly elevated in both race groups (p=0.0196 for blacks and p=0.0144 for whites) 
when fish oil was ingested in tandem with vitamin E. Although this is in agreement with a 
study by Nair and co-workers (1993), in which protocol 2 (15g1day FO in tandem with 
200 mg all-rac-a-tocopherol, 8 weeks) increased plasma a-tocopherol in healthy men, it 
contradicts findings in a double-blinded, parallel design study by Turley and co-workers 
(1998), in which plasma a-tocopherol concentrations were raised compared with 
baseline values after protocol 1 (2.4 glday, providing 0.72g of EPA and DHA) or protocol 
2 (2.4 g/day, providing 0.72g of EPA and DHA in tandem with 3 IU vitamin E/g oil) for 28 
days in healthy women. 
As mentioned in the previous Chapter, studies usually associate decreased plasma a-
tocopherol with increased susceptibility to lipid peroxidation and increased plasma a-
tocopherol levels with prevention of membrane injury and consequently, the risk of stone 
formation (Belcher et al. 1993, Srinivisan et al. 2004). Thus, a favourable and significant 
increase in plasma a-tocopherol for both race groups is apparent in both studies 
following vitamin E ingestion protocols. 
It has been postulated that the overall antioxidant status of the biological system may be 
more important than the levels of any single antioxidant 0/Vayner et al. 1987, Selvam 
2002, Panza et al. 2008). Some studies have shown that the total 'antioxidant power of 
a variety of biological fluids and tissues can be evaluated using the ferric reducing 
antioxidant power (FRAP) assay (Benzie and Strain 1996, Choi et al. 2004, Rabovsky et 
al. 2006). In the present study, plasma FRAP was investigated in the two race groups 
before and following ingestion of n-3 fish oil alone and in tandem with vitamin E. Data 
showed that this parameter was not significantly affected by either protocol 1 or 2 in both 
race groups. There is in general, scant data in the literature, of studies that have 
investigated plasma FRAP as a measure of total antioxidant power. In particular, the 
present author could not find human studies that have measured this parameter 
following protocols 1 and 2. Thus, no comparisons of the present result with those of 
others could be made in this regard. 
The FRAP values obtained in this study are comparable to those obtained in a study by 
Benzie and Strain (1996) who measured this parameter in healthy Chinese subjects. 
178 Chapter Five fish oil, vitamin E & urolithiasis 
The baseline range of fresh plasma FRAP values in the latter study was 612-1634 
~mol/L in healthy Chinese subjects while in the present study the baselines ranges of 
fresh plasma FRAP values were 992-1662 ~mollL for blacks and 1207 -1692 ~mollL for 
whites (protocol 1). In protocol 2, the respective ranges were 1042-1768 ~mollL for 
blacks and 1181-1481 ~mollL for whites. 
In addition, although not directly applicable to the present study, supplementation with 
vitamin E (400IU) on its own in healthy Caucasian and Chinese males did not 
significantly change plasma FRAP values 90 and 180 min post supplementation (Choi et 
al. 2004). In a study by Rabovsky and co-workers (2006), on healthy male and female 
subjects, it was also observed that supplementation with different antioxidants including 
vitamin E (1000 IU, 4hrs) on its own did not significantly change plasma FRAP values. 
The reasons for the lack of effects of antioxidants on plasma FRAP values is not clear in 
literature (Choi et al. 2004, Rabovsky et al. 2006). It was noted in the latter study that 
measures of antioxidant capacity in plasma have not been standardized or validated and 
therefore results are also inconsistent from lab to lab. 
Plasma uric acid, a purine degradation product and a major water soluble antioxidant 
present in blood has also been previously investigated (Maxwell et al. 2006, Feig et al. 
2008). It has been reported that uric acid contributes up to 60% of the total plasma 
FRAP and that its increased levels might also interfere with calcium oxalate solubility 
(Serafini et al. 1998, Dotan et al. 2004, Panza et al. 2008). It has also been suggested 
that uric acid must be evaluated when measuring plasma FRAP in order to accurately 
predict antioxidant capacity. Thus, once it is removed, the antioxidant protection of other 
antioxidants present in the blood such as vitamins, phytochemicals, carotenoids and 
others can then be measured (Rabovsky et al. 2006). 
In the latter study, in order to measure the effect of antioxidant supplementation on 
plasma FRAP, uric acid was removed by the addition of uricase so that the effects of 
only supplemented antioxidants were measured and not the activity due to uric acid. In 
the present study, plasma uric acid did not undergo any statistically significant change in 
either race group in both protocols 1 and 2. Thus, the contribution of plasma uric acid 
was deemed to be similar in both groups. Hence comparisons of non-urate FRAP in the 
two race groups were not evaluated in this study. 
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Owing to the limitations of the TBARS (MDA equivalents) assay mentioned in Chapter 4, 
section 4.8, it was deemed more appropriate and prudent to investigate lipid 
peroxidation using the more specific MDA-586 assay in the present study. It is 
recognized that even with this more specific method, there is evidence that peroxidates 
and aldehydes in food can be absorbed through the gut to a limited extent and can also 
potentially confound measures of MDA and perhaps of other plasma peroxides as well 
(Frietsche and Johnston 1988, Gonzalez et al. 1992, Allard et a/. 1997). Nonetheless, of 
particular importance, in the MDA-586 method, is that the assay conditions serve to 
minimize interference from other lipid peroxidation products, such as 4-hydroxyalkenals 
(Gerard-Monnier et al. 1997). 
In the present study, data showed that n-3 fish oil ingestion (protocol 1) did not 
significantly change plasma free MDA in either race group (p=0.7109 for blacks and 
p=O. 7047 for whites). This finding suggests that supplementation with n-3 fish oil for 30 
days did not induce lipid peroxidation in the studied groups of subjects. This is in 
contrast to a study by Nair and co-workers (1993) in which protocol 1 (15 glday Fa, 10 
weeks) raised plasma MDA in healthy males inducing lipid peroxidation. On the other 
hand, the present result supports findings of a study by Turley and co-workers (1998) 
that have reported that protocol 1 (18% EPA and 12% DHA, 28 days) does not 
significantly change this parameter in healthy women as well as those of Hansen and 
co-workers (W98) in which protocol 1 (providing 4g EPA and DHA) was administered in 
healthy mal~; with no significant change in lipid peroxidation. 
A lack of consistency in results involving protocol 2 are also apparent. In the present 
study, protocol 2 (Fa plus 400lU dl--a-tocopheryl acetate, 30 days) did not significantly 
change plasma free MDA levels in either race group (p=0.0905 for blacks and p=0.1622 
for whites). Similarly, protocol 2 (Fa plus 31U vitamin E /g oil) did not significantly change 
plasma MDA levels in the study by Turley and co-workers (1998) while in contrast, in the 
study by Nair and ccrworkers (1993), protocol 2 (Fa plus 200mg all-rac-a-tocophero/, 8 
weeks) counter-acted the rise in plasma MDA observed in protocol 1. According to 
Wander and Du (2000), many stUdies investigating increased consumption of n-3 fatty 
acids report no changes in lipid peroxides. 
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It has been reported that long-chain n-3 PUFA dose, duration of exposure, differences 
between subjects and differences in experimental design might contribute to different 
findings (Lapointe et a/. 2006, Yusof et al. 2008). For example, in a study by Higdon and 
co-workers (2001), it was shown that fish oil (providing EPA and DHA) does not increase 
overall oxidation as compared to sunflower oil (providing oleate) and safflower oil 
(providing linoleate). It is worth mentioning that although the study by Turley and co-
workers (1998) involved healthy women, they administered fish oil (providing EPA and 
DHA) as in the present study as opposed to the study by Nair and co-workers (1993), in 
which a 50% concentrate of refined anchovy oil (ROPUFA 50%) was administered 
(contents were not identified). 
The duration of the study by Turley and co-workers (1998) was also comparable to the 
present study (28 days in their study vs 30 days in the present study) while the study by 
Nair and co-workers (1993) was for a longer period (10 weeks). It is also noted that 
different dosages of both fish oil and vitamin E supplements were administered in these 
three studies as indicated above. Moreover, while plasma free MDA was measured in 
the present study, the other studies did not indicate whether they measured plasma free 
MDA, protein-bound MDA or total MDA. Thus, it is perfectly reasonable to conclude that 
the differences in design, dosage and duration may explain the different observations in 
these stu~ies. 
, 
There are reports that suggest that vitamin E may also act as a prooxidant molecule 
when it reacts with lipid radicals in vivo and form the a.-tocopheroxyl radical, which might 
promote lipid peroxidation (Kontush et al. 1996, Brigelius-Flohe and Traber 1999, Carr et 
al. 2000, Lapointe et al. 2006, Thabet and Chan 2006). However, there is no evidence in 
the present study that lipid peroxidation occurred as demonstrated by plasma free MDA 
levels that were not altered significantly in the two protocols for both race groups. 
Data in the present study also showed that urinary parameters (notably urinary calcium 
and oxalate) were not significantly altered by either protocol 1 or 2 in both race groups. 
This is in contrast with studies that have reported reductions of these parameters in 
stone patients (Claassen et al. 1995, Kruger et a/. 1995, Kruger et al. 1998, Schlemmer 
et al. 1999, Kelly et al. 2003, Kruger and Schollumb 2005), although it is in agreement 
with studies that have reported unchanged levels of these parameters following protocol 
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1 in stone patients and healthy subjects (Rothwell et al. 1993, Yasui et al. 2001). In the 
study by Rothwell (1993) on 18 hypercalciuric recurrent stone patients, it was reported 
that urinary calcium excretion was reduced but urinary oxalate levels were unchanged, 
while in a study by Yasui and co-workers (2001), a significant reduction in urinary 
calcium was only observed in the hypercalciuric group but not in the normocalciuric 
group after administration of a highly purified preparation of EPA (1800 mg/day) for 3 
months (short tenn) and 18 months (long tenn). The reasons for the lack of significant 
effects of protocol 1 and 2 on urinary parameters such as calcium and oxalate in the 
present study as well as in other studies (Rothwell et al. 1993, Yasui et al. 2001) are not 
clear. 
It has been reported that it is possible that lipid peroxidation can occur in the capsules 
during storage (Sanders and Hinds 1992). However, this seems unlikely in the present 
study as the capsules were provided in dark sealed opaque containers and subjects 
were instructed to keep them refrigerated at 4 °C (Wander et al. 1996). 
Although urinary parameters were not significantly altered in both protocol 1 and 2 in the 
two race groups in this Chapter, it was deemed prudent to investigate whether these 
protocols had any effects on the relative supersaturation values of stone forming salts 
and on the Tiselius risk index values because subtle changes in individual urinary 
parameters may have significant effects on the more complex indices. Data showed that 
there were no significant changes in RS CaOx (COM) (p=0.3441 for blacks and 
p=O. 8~ 1 for whites), RS brushite (p=0.4417 for blacks and p=O. 2279 for whites) and RS 
,;,.' 
uric acid (p=0.4926 for blacks and p=0.7053 for whites) following protocol 1. Although 
RS brushite was significantly lower in blacks than in whites at baseline (day 0) 
(p=0.0434), there were no significant differences between the two race groups following 
protocol 1 (p=0.7549). The significantly lower value of RS brushite in blacks at baseline 
is in conformity with the low stone incidence in this group as opposed to in the white 
subjects. However, the lack of significant differences in the two race groups following 
protocol 1, is noteworthy as it points towards a more therapeutic effect of this protocol on 
this parameter for white subjects. It is noted that there were no significant changes or 
differences in the RS CaOx (COM), RS brushite and RS uric acid in the two race groups 
following protocol 2. 
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Tiselius risk index values were not significantly altered in both race groups following 
protocol 1. However, this parameter was significantly lower in blacks than in whites at 
baseline (p=0.0201), which is also in conformity with the low incidence of stone 
formation in the black group. Following protocol 1, there were no significant differences 
between the two race groups for this parameter (p=0. 1850). This could be attributable to 
the more profound effects of protocol 1 in whites in reducing the Tiselius risk index 
values (from 256±35 to 190±21) as opposed to the low reduction of this parameter in 
blacks for protocol 1 (from 141±35 to 133±21). However, it is noted that these reductions 
of Tiselius risk index values following protocol 1 were not statistically significant in both 
race groups. Following protocol 2, Tiselius risk index values were significantly reduced in 
blacks (p=0.0163) while there were no significant changes for this parameter in whites 
(p=0.1002). This suggests a more profound effect of protocol 2 for this parameter in the 
black group. Although this parameter was also significantly lower in blacks following 
protocol 2 (p=0.0047), this could not be attributable to the effects of protocol 2 as this 
parameter was also sjgnificantly lower in blacks than in whites at baseline (day 0) 
(p=0.0429). 
In the present study, comparisons of mean dietary intakes within the two race groups 
revealed that subjects maintained their habitual intake throughout the respective study 
periods as demonstrated by the absence of significant differences when making 
comparisons at baseline and postsupplementation in both protocols 1 and 2 and for both 
race groups. The mean intakes of other nutrients followed similar sequences as 
A 
described in Chapters 2, 3 and 4 of this thesis, with blacks having significantly higher 
intakes of oxalate while the other nutrients namely energy, moisture, total protein, total 
sugar, calcium magnesium and potassium were significantly lower in blacks than in 
whites at baseline and postsupplementation. The only exceptions were the mean dietary 
intakes of oxalate ,and phosphate which were similar between the two race groups in 
protocol 1 of this Chapter. It is possible that this anomaly might be due to the small 
number of subjects (n=5) who participated in this protocol. The implication of the 
differences in mean dietary intakes of the aforementioned nutrients in the incidences of 
stone formation between the two race groups has been fully described in Chapter 2 of 
this thesis (section 2.4). 
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There were no statistically significant differences with regard to mean dietary intakes of 
vitamin E between the two race groups in protocols 1 and 2 described in this Chapter, 
compared to those reported in the previous Chapter of this thesis. In addition, since 
both protocols 1 and 2 of the present study involved ingestion of essential fatty acids (n-
3 fish oi/), it was deemed appropriate and prudent to also investigate regular mean 
dietary intakes of essential fatty acids in the two race groups. Data showed that there 
were no significant differences in the mean dietary intakes of total fat, saturated fat, 
monounsaturated fat and polyunsaturated fat in both race groups for both protocols 1 
and 2 of this Chapter. Therefore, the results obtained in the present Chapter could be 
attributed to the effects of protocols 1 and 2 with some degree of confidence. It is noted 
that the absence of significant differences in these parameters (vitamin E, total fat, 
saturated fat, monounsaturated fat, polyunsaturated fat) between healthy black and 
white subjects is in agreement with observations of a previous study by Allen and co-
workers (2003) in the two race groups. 
It is widely accepted that the metabolic pathway of n-3 fatty acids occurs as shown in 
figure 5.2 and that n-3 PUFAs inhibit the conversion of linoleic acid into arachidonic acid 
and directly influence the conversion from arachidonic acid into a series of 
prostaglandins (Calder 2003, Accinni et al. 2006). These analytes were not measured in 
the present study as they were deemed to be beyond its scope. Future studies in this 
area should address these pathways. 
Despite this limitation, the results of the present study have shown that protocol 1 was 
neither beneficial (e.g. no favourable significant changes in plasma a-tocopherol, FRAP, 
urinary calcium) nor harmful (e.g. no adverse or unfavourable significant changes in 
plasma uric acid, plasma free MDA, urinary oxalate) in the two race groups. Protocol 2 
favourably and significantly raised plasma a-tocopherol levels in both groups but did not 
have any effect on the other parameters. Although this supports findings in other studies 
(Turley et al. 1998, Higdon et al. 2000, Wander and Du 2000, Higdon et al. 2001, 
Rabovsky et al. 2006), it is apparent that same limitations as observed in Chapter 4 
apply due to the small number of subjects and lack of dietary control. Large cohort 
studies with dietary control are needed before firm conclusions can be drawn. 
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It is noted that although the overall responses to the two protocols appear to be in 
concert in the two race groups, the findings of a significantly higher plasma a-tocopherol 
post-supplementation (day 30) in whites than in blacks in protocol 1 (p=0.0372) and 
protocol 2 (p=0.0577) is counter-intuitive considering the lower incidence of stone 
formation in the black group. Nonetheless, it is worthy of attention as it tentatively points 
towards therapeutic properties of this nutrient in this small groups of white subjects. 
Further research is undoubtedly warranted in this area. 
According to Choi and co-workers (2004), although oxidative stress is implicated in the 
aetiology of many diseases, most supplementation trials with antioxidant micronutrients 
have also not shown expected beneficial effects. In fact, results of large-scale, long-term 
intervention studies have also cast some doubts on the oxidative modification hypothesis 
(Stocker and Keaney 2004, Niki et al. 2005). 
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Figure 5.2 Essential fatty acid pathway (Rodgers et al. 2009) 
186 Chapter Five fish oil, vitamin E & urolithiasis 
5.12 References 
• Accinni R, Rosina M, Bamonti F, et al. Effects of combined dietary 
supplementation on oxidative and inflammatory status in dyslipidemic subjects. 
Nutr Met Cardiovasc Dis 2006; 16: 121-7. 
• Ali BH, Bashir AA. Effect of fish oil treatment on gentamicin nephrotoxicity in rats. 
Ann Nutr Metab 1994; 38: 336-9. 
• Allard JP, Kurian R, Aghdassi E, et al. Lipid peroxidation during n-3 fatty acid and 
vitamin E supplementation in humans. Lipids 1997; 32: 535-1. 
• Allen HG, Allen JC, Boyd LC, et al. Can anthropometric measurements and diet 
analysis serve as useful tools to determine risk factors for insulin-resistant 
diabetes Type 2 among white and black Americans? Nutrition 2003; 19: 584-8. 
• Baggio B, Gambaro G, Zambou S, et al. Anomalous phospholipid n-6 
polyunsaturated fatty acid composition in idiopathic calcium nephrolithiasis. J Am 
Soc Nephro/1996; 7(4): 613-0. 
• Baggio B, Budakovic A, Nassuato MA, et al. Plasma phospholipid arachidonic 
acid content and calcium metabolism in idiopathic calcium nephrolithiasis. Kidney 
l'lt 2000; 58: 1278-4. 
• B~ggio B, Budakovic A, Priante G, et al. Dietary fatty acid supplementation , 
modulates the urinary excretion of calcium and oxalate in the rat. Insight into 
calcium lithogenesis. Nephron 2002; 91 (93): 486-1. 
• Baggio B, Budakovic A Fatty acids and idiopathic calcium nephrolithiasis. Urol 
Int 2005; 75(2): 97-1. 
• Bartoli GM, Giannatasio B, Palozza P, et al. Superoxide dismutase depletion and 
lipid peroxidation in rat liver carcinogenesis. Biochim Biophys Acta 1988; 996: 
214-1. 
• Belcher .ID, Balla J, Balla G, et al. Vitamin E, LDL and endothelium. Brief oral 
vitamin supplementation prevents oxidizing LDL-mediated vascular injury in vitro. 
Arter Thromb 1993; 13(12): 1779-9. 
• Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure 
of "antioxidant capacity": the FRAP assay. Anal Biochem 1996; 239: 70-6. 
• Brigelius-Flohe R, Traber MG. Vitamin E, oxidative stress and inflammation. 
FASEBJ 1999; 13: 1145-5. 
187 Chapter Five fish oil, vitamin E & urolithiasis 
• Buck AC, Davies RL, Harrison T. The protective role of eicosapentanoic acid 
[EPA] in the pathogenesis of nephrolithiasis. J Uro/1991; 146(1): 188-4. 
• Calder PC. N-3 polyunsaturated fatty acids and inflammation: from molecular 
biology to the clinic. Lipids 2003; 38(4): 343-2. 
• Carr AC, Zhu BZ, Frei B. Potential antiatherogenic mechanisms of ascorbate 
(vitamin C) and alpha-tocopherol (vitamin E). Cire Res 2000; 87: 349-4. 
• Chautan M, Calaf R, Leonardi J et al. Inverse modification of heart and liver a 
tocopherol status by various dietary n-6/n-3 polyunsaturated fatty acid ratios. J 
Lipid Res 1990; 31: 2201-8. 
• Choi SW, Benzie IFF, Collins AR, et al. Vitamins C and E: acute interactive 
effects on biomarkers of antioxidant defence and oxidative stress. Mut Res 2004; 
551: 109-7. 
• Chow CK. Vitamin E and oxidative stress. Free Rad BioI Med 1991; 11: 215-2. 
• Daly ES. Effect of methimazole and fish oil treatment on gentamicin 
nephrotoxicity in rats. J Islamic Acad Sc 1996; 9(2): 37-8. 
• Claassen N, Coetzer H, Steinmann CML, et al. The effect of different n-6/n-3 
essential fatty acid ratios on calcium balance and bone in rats, Prostaglandins 
LeukQl Essent Fatty Acids 1995; 53: 13-9. 
• Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a 
universal criterion of oxidative stress. Prog Lipid Res 2004; 43: 200-7. 
• Dreher D, Junod AF. Role of oxygen free radicals in cancer development. Eur J 
Cancer 1996; 32A(1): 30-38. 
• Feig DI, Kang D, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 
2008; 359: 1811-1. 
• Femandez R, Piechnik J, Fabris R, et al. Effect of chronic fish oil 
supplementation on renal function of normal and cachectic rats. Braz J Med BioI 
Res 2004; 37(10): 1481-9. 
• Fossati P, Prencipe L, Berti G. Use of 3.5 dichloro-2-hydroxybenzenesulfonic 
acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid 
in serum and urine. Cfin Chem 1980; 26(2): 227-1. 
• Frietsche KL, Johnston PV. Rapid autoxidation of fish oil in diets without added 
antioxidants. J Nutr 1988; 118: 425-6. 
188 Chapter Five fish oil, vitamin E & urolithiasis 
• Gerard-Monnier D, Erdelmeier I, Regnard K, et al. Reactions of N-methyl-2-
phenilindole with malondialdehyde and 4-Hydroxyalkenals. Analytical 
applications to a colorimetric assay of lipid peroxidation. Chem Res Toxico/1997; 
11(10): 1176-3. 
• Gonzalez MJ, Gray ~II, Schemmel RA, et al. Lipid peroxidation products are 
elevated in fish oil diets in the presence of added antioxidants. J Nutr 1992; 122: 
2190-5. 
• Halliwell B. Oxidants and human disease: some new concepts. FASEB 1987; 1: 
358-4. 
• Hansen JB, Berge RK, Nordoy A, et al. Lipid peroxidation of isolated 
chylomicrons and oxidative status in plasma after intake of highly purified 
eicosapentaenoic or docosahexaenoic acids. Lipids 1998; 33: 1123-9. 
• Harmon EM, Witting LA, Horwitt MK. Relative rates of depletion of alpha-
tocopherol and linoleic acid after feeding polyunsaturated fats. Am J Clin Nutr 
1966; 18: 243-7. 
• Higdon JV, Liu J, Du SH, et al. Supplementation of postmenopausal women with 
fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated 
with greater in vivo lipid peroxidation compared with oils rich in oleate and 
linoleaa as assessed by plasma malondialdehyde and F2 isoprostanes. Am J 
Clin Ntltr2000; 72(3): 714-2. 
• Higdon JV, Du SH, Lee YS, et al. Supplementation of postmenopausal women 
with fish oil does not increase overall oxidation of LDL ex vivo compared to 
dietary oils rich in oleate and linoleate. J Lipid Res 2001; 42: 407-418. 
• Horoz M, Bolukbas C, Bolukbas FF, et al. Measurement of the total antioxidant 
response using a novel automated method in subjects with nonalcoholic 
steatohepatitis. BMC Gastroentro/2005; 5: 35-0. 
• Kelly 0, Cusack S, Jewell C, et al. The effect of polyunsaturated fatty acids, 
including conjugated linoleic acid, on calcium absorption and bone metabolism 
and composition in young growing rats, Br J Nutr 2003; 90: 743-0. 
• Kontush A, Finckh B, Karten B, et al. Antioxidant and pro-oxidant activity of a-
tocopherol in human plasma and low density lipoprotein. J Lipid Res 1996; 37: 
1436-8. 
189 Chapter Five fish oil, vitamin E & urolithiasis 
• Kruger MC, Coetzer H, de Winter R, et a/. Eicosapentaenoic acid and 
docosahexaenoic acid supplementation increases calcium balance. Nutr Res 
1995; 15(2): 211-9. 
• Kruger MC, Coetzer H, de Winter R, et a/. Calcium, gamma-linolenic acid and 
eicosapentaenoic acid supplementation in senile osteoporosis. Ageing Glin Exp 
Res 1998; 10(5): 385-4. 
• Kruger MC, Schollumb LM. Is docosahexaenoic acid more effective than 
eicosapentaenoic acid for increasing calcium bioavailability? Prostaglandins 
Leukot Essent Fatty Acids 2005; 73: 327-4. 
• Langenhoven ML, Conradie PJ, Wolmarans P, et a/. Medical Research Council 
Food Quantities Manual, 2nd ed, Cape Town, South African Medical Research 
Council, 1991. 
• Lapointe A, Couillard C, Lemieux S. Effects of dietary factors on oxidation of low 
density lipoprotein particles. J Nutr Biochem 2006; 17: 645-8. 
• Luostarinen R, Wallin R, Wibell L, et a/. Vitamin E supplementation counteracts 
the fish oil induced increase of blood glucose in humans. Nutr Res 1995; 15: 
953-8. 
• M~ell SR, Dietrich T, Chapple ILC. Prediction of serum total antioxidant 
acttVlty from the concentration of individual serum antioxidants. Glin Ghim Acta 
2006; 372: 188-4. 
• Mazor D, Brill G, Shorer Z, et a/. oxidative damage in red blood cells of vitamin E 
deficient patients. Glin Ghim Acta 1997; 265: 131-7. 
• McCall MR, Frei B. Can antioxidant vitamins materially reduce oxidative damage 
in humans. Free Radic BioI Med 1999; 26(7): 1034-3. 
• Meydani SN, Shapiro AC, Meydani MM, et a/. Effect of age and dietary fat (fish, 
corn and coconut oils) on tocopherol status of C57BU6Nia mice. Lipids 1987; 22: 
345-0. 
• Meydani M, Natiello F, Goldin B, et a/. Effect of long-term fish oil supplementation 
on vitamin E status and lipid peroxidation in women. J Nutr 1991; 121: 484.-1. 
• Mills DE, Murthy M, Galey WR. Dietary fatty acids, membrane transport and 
oxidative sensitivity in human erythrocytes. Lipids 1995; 30: 657-6. 
190 Chapter Five fish oil, vitamin E & urolithiasis 
• Nair PP, Judd JT, Berlin E, et al. Dietary fish oil-induced changes in the 
distribution of a. tocopherol, retinol and 13-carotene in plasma, red blood cells and 
platelets: modulation by vitamin E. Am J Clin Nutr 1993; 58: 98-2. 
• Niki E, Yoshida Y, Saito Y, et al. Lipid peroxidation: mechanisms, inhibition and 
biological effects. Biochem Biophys Res Comm 2005; 338: 668-6. 
• Panza VSP, Wazlawik E, Schutz GR, et al. Consumption of green tea favourably 
affects oxidative stress markers in weight-trained men. Nutrition 2008; 24: 433-2. 
• Rabovsky A, Cuomo J, Eich N. Measurement of plasma antioxidant reserve after 
supplementation with various antioxidants in healthy subjects. Clin Chim Acta 
2006; 371: 55-0. 
• Ricciarelli R, Zingg ~IM, Azzi A Vitamin E reduces the uptake of oxidized LDL by 
inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle 
cells. Circulation 2000; 102: 82-7. 
• Richard MJ, Portal B, Meo J, et al. Malondialdehyde kit evaluated for determining 
plasma and lipoprotein fractions that react with thiobarbuturic acid. Clin Chem 




Rflgers A, Lewandowski S, Allie-Hamdulay S, et al. Evening primrose oil 
S\.,(pPlementation increases citraturia and reduces other urinary risk factors for 
catium oxalate urolithiasis (Unpublished, submitted to J UroI2009). 
" 
Rqthwell PJ, Green R, Blacklock NJ, et al. Does fish oil benefit stone formers? J 
U,b/1993; 150 (5 pt 1): 1391-4. 
Sanders TAB, Hinds A The influence of a fish oil high in docosahexaenoic acid 
on plasma lipoprotein and vitamin E concentrations and haemostatic function in 
healthy male volunteers. Br J Nutr 1992; 68: 163-3. 
• Saygjli EI, Konukoglu D, Papilla C, et al. levels of plasma vitamin E, vitamin C, 
TBARS and cholesterol in male patients with colorectal tumors. Biochem 
(Moscow) 2003; 68(3): 325-8. 
• Schlemmer CK, Coetzer H, Claassen M, et al. Oestrogen and essential fatty acid 
supplementation corrects bone loss due to ovariectomy in the female Sprague 
Dawley rat. Prostaglandins Leukot Essent Fatty Acids 1999; 61(6): 381-0. 
• Selvam R. Calcium oxalate stone disease: role of lipid peroxidation and 
antioxidants. Urol Res 2002; 30: 35-7. 
191 Chapter Five fish oil, vitamin E & urolithiasis 
• Serafini M, Maiani G, Ferro-Luzzi A. Alcohol-free red wine enhances plasma 
antioxidant capacity in humans. J Nutr 1998; 128: 1003-7. 
• Shapiro AC, Meydani SN, Meydani M, et al. The effect of fish oil supplementation 
on plasma a-tocopherol, retinol, lipid and lipoproteins levels in normolipidemic 
subjects. Nutr Res 1991; 11: 539-8. 
• Sivrioglu EY, Kirli S, Sipahioglu D, et al. The impact of n-3 fatty acids, vitamin E 
and C supplementation on treatment outcome and side effects in schizophrenia 
patients treated with haloperiodol: An open-label pilot study. Prog Neuro-
Psychopharm BioI Psych 2007; 31: 1493-9. 
• Srinivasan S, Jenita X, Kalaiselvi P, et al. Salubrious effect of vitamin E 
supplementation on renal stone forming risk factors in urogenital tuberculosis 
patients. Renal Failure 2004; 26(2): 135-0. 
• Stocker R, Keaney .IF Jr. Role of oxidative modifications in atherosclerosis. 
Physiol Rev 2004; 84: 1381-8. 
• Sundl I, Guardiola M, Khoschsorur G, et al. Increased concentrations of 
circulating vitamin E in carriers of the apolipoprotein A5 gene-1131T>C variant 
and association with plasma lipids and lipid peroxidation. J Lipid Res 2007; 48: 
2506-3. 
• Thabet MA, Chan JCM. Vitamin E in renal therapeutic regimens. Pediatr Nephrol 
2006; 21: 1790-1. 
• Thamilselvam S, Khan SR, Menon M. Oxalate and calcium oxalate mediated free 
radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 2003; 31: 
3-9. 
• Tulloch I, Smellie WS, Buck AC. Evening primrose oil reduces urinary calcium 
excretion in both normal and hypercalciuric rats. Urol Res 1994; 22(4): 227-0. 
• Turley E, Wallace JMW, Gilmore WS, et a/. Fish oil supplementation with and 
without added vitamin E differentially modulates plasma antioxidant 
concentrations in healthy women. Lipids 1998; 33: 1163-7. 
• Wander RC, Du S, Ketchum SO, et al. a-Tocopherol influences in vivo indices of 
lipid peroxidation in postmenopausal women given fish oil. J Nutr 1996; 126: 643-
2. 
192 Chapter Five fish oil, vitamin E & urolithiasis 
• Wander RC, Du S. Oxidation of plasma proteins is not increased after 
supplementation with eicosapentaenoic and docosahexaenoic acids. Am J Clin 
Nutr2000; 72: 731-7. 
• Wayner DO, Burton GW, Ingold KU, et al. The relative contributions of vitamin E, 
urate, ascorbate, and proteins to the total peroxyl radical-trapping antioxidant 
activity of human blood plasma. Biochim Biophys Acta 1987; 924: 408-9. 
• Wood LG, Fitzgerald DA, Garg ML. Hypothesis: Vitamin E complements 
polyunsaturated fatty acids in essential fatty acids deficiency in cystic fibrosis. J 
Am Call Nutr 2003; 22(4): 253-7. 
• Vagi K. Lipid peroxidation and human diseases. Chem Phys Lipids 1987; 45: 
337-1. 
• Vagi K. Simple assay for the level of total lipid peroxides in serum or plasma. 
Methods Mol BioI 1998; 108: 101-6. 
• Yamamoto Y, Niki F, Eguchi J, et al. Oxidation of biological membranes and its 
inhibition. Free radical chain oxidation of erythrocyte ghost membranes by 
oxygen. Biochim Biophys Acta 1985; 819: 29-6. 
• Yasui T, Tanaka H, Fujita K, et al. Effects of eicosapentanoic acid on urinary 
calcium excretion in calcium stone formers. Eur Uro/2001; 39(5): 580-5. 
• Yusof HM, Miles EA, Calder P. Influence of very long-chain n-3 fatty acids on 
plasma markers of inflammation in middle-aged men. Prost Leuk Ess Fatty Acids 
2008; 78: 219-8. 
Chapter Six 
General Discussion I Concluding remarks 
193 Chapter Six General discussion I Concluding remarks 
6.1 General discussion 
6.2 Dietary analysis 
In all of the studies described in this thesis, dietary intakes were assessed by means of 
24hr dietary recalls and/or food frequency questionnaires. Although it has been shown 
that this method seems to be precise (Fellstrom et al. 1989), it has also been suggested 
that the 24hr dietary recall tends to underestimate and the food frequency 
questionnaires tends to overestimate nutrients intakes (Kennedy et a/. 2004). 
Comparisons of mean dietary intakes from the various Chapters of this thesis (table 6.1) 
shows that energy, moisture, total protein, total sugar, calcium, magnesium, phosphate, 
potassium were significantly lower in blacks than in whites while there were no 
significant differences in the mean dietary intakes of total fat, carbohydrate, fibre, 
sodium, vitamins A, 86, C, D and E. In fact, the intakes of saturated fat, 
monounsaturated fat and polyunsaturated fat in protocols 1 and 2 of Chapter 5 were also 
not significantly different between the two race groups. The intakes of these parameters 
(saturated fat, monounsaturated fat and polyunsaturated fat) were only investigated in 
protocols 1 and 2 of Chapter 5 of this thesis because these were the only protocols in 
which the effects of ingestion of essential fatty acid (omega-3 fish oif) in the two race 
Q£QUps were investigated. 
The only mean nutrient intake that was significantly higher in blacks than in whites in all 
studies described in this thesis was dietary intake of oxalate albeit its intake was similar 
for black and white subjects who participated in protocol 1 of Chapter 5 of this thesis. 
The clinical significance of the aforementioned observed differences in mean dietary 
intakes between the two race groups with regard to kidney stone disease in general and 
more specifically with the low incidence of stone formation in the black population as 
compared to in the white population were fully described in Chapter 2 of this thesis 
(section 2.4). Moreover, the aforementioned observations of different mean dietary 
nutrient intakes between the two race groups are in conformity with findings in other 
studies (Lewandowski et al. 2001, Rodgers and Lewandowski 2002, Allie and Rodgers 
2003, Lewandowski and Rodgers 2004). 
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It is noteworthy that slight differences were observed in the mean dietary intakes of black 
and white subjects who participated in the various studies of this thesis. For example, 
although the mean dietary intakes of energy was consistently significantly lower in blacks 
than in whites in Chapters 2, 3, 4 and in protocol 2 of Chapter 5 of this thesis, this 
difference was only approaching significance in protocol 1 of the latter Chapter. 
Furthermore, the mean dietary intakes of phosphate were significantly lower in blacks 
than in whites in most studies of this thesis. The exceptions were in Chapter 4 and in 
protocol 1 of Chapter 5, where although the mean dietary intakes of this parameter were 
lower in blacks than in whites, this difference was not statistically significant. Similarly, 
the mean dietary intakes of potassium were significantly lower in blacks than in whites in 
most studies of this thesis albeit this was not statistically different in Chapter 4 of this 
thesis. The reasons for the aforementioned minor discrepancies are not clear. It is 
probable that it could be attributable to the small and varying number of subjects who 
participated in the various studies/Chapters of this thesis. 
Table 6.1 Comparisons of mean dietary intakes (SE) of black and white subjects in the 
. d· ICh f h· h . vanous stu les apters 0 t IS t eSls 
Nutrients Chapter Chapter Chapter 4 ChapterS 
2 3 FO protocol FOE protocol 
OayO OayO OayO Day 60 OayO Day 30 OayO Day 30 
Energy S8<w* S8<w* S8<w* S8<w* S8<w** S8<W** S8<w* S8<w* 
Moisture S8<w* S8<w* S8<w* S8<w* S8<W* S8<w* S8<w* S8<W* 
Total Protein S8<w* S8<w* S8<w* S8<w* S8<w* S8<w* S8<W* S8<W* 
Fat S8<w* S8<W·· S8<W"" S8<W"" S8<W'" S8<W"" S8<W"" S8<W'" 
Carbohydrate S8=W"''' S8=W"'''' S8=W'" S8=W"'''' S8=W'" S8=W''' S8=W''' S8=W"" 
Fibre S8=W'''' S8=W'''' S8=W"'''' S8=W'''' S8=W'''' S8=W'''' S8=W"''' S8=W'" 
Total sugars S8<w* S8<W* S8<W** S8<W** S8<W* S8<w* S8<W* S8<w* 
Oxalate S8>W· S8>w* S8>w* S8>w** S8>W'''' S8>W'''' S8>w* S8>w** 
Calcium S8<W* S8<w* S8<W* S8<W* S8<W* S8<w* S8<w* S8<w* 
Magnesium S8<w* S8<w* S8<w* S8<w* S8<w** S8<W** S8<w* S8<W* 
Phosphate S8<w* S8<w* S8<W"'''' S8<W"'''' S8<W'''' S8<W"''' S8<W* S8<W* 
Potassium S8<w* S8<w* S8<W'''' S8<W"'''' S8<W S8<W S8<W* S8<w* 
Sodium S8<W'''' S8<W'''' S8<W'''' S8<W''' S8<W'''' S8<W''' S8<W''' S8<W''' 
Vitamin A S8<W"" S8<W'" S8<W"" S8<W"" S8<W"" S8<W"" S8<W"'''' S8<W''' 
Vitamin 86 S8<W'" S8<W S8=W'" S8=W'" S8<W'" S8=W"'''' S8<W"'''' S8<W"'''' 
Vitamin C S8<W''' S8>W''' S8>W"''' S8>W'''' S8<W'''' S8<W''' S8<W"''' S8<W'" 
Vitamin D S8=W''' S8=W''' S8=W''' S8=W''' S8>W''' S8>W'''' S8<W'''' S8<W'" 
Vitamin E S8=W"'''' S8=W"'''' S8=W"'''' S8=W"''' S8=W''' S8=W''' S8=W''' S8=W''' 
* . . . IV;) .. ( Significance at p~O. 05, approachmg slgnfflcance, no slgnfflcant differences) 
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6.3 Urinary analysis 
It is uncertain whether the trends with respect to urine compositions for the various 
studies described in this thesis can be reliably compared due to the relatively small 
sample sizes. Moreover, it has been suggested that irrespective of differences or 
similarities in mean dietary intakes, differences in urinary outputs might occur due to 
variations in gastrointestinal uptake of nutrients between subjects irrespective of race 
group (Fellstrom et a/. 1989). 
Analysis of spot urine samples 
In the present thesis, data of mean urine parameters obtained from spot morning urine 
samples in Chapter 2 could not be reliably compared with the data obtained from 24hr 
urine samples in Chapters 3 to 5. Instead, it was compared with those of a study by 
Ogawa and co-workers (2003) which have also reported measurements of urine 
parameters in spot morning urine samples in healthy subjects. 
It is noted that more parameters (pH, volume, sodium, potassium, urate, phosphate) 
were measured in the present study as compared to the latter study. Therefore, only the 
parameters (calcium, oxalate, citrate and magnesium) that were measured in the latter 
study were compared between the two studies. These parameters were corrected for 
creatinine excretions and were expressed as mg parameter/mg creatinine in both 
studies. 
As shown in table 6.2, data for healthy black subjects obtained in the present study are 
similar to that of the study by Ogawa and co-workers (2003) albeit urinary excretion of 
magnesium appears to be higher in the latter study. In addition, the values for urinary 
excretions of citrate of these two groups were relatively higher than those obtained for 
healthy white subjects in the present study. The observation of a relatively higher mean 
urinary citrate excretion in black subjects than in whites has been previously reported 
(Lewandowski et al. 2001) although studies have not been consistent in this regard 
(Modlin 1967, Whalley et al. 1998). Given that citrate is one of the most widely 
recognized natural inhibitors of calcium oxalate stone formation (Fleisch 1978, Pak 1994, 
Ryall 1997, Chow et al. 2004, Rodgers et al. 2005). The observation of higher values of 
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this parameter in blacks although not statistically significant in the present study 
(p=O. 1588), is consistent with their lower stone incidence. However, as has been 
previously pointed in this thesis, values lie within the normal range. As such higher 
urinary citrate in blacks could account for a relatively lower stone incidence in this group, 
but cannot adequately account for absolute rarity of this disease in this group. It is 
extremely interesting that although the race of participants was not identified in the study 
by Ogawa and co-workers (2003), their study was conducted in Okinawa, Japan, where 
the inhabitants also have a low incidence of stone formation (Yoshida and Okada 1990). 
Table 6.2 Comparisons of mean spot urine parameters from urines of black and white subjects in 
Chapter 2 of this thesis (SE) with that from a previous study (SO) 









* Ogawa et al. 2003 















Data comparisons of mean urine parameters from 24hr urine samples of black and white 
subjects in Chapters 3 to 5 of the present thesis (table 6.3) show that the parameters pH, 
volume, oxalate, creatinine and uric acid were not significantly different between the two 
race groups while urinary excretions of calcium and magnesium were significantly lower 
in blacks than in whites in studies of Chapters 3, 4 and 5 of this thesis. 
There were variable differences in the mean urinary excretions of 24hr urine parameters 
in the various studies of this thesis. For example, although urinary potassium and 
phosphate excretions were lower in blacks than in whites, these differences only 
reached statistical significance in protocol 2 of Chapter 5. In addition, there were no 
significant differences in the urinary excretions of citrate between blacks and whites in 
Chapters 4 and 5 of this thesis, although this parameter was significantly lower in blacks 
than in whites in the latter Chapter. 
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The mean urinary excretions of sodium of black and white subjects who participated in 
the various studies of this thesis were inconsistent. It was significantly lower in blacks 
than in whites in Chapter 3 and in protocol 1 of Chapter 5, while it was significantly 
higher in blacks than in whites in Chapter 4 and there were no significant difference for 
this parameter in protocol 2 of Chapter 5. These aforementioned observations of 
differences in the urinary excretions of these risk factors of stone formation in black and 
white subjects are in conformity with values reported by other workers who have 
investigated 24hr urine parameters in the two race groups (Modlin 1967, Whalley et al. 
1998, Lewandowski et al. 2001, Rodgers and Lewandowski 2002, Lewandowski and 
Rodgers 2004). 
The inconsistencies in the findings of urinary excretions of sodium and citrate in the two 
race groups in the present study as well as in the studies by other workers are 
noteworthy. Some authors have observed a significantly higher urinary excretion of 
sodium in blacks than in whites (Modlin 1967, Whalley et al. 1998, Lewandowski and 
Rodgers 2004) while in a study by Rodgers and Lewandowski (2002), it was reported 
that blacks had significantly lower mean urinary sodium excretions than whites. It is 
noted that the urinary excretions of this parameter were not significantly different in the 
latter two studies. Equally inconsistent is the findings of urinary excretions of citrate in 
the two race groups. Studies have observed significantly lower (Modlin 1967, Whalley et 
al. 1998), no significant differences (Rodgers and Lewandowski 2002) or significantly 
higher (Lewandowski and Rodgers 2004) excretions of this parameter in blacks than in 
whites. The reasons for these discrepancies are not clear in literature. Further research 
is warranted in this area. 
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Table 6.3 Comparisons of mean 24hr urine parameters from urines of black and white subjects 
obtained at baseline in Chapters 3 to 5 of this thesis 
Chapter 3 Chapter 4 Cha!)ter 5 
Urine SBvsW SBvsW Protocol 1 Protocol 2 
parameters SBvsW SBvsW 
pH SB = W"'" SB = W"'" SB = W"'~ SB = W"'''' 
Volume SB<W'''' SB = W"'" SB < W"~ SB = W"'''' 
Citrate SB<W· SB = W"" SB = W"'" SB = W"''' 
Oxalate SB = W"''' SB =W'" SB = W"'~ SB = W"'" 
Calcium SB<W· SB<W· SB<W· SB<W· 
Magnesium SB<W· SB<W· SB<W· SB<W· 
Sodium SB<W· SB>W· SB<W- SB = W'" 
Potassium SB<W'''' SB <W'''' SB < W·'" SB<W* 
Urate SB < W"'''' SB < W"'" SB < W"'~ SB < W"'" 
Creatinine SB < W"'~ SB = W"'" SB = W"'~ SB < W"'" 
Phosphate SB<W""" S8 < W"'" SB <W'''' SB<W .. . . IV'::'. ( Significance at P:5.0.05, approachmg significance, no significant differences) 
6.4 Concluding remarks 
The present thesis was focused at investigating the genetic, gastrointestinal, renal and 
dietary factors in white and black South African subjects as a possible key to 
understanding the relative absence of calcium oxalate kidney stone disease in the black 
population. It is deemed appropriate to appraise the degree to which the main objectives 
of the various studies of this thesis were accomplished. 
The absence of any genetic studies attempting to explain this anomaly prompted the 
present author to investigate whether the frequency of the alanine:glyoxylate 
aminotransferase Proline11 Leucine polymorphism (a genetic aspect) might be a 
contributory factor towards explaining the differences in stone incidences between the 
two race groups. The most important finding of Chapter 2 of this thesis was that the 
frequency of this polymorphism is similar in the two race groups and therefore does not 
appear to explain the variation in stone occurrence between subjects from the two race 
groups who participated in this study. This observation is being reported for the first time 
in the present thesis. Thus, researchers of stone risk factors in the two race groups can 
in future focus their attention on other genetic and non-genetic factors in attempts to 
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elucidate the reasons for the differences in stone incidences between the two race 
groups with some degree of confidence in the knowledge that this polymorphism does 
not seem to playa key role in this anomaly. 
Previous studies that have investigated urinary oxalate excretion (the most important risk 
factor for calcium oxalate stone formation) in the two race groups have yielded surprising 
results in light of the low incidence of stone formation in the black group. In most cases, 
the results have been contrary to that which might have been reasonably expected when 
comparing relatively stone-free and stone-prone population groups. For example, it has 
been shown that despite the hyperoxalurogenic eating habits of the black population, 
urinary oxalate excretion is within the normal range in this group. 
In Chapter 3 of this thesis, the role of gut permeability as a possible key in identifying 
possible differences in the handling mechanisms of oxalate in the two race groups 
following various dietary challenges was investigated. The most important finding of this 
study was that the gut permeability index was slightly higher in black subjects than in 
white subjects when on a high oxalate standardized diet. This is counter-intuitive 
considering the low incidence of stone formation in the black group. Equally surprising 
was the finding that blacks handled oxalate more transiently than their white compatriots. 
The factors that might contribute to this anomaly were fully described in Chapter 3 of the 
present thesis (section 3.5). Further research is warranted in this area as it is the present 
author's contention that elucidation of factors contributing to the different handling 
mechanisms of oxalate in the two race groups might shed more light in the low incidence 
of stone formation in the black group. 
The important finding in Chapter 4 of the present thesis was that administration of 
vitamin E in the two race groups provoked a favourable and significant increase in the 
mean urinary excretions of citrate coupled with a favourable and significant increase of 
plasma a-tocopherol levels in both groups. This supports the protective role of vitamin E 
ingestion in calcium oxalate urolithiasis albeit it does not explain the differences in stone 
incidences in the two South African race groups. Nonetheless, clinicians can be assured 
that this intervention can be offered as another mode of therapy in the quest for 
treatment modalities in urolithiasis. However, caution should be exercised, as 
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undesirable side effects have been attributed to prolonged administration of vitamin E in 
a daily dose greater than 300 mg (Miller III et al. 2005). 
In consideration of the fact that there is a theoretical concern, that overwhelming the 
human system with one constituent could damage it as a whole in the long term (Herbert 
1998, Emmert and Kirchner 1999) and the potential for increased oxidative stress 
following fish oil ingestion (Yamamoto et al. 1985, Bartoli et al. 1988, Meydani et al. 
1993, Wander et al. 1996, Wood et al. 2003) as well as the present author's interest in 
vitamin E therapy, the effects of n-3 fish oil ingestion alone and in tandem with vitamin E 
ingestion was investigated in Chapter 5 of this thesis. The important finding in this 
Chapter was that following administration of fish oil alone and in tandem with vitamin E, 
there were significantly higher plasma a-tocopherol levels in whites than in blacks in 
both protocols. Although this is counter-intuitive considering the lower incidence of stone 
formation in the black group, it is worthy of attention as it tentatively points towards 
therapeutic properties of this nutrient in this small group of white subjects. 
The aforementioned synopsis depicts findings of various investigations in the two race 
groups that are being reported for the very first time in this thesis. Thus, many other 
researchers in the urolithiasis field might benefit a lot from the knowledge generated in 
these studies. In retrospect, the present thesis has made significant contributions to the 
body of scientific knowledge. 
With regard to the overall objective of this thesis, that is gaining more insights into the 
complex nature of the physicochemical, biochemical and physiological mechanisms in 
black South Africans which provide this group with a natural protection against 
urolithiasis in contrast to their white compatriots, it is noted that profound revelations did 
not emerge. However, the type of studies described in this thesis are "core" for gaining a 
fundamental, basic understanding of this anomaly and have the potential to provide the 
"key" mentioned in the title of this thesis. The philosophy and the approach remain 
sound. Clearly, many more subjects are needed for firm conclusions to be drawn. 
The results of this thesis have demonstrated that explanation of the phenomenon of 
stone rarity in blacks is extremely complex - no simple answers exist. Synergies of 
multiple physicochemical, physiological, gastrointestinal, renal and other mechanisms 
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are likely to be involved. Perhaps, an aspect that could be responsible for the 
observations from studies in this thesis is the origin of selected individuals of the black 
group. It is possible that changes in the ancient habits of the black population to the 
habits of modern industrial civilization had also implied an increase of the risk of stone 
formation capacity in blacks, similar to that of white population. The results of this thesis 
serve to motivate further studies to elucidate this intriguing phenomenon. 
One such study might be to investigate whether the difference in stone incidence 
between blacks and whites reflects reduced Randall's plaques formation in blacks or 
whether they have similar amounts of plaques to whites but fail to grow calcium oxalate 
upon it. It might also be interesting to evaluate the morphoanatomic features of the 
kidneys of black population. The lack of differences between common urinary 
biochemical parameters of the two populations seems to point out that the black 
population has a specially protected kidney against stone development. This could 
involve, for example, the presence of a slight deep calyx and with few void spaces in the 
interior of their kidneys. Another aspect that should not be forgotten, is the Modlin 
hypothesis about the role that phytate, as a powerful crystallization inhibitor, could play 
as an important protective function in the black population, due to their dietetic habits. 
Further studies are warranted in these areas. 
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